"KEGG_CHEBI","GENE","DRUGBANK_CHEBI","KEGG_NAME","DRUGBANK_NAME","DRUGBANK_CATEGORY","DRUGBANK_GROUPS","DRUGBANK_ID","KEGG_PATHWAY_NAMES"
"CHEBI:1387","COMT","CHEBI:4798","3,4-dihydroxyphenylethyleneglycol","entacapone","Anti-Dyskinesia Agents;Anti-Parkinson Drugs;Catechol O-Methyltransferase Inhibitors;Central Nervous System Agents;Central Nervous System Depressants;Chemical Actions and Uses;COMT Inhibitors;CYP2D6 Inhibitors (Weak);Dopamine Agents;Enzyme Inhibitors;Molecular Mechanisms of Pharmacological Action;Nervous System;Pharmacologic Actions;Therapeutic Uses","approved;investigational","DB00494","Tyrosine metabolism"
"CHEBI:15346","PLA2G2A","CHEBI:49662","coenzyme A","indometacin","Acetic Acid Derivatives and Related Substances;Analgesics;Analgesics, Non-Narcotic;Anti-Inflammatory Agents;Anti-Inflammatory Agents, Non-Steroidal;Antiinflammatory Agents, Non-Steroids;Antiinflammatory and Antirheumatic Products;Antiinflammatory and Antirheumatic Products, Non-Steroids;Antiinflammatory Preparations, Non-Steroids for Topical Use;Antirheumatic Agents;Cardiac Therapy;Cardiovascular Agents;Cardiovascular System;Central Nervous System Agents;Chemical Actions and Uses;Cyclooxygenase Inhibitors;Cytochrome P-450 CYP2C19 Inhibitors;Cytochrome P-450 CYP2C19 Substrates;Cytochrome P-450 CYP2C9 Substrates;Enzyme Inhibitors;Gout Suppressants;Heterocyclic Compounds;Heterocyclic Compounds, 2-Ring;Indoles;Molecular Mechanisms of Pharmacological Action;Musculo-Skeletal System;Ophthalmologicals;P-glycoprotein/ABCB1 Inhibitors;P-glycoprotein/ABCB1 Substrates;Peripheral Nervous System Agents;Pharmacologic Actions;Physiological Effects of Drugs;Reproductive Control Agents;Sensory Organs;Sensory System Agents;Therapeutic Uses;Tocolytic Agents;Topical Products for Joint and Muscular Pain;UGT1A1 Inhibitors","approved;investigational","DB00328","Ether lipid metabolism"
"CHEBI:15346","OGDH","CHEBI:39867","coenzyme A","valproic acid","Acids, Acyclic;Anticonvulsants;Antimanic Agents;Carboxylic Acids;Central Nervous System Agents;Central Nervous System Depressants;Chemical Actions and Uses;Cytochrome P-450 CYP1A2 Inhibitors;Cytochrome P-450 CYP2A6 Inducers;Cytochrome P-450 CYP2A6 Substrates;Cytochrome P-450 CYP2B6 Substrates;Cytochrome P-450 CYP2C19 Inhibitors;Cytochrome P-450 CYP2C19 Substrates;Cytochrome P-450 CYP2C8 Inhibitors;Cytochrome P-450 CYP2C9 Inhibitors;Cytochrome P-450 CYP2C9 Inhibitors (moderate);Cytochrome P-450 CYP2C9 Substrates;Cytochrome P-450 CYP3A Inhibitors;Enzyme Inhibitors;Fatty Acid Derivatives;Fatty Acids;Fatty Acids, Volatile;GABA Agents;Lipids;Molecular Mechanisms of Pharmacological Action;Nervous System;Neurotransmitter Agents;Organic Chemicals;Pentanoic Acids;Pharmacologic Actions;Physiological Effects of Drugs;Psychotropic Drugs;Therapeutic Uses;Tranquilizing Agents;Valerates","approved;investigational","DB00313","Citrate cycle (TCA cycle);Tryptophan metabolism"
"CHEBI:15346","SOAT1","CHEBI:49040","coenzyme A","ezetimibe","Anticholesteremic Agents;Antimetabolites;Azetidines;Azetines;BCRP/ABCG2 Substrates;Cardiovascular System;Chemical Actions and Uses;Cytochrome P-450 CYP3A Inhibitors;Heterocyclic Compounds;Heterocyclic Compounds, 1-Ring;Hypolipidemic Agents;Lipid Modifying Agents;Lipid Modifying Agents, Plain;Lipid Regulating Agents;Molecular Mechanisms of Pharmacological Action;Noxae;OATP1B1/SLCO1B1 Substrates;P-glycoprotein/ABCB1 Substrates;Pharmacologic Actions;Therapeutic Uses;Toxic Actions","approved","DB00973","Steroid biosynthesis"
"CHEBI:15346","PLA2G6","CHEBI:8711","coenzyme A","quinacrine","Acridines;Aminoacridines;Anthelmintics;Anti-Infective Agents;Anticestodal Agents;Antimalarials;Antinematodal Agents;Antineoplastic Agents;Antiparasitic Agents;Antiparasitic Products, Insecticides and Repellents;Antiplatyhelmintic Agents;Antiprotozoals;Chemical Actions and Uses;Cytochrome P-450 CYP3A4 Substrates;Enzyme Inhibitors;Heterocyclic Compounds;Heterocyclic Compounds, 3-Ring;Molecular Mechanisms of Pharmacological Action;P-glycoprotein/ABCB1 Inhibitors;Pharmacologic Actions;Therapeutic Uses","approved","DB01103","Ether lipid metabolism"
"CHEBI:15346","PLA2G4A","CHEBI:8711","coenzyme A","quinacrine","Acridines;Aminoacridines;Anthelmintics;Anti-Infective Agents;Anticestodal Agents;Antimalarials;Antinematodal Agents;Antineoplastic Agents;Antiparasitic Agents;Antiparasitic Products, Insecticides and Repellents;Antiplatyhelmintic Agents;Antiprotozoals;Chemical Actions and Uses;Cytochrome P-450 CYP3A4 Substrates;Enzyme Inhibitors;Heterocyclic Compounds;Heterocyclic Compounds, 3-Ring;Molecular Mechanisms of Pharmacological Action;P-glycoprotein/ABCB1 Inhibitors;Pharmacologic Actions;Therapeutic Uses","approved","DB01103","Ether lipid metabolism"
"CHEBI:15346","PLA2G2A","CHEBI:47381","coenzyme A","Diclofenac;diclofenac","Acetic Acid Derivatives and Related Substances;Acids, Carbocyclic;Analgesics;Analgesics, Non-Narcotic;Anti-Inflammatory Agents;Anti-Inflammatory Agents, Non-Steroidal;Antiinflammatory Agents, Non-Steroids;Antiinflammatory and Antirheumatic Products;Antiinflammatory and Antirheumatic Products, Non-Steroids;Antiinflammatory Preparations, Non-Steroids for Topical Use;Antirheumatic Agents;Carboxylic Acids;Central Nervous System Agents;Chemical Actions and Uses;Cyclooxygenase Inhibitors;Cytochrome P-450 CYP1A2 Inhibitors;Cytochrome P-450 CYP1A2 Substrates;Cytochrome P-450 CYP2B6 Substrates;Cytochrome P-450 CYP2C19 Substrates;Cytochrome P-450 CYP2C8 Substrates;Cytochrome P-450 CYP2C9 Inhibitors;Cytochrome P-450 CYP2C9 Substrates;Cytochrome P-450 CYP2E1 Inhibitors;Cytochrome P-450 CYP3A4 Substrates;Dermatologicals;Enzyme Inhibitors;Molecular Mechanisms of Pharmacological Action;Musculo-Skeletal System;Ophthalmologicals;Organic Chemicals;P-glycoprotein/ABCB1 Inhibitors;Peripheral Nervous System Agents;Pharmacologic Actions;Phenylacetates;Physiological Effects of Drugs;Sensory Organs;Sensory System Agents;Therapeutic Uses;Topical Products for Joint and Muscular Pain","approved;vet_approved","DB00586","Ether lipid metabolism"
"CHEBI:15355","ACHE","CHEBI:78330","acetylcholine","huperzine A","Central Nervous System Agents;Chemical Actions and Uses;Cholinergic Agents;Cholinesterase Inhibitors;Enzyme Inhibitors;Molecular Mechanisms of Pharmacological Action;Neuroprotective Agents;Neurotransmitter Agents;Pharmacologic Actions;Physiological Effects of Drugs;Protective Agents;Specialty Uses of Chemicals;Therapeutic Uses","investigational","DB04864","Glycerophospholipid metabolism"
"CHEBI:15355","BCHE","CHEBI:42944","acetylcholine","galanthamine","Alkaloids;Amaryllidaceae Alkaloids;Anti-Dementia Drugs;Autonomic Agents;Benzazepines;Bradycardia-Causing Agents;Central Nervous System Agents;Chemical Actions and Uses;Cholinergic Agents;Cholinesterase Inhibitors;Cytochrome P-450 CYP2D6 Substrates;Cytochrome P-450 CYP3A4 Substrates;Enzyme Inhibitors;Heterocyclic Compounds;Heterocyclic Compounds, 2-Ring;Molecular Mechanisms of Pharmacological Action;Nervous System;Neurotransmitter Agents;Nootropic Agents;Parasympathomimetics;Peripheral Nervous System Agents;Pharmacologic Actions;Physiological Effects of Drugs;Psychoanaleptics;QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying);Therapeutic Uses","approved","DB00674","Glycerophospholipid metabolism"
"CHEBI:15355","BCHE","CHEBI:4391","acetylcholine","demecarium bromide","Antiglaucoma Preparations and Miotics;Chemical Actions and Uses;Cholinergic Agents;Cholinesterase Inhibitors;Enzyme Inhibitors;Molecular Mechanisms of Pharmacological Action;Neurotransmitter Agents;Ophthalmologicals;Parasympathomimetics;Pharmacologic Actions;Physiological Effects of Drugs;Sensory Organs","approved","DB00944","Glycerophospholipid metabolism"
"CHEBI:15355","ACHE","CHEBI:4391","acetylcholine","demecarium bromide","Antiglaucoma Preparations and Miotics;Chemical Actions and Uses;Cholinergic Agents;Cholinesterase Inhibitors;Enzyme Inhibitors;Molecular Mechanisms of Pharmacological Action;Neurotransmitter Agents;Ophthalmologicals;Parasympathomimetics;Pharmacologic Actions;Physiological Effects of Drugs;Sensory Organs","approved","DB00944","Glycerophospholipid metabolism"
"CHEBI:15355","ACHE","CHEBI:27953","acetylcholine","physostigmine","Acids, Acyclic;Alkaloids;Antidotes;Antiglaucoma Preparations and Miotics;Autonomic Agents;Carbamates;Carboxylic Acids;Chemical Actions and Uses;Cholinergic Agents;Cholinesterase Inhibitors;Enzyme Inhibitors;Heterocyclic Compounds;Heterocyclic Compounds, 2-Ring;Indole Alkaloids;Indoles;Miotics;Molecular Mechanisms of Pharmacological Action;Neurotransmitter Agents;Ophthalmologicals;Organic Chemicals;Parasympathomimetics;Peripheral Nervous System Agents;Pharmacologic Actions;Phenylcarbamates;Physiological Effects of Drugs;Sensory Organs","approved","DB00981","Glycerophospholipid metabolism"
"CHEBI:15355","BCHE","CHEBI:6651","acetylcholine","malathion","Agrochemicals;Antiparasitic Products, Insecticides and Repellents;Chemical Actions and Uses;Cholinergic Agents;Cholinesterase Inhibitors;Cytochrome P-450 CYP1A2 Substrates;Cytochrome P-450 CYP2B6 Substrates;Ectoparasiticides, Incl. Scabicides;Ectoparasiticides, Incl. Scabicides, Insecticides and Repellents;Enzyme Inhibitors;Inorganic Chemicals;Insecticides;Molecular Mechanisms of Pharmacological Action;Neurotransmitter Agents;Organic Chemicals;Organophosphates;Organophosphorus Compounds;Organothiophosphates;Organothiophosphorus Compounds;Pesticides;Pharmacologic Actions;Physiological Effects of Drugs;Specialty Uses of Chemicals;Sulfur Compounds;Toxic Actions","approved;investigational","DB00772","Glycerophospholipid metabolism"
"CHEBI:15355","ACHE","CHEBI:42944","acetylcholine","galanthamine","Alkaloids;Amaryllidaceae Alkaloids;Anti-Dementia Drugs;Autonomic Agents;Benzazepines;Bradycardia-Causing Agents;Central Nervous System Agents;Chemical Actions and Uses;Cholinergic Agents;Cholinesterase Inhibitors;Cytochrome P-450 CYP2D6 Substrates;Cytochrome P-450 CYP3A4 Substrates;Enzyme Inhibitors;Heterocyclic Compounds;Heterocyclic Compounds, 2-Ring;Molecular Mechanisms of Pharmacological Action;Nervous System;Neurotransmitter Agents;Nootropic Agents;Parasympathomimetics;Peripheral Nervous System Agents;Pharmacologic Actions;Physiological Effects of Drugs;Psychoanaleptics;QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying);Therapeutic Uses","approved","DB00674","Glycerophospholipid metabolism"
"CHEBI:15355","ACHE","CHEBI:7514","acetylcholine","neostigmine","Amines;Ammonium Compounds;Antiglaucoma Preparations and Miotics;Autonomic Agents;Chemical Actions and Uses;Cholinergic Agents;Cholinesterase Inhibitors;Enzyme Inhibitors;Inorganic Chemicals;Molecular Mechanisms of Pharmacological Action;Nervous System;Neurotransmitter Agents;Nitrogen Compounds;Onium Compounds;Ophthalmologicals;Organic Chemicals;P-glycoprotein/ABCB1 Inhibitors;Parasympathomimetics;Peripheral Nervous System Agents;Pharmacologic Actions;Phenylammonium Compounds;Physiological Effects of Drugs;Quaternary Ammonium Compounds;Sensory Organs","approved;vet_approved","DB01400","Glycerophospholipid metabolism"
"CHEBI:15355","BCHE","CHEBI:59849","acetylcholine","Echothiophate;ecothiopate iodide","Autonomic Agents;Chemical Actions and Uses;Cholinergic Agents;Cholinesterase Inhibitors;Enzyme Inhibitors;Inorganic Chemicals;Miotics;Molecular Mechanisms of Pharmacological Action;Neurotransmitter Agents;Organic Chemicals;Organophosphates;Organophosphorus Compounds;Organothiophosphates;Organothiophosphorus Compounds;Parasympathomimetics;Peripheral Nervous System Agents;Pharmacologic Actions;Physiological Effects of Drugs;Sulfur Compounds","approved","DB01057","Glycerophospholipid metabolism"
"CHEBI:15468","ENPP1","CHEBI:63580","3'-dephospho-CoA","ribavirin","Anti-Infective Agents;Antiinfectives for Systemic Use;Antimetabolites;Antiviral Agents;Antivirals for Systemic Use;Carbohydrates;Chemical Actions and Uses;Direct Acting Antivirals;Glycosides;Molecular Mechanisms of Pharmacological Action;Noxae;Nucleic Acids, Nucleotides, and Nucleosides;Nucleosides;Nucleosides and Nucleotides Excl. Reverse Transcriptase Inhibitors;Pharmacologic Actions;Ribonucleosides;Therapeutic Uses;Toxic Actions","approved","DB00811","Pantothenate and CoA biosynthesis"
"CHEBI:15694","GLO1","CHEBI:49662","(R)-S-lactoylglutathione","indometacin","Acetic Acid Derivatives and Related Substances;Analgesics;Analgesics, Non-Narcotic;Anti-Inflammatory Agents;Anti-Inflammatory Agents, Non-Steroidal;Antiinflammatory Agents, Non-Steroids;Antiinflammatory and Antirheumatic Products;Antiinflammatory and Antirheumatic Products, Non-Steroids;Antiinflammatory Preparations, Non-Steroids for Topical Use;Antirheumatic Agents;Cardiac Therapy;Cardiovascular Agents;Cardiovascular System;Central Nervous System Agents;Chemical Actions and Uses;Cyclooxygenase Inhibitors;Cytochrome P-450 CYP2C19 Inhibitors;Cytochrome P-450 CYP2C19 Substrates;Cytochrome P-450 CYP2C9 Substrates;Enzyme Inhibitors;Gout Suppressants;Heterocyclic Compounds;Heterocyclic Compounds, 2-Ring;Indoles;Molecular Mechanisms of Pharmacological Action;Musculo-Skeletal System;Ophthalmologicals;P-glycoprotein/ABCB1 Inhibitors;P-glycoprotein/ABCB1 Substrates;Peripheral Nervous System Agents;Pharmacologic Actions;Physiological Effects of Drugs;Reproductive Control Agents;Sensory Organs;Sensory System Agents;Therapeutic Uses;Tocolytic Agents;Topical Products for Joint and Muscular Pain;UGT1A1 Inhibitors","approved;investigational","DB00328","Pyruvate metabolism"
"CHEBI:15698","DCK","CHEBI:63599","2'-deoxycytidine","fludarabine phosphate","Antimetabolites;Antimetabolites, Antineoplastic;Antineoplastic Agents;Antineoplastic and Immunomodulating Agents;Chemical Actions and Uses;DNA (Cytosine-5-)-Methyltransferase, antagonists & inhibitors;Enzyme Inhibitors;Immunologic Factors;Immunosuppressive Agents;Molecular Mechanisms of Pharmacological Action;Myeloablative Agonists;Myelosuppressive Agents;Noxae;Pharmacologic Actions;Physiological Effects of Drugs;Purine Analogues;Therapeutic Uses;Toxic Actions","approved","DB01073","Pyrimidine metabolism"
"CHEBI:15741","DHODH","CHEBI:575568","succinic acid","atovaquone","Anti-Infective Agents;Antimalarials;Antiparasitic Agents;Antiparasitic Products, Insecticides and Repellents;Antiprotozoals;Chemical Actions and Uses;Cytochrome P-450 CYP2C9 Inhibitors;Enzyme Inhibitors;Hydrocarbons;Hydrocarbons, Aromatic;Hydrocarbons, Cyclic;Molecular Mechanisms of Pharmacological Action;Naphthalenes;Naphthoquinones;Organic Chemicals;Pharmacologic Actions;Polycyclic Compounds;Polycyclic Hydrocarbons, Aromatic;Quinones;Therapeutic Uses","approved","DB01117",""
"CHEBI:15741","DHODH","CHEBI:6402","succinic acid","leflunomide","Adjuvants;Adjuvants, Immunologic;Anti-Inflammatory Agents, Non-Steroidal;Antineoplastic Agents;Antineoplastic and Immunomodulating Agents;Antirheumatic Agents;Antiviral Agents;BCRP/ABCG2 Substrates;Chemical Actions and Uses;Cytochrome P-450 CYP1A2 Substrates;Cytochrome P-450 CYP2C9 Inhibitors;Cytochrome P-450 CYP2C9 Inhibitors (moderate);Cytochrome P-450 CYP2C9 Substrates;Enzyme Inhibitors;Immunologic Factors;Immunosuppressive Agents;Molecular Mechanisms of Pharmacological Action;Pharmacologic Actions;Physiological Effects of Drugs;Selective Immunosuppressants;Therapeutic Uses","approved;investigational","DB01097",""
"CHEBI:15741","ALDH5A1","CHEBI:39867","succinic acid","valproic acid","Acids, Acyclic;Anticonvulsants;Antimanic Agents;Carboxylic Acids;Central Nervous System Agents;Central Nervous System Depressants;Chemical Actions and Uses;Cytochrome P-450 CYP1A2 Inhibitors;Cytochrome P-450 CYP2A6 Inducers;Cytochrome P-450 CYP2A6 Substrates;Cytochrome P-450 CYP2B6 Substrates;Cytochrome P-450 CYP2C19 Inhibitors;Cytochrome P-450 CYP2C19 Substrates;Cytochrome P-450 CYP2C8 Inhibitors;Cytochrome P-450 CYP2C9 Inhibitors;Cytochrome P-450 CYP2C9 Inhibitors (moderate);Cytochrome P-450 CYP2C9 Substrates;Cytochrome P-450 CYP3A Inhibitors;Enzyme Inhibitors;Fatty Acid Derivatives;Fatty Acids;Fatty Acids, Volatile;GABA Agents;Lipids;Molecular Mechanisms of Pharmacological Action;Nervous System;Neurotransmitter Agents;Organic Chemicals;Pentanoic Acids;Pharmacologic Actions;Physiological Effects of Drugs;Psychotropic Drugs;Therapeutic Uses;Tranquilizing Agents;Valerates","approved;investigational","DB00313","Alanine, aspartate and glutamate metabolism;Butanoate metabolism"
"CHEBI:15843","PLA2G4A","CHEBI:8711","arachidonic acid","quinacrine","Acridines;Aminoacridines;Anthelmintics;Anti-Infective Agents;Anticestodal Agents;Antimalarials;Antinematodal Agents;Antineoplastic Agents;Antiparasitic Agents;Antiparasitic Products, Insecticides and Repellents;Antiplatyhelmintic Agents;Antiprotozoals;Chemical Actions and Uses;Cytochrome P-450 CYP3A4 Substrates;Enzyme Inhibitors;Heterocyclic Compounds;Heterocyclic Compounds, 3-Ring;Molecular Mechanisms of Pharmacological Action;P-glycoprotein/ABCB1 Inhibitors;Pharmacologic Actions;Therapeutic Uses","approved","DB01103","Arachidonic acid metabolism"
"CHEBI:15843","PLA2G6","CHEBI:8711","arachidonic acid","quinacrine","Acridines;Aminoacridines;Anthelmintics;Anti-Infective Agents;Anticestodal Agents;Antimalarials;Antinematodal Agents;Antineoplastic Agents;Antiparasitic Agents;Antiparasitic Products, Insecticides and Repellents;Antiplatyhelmintic Agents;Antiprotozoals;Chemical Actions and Uses;Cytochrome P-450 CYP3A4 Substrates;Enzyme Inhibitors;Heterocyclic Compounds;Heterocyclic Compounds, 3-Ring;Molecular Mechanisms of Pharmacological Action;P-glycoprotein/ABCB1 Inhibitors;Pharmacologic Actions;Therapeutic Uses","approved","DB01103","Arachidonic acid metabolism"
"CHEBI:15843","PLA2G2A","CHEBI:47381","arachidonic acid","Diclofenac;diclofenac","Acetic Acid Derivatives and Related Substances;Acids, Carbocyclic;Analgesics;Analgesics, Non-Narcotic;Anti-Inflammatory Agents;Anti-Inflammatory Agents, Non-Steroidal;Antiinflammatory Agents, Non-Steroids;Antiinflammatory and Antirheumatic Products;Antiinflammatory and Antirheumatic Products, Non-Steroids;Antiinflammatory Preparations, Non-Steroids for Topical Use;Antirheumatic Agents;Carboxylic Acids;Central Nervous System Agents;Chemical Actions and Uses;Cyclooxygenase Inhibitors;Cytochrome P-450 CYP1A2 Inhibitors;Cytochrome P-450 CYP1A2 Substrates;Cytochrome P-450 CYP2B6 Substrates;Cytochrome P-450 CYP2C19 Substrates;Cytochrome P-450 CYP2C8 Substrates;Cytochrome P-450 CYP2C9 Inhibitors;Cytochrome P-450 CYP2C9 Substrates;Cytochrome P-450 CYP2E1 Inhibitors;Cytochrome P-450 CYP3A4 Substrates;Dermatologicals;Enzyme Inhibitors;Molecular Mechanisms of Pharmacological Action;Musculo-Skeletal System;Ophthalmologicals;Organic Chemicals;P-glycoprotein/ABCB1 Inhibitors;Peripheral Nervous System Agents;Pharmacologic Actions;Phenylacetates;Physiological Effects of Drugs;Sensory Organs;Sensory System Agents;Therapeutic Uses;Topical Products for Joint and Muscular Pain","approved;vet_approved","DB00586","Arachidonic acid metabolism"
"CHEBI:15843","CYP2C19","CHEBI:6030","arachidonic acid","isoniazide","Acids, Heterocyclic;Anti-Bacterial Agents;Anti-Infective Agents;Antiinfectives for Systemic Use;Antimetabolites;Antimycobacterials;Antitubercular Agents;Chemical Actions and Uses;CYP3A4 Inhibitors (Weak);Cytochrome P-450 CYP1A2 Inhibitors;Cytochrome P-450 CYP2A6 Inhibitors;Cytochrome P-450 CYP2C19 Inhibitors;Cytochrome P-450 CYP2C19 Inhibitors (moderate);Cytochrome P-450 CYP2C8 Inhibitors;Cytochrome P-450 CYP2C9 Inhibitors;Cytochrome P-450 CYP2D6 Inhibitors;Cytochrome P-450 CYP2D6 Inhibitors (moderate);Cytochrome P-450 CYP2E1 Inducers;Cytochrome P-450 CYP2E1 Inhibitors;Cytochrome P-450 CYP2E1 Inhibitors (moderate);Cytochrome P-450 CYP2E1 Substrates;Cytochrome P-450 CYP3A Inhibitors;Drugs for Treatment of Tuberculosis;Fatty Acid Synthesis Inhibitors;Heterocyclic Compounds;Heterocyclic Compounds, 1-Ring;Hydrazides;Hydrazines;Hypolipidemic Agents;Isonicotinic Acids;Lipid Regulating Agents;Molecular Mechanisms of Pharmacological Action;Noxae;Organic Chemicals;Pharmacologic Actions;Pyridines;Therapeutic Uses;Toxic Actions","approved","DB00951","Arachidonic acid metabolism"
"CHEBI:15843","PLA2G2A","CHEBI:49662","arachidonic acid","indometacin","Acetic Acid Derivatives and Related Substances;Analgesics;Analgesics, Non-Narcotic;Anti-Inflammatory Agents;Anti-Inflammatory Agents, Non-Steroidal;Antiinflammatory Agents, Non-Steroids;Antiinflammatory and Antirheumatic Products;Antiinflammatory and Antirheumatic Products, Non-Steroids;Antiinflammatory Preparations, Non-Steroids for Topical Use;Antirheumatic Agents;Cardiac Therapy;Cardiovascular Agents;Cardiovascular System;Central Nervous System Agents;Chemical Actions and Uses;Cyclooxygenase Inhibitors;Cytochrome P-450 CYP2C19 Inhibitors;Cytochrome P-450 CYP2C19 Substrates;Cytochrome P-450 CYP2C9 Substrates;Enzyme Inhibitors;Gout Suppressants;Heterocyclic Compounds;Heterocyclic Compounds, 2-Ring;Indoles;Molecular Mechanisms of Pharmacological Action;Musculo-Skeletal System;Ophthalmologicals;P-glycoprotein/ABCB1 Inhibitors;P-glycoprotein/ABCB1 Substrates;Peripheral Nervous System Agents;Pharmacologic Actions;Physiological Effects of Drugs;Reproductive Control Agents;Sensory Organs;Sensory System Agents;Therapeutic Uses;Tocolytic Agents;Topical Products for Joint and Muscular Pain;UGT1A1 Inhibitors","approved;investigational","DB00328","Arachidonic acid metabolism"
"CHEBI:15843","CYP2C8","CHEBI:6030","arachidonic acid","isoniazide","Acids, Heterocyclic;Anti-Bacterial Agents;Anti-Infective Agents;Antiinfectives for Systemic Use;Antimetabolites;Antimycobacterials;Antitubercular Agents;Chemical Actions and Uses;CYP3A4 Inhibitors (Weak);Cytochrome P-450 CYP1A2 Inhibitors;Cytochrome P-450 CYP2A6 Inhibitors;Cytochrome P-450 CYP2C19 Inhibitors;Cytochrome P-450 CYP2C19 Inhibitors (moderate);Cytochrome P-450 CYP2C8 Inhibitors;Cytochrome P-450 CYP2C9 Inhibitors;Cytochrome P-450 CYP2D6 Inhibitors;Cytochrome P-450 CYP2D6 Inhibitors (moderate);Cytochrome P-450 CYP2E1 Inducers;Cytochrome P-450 CYP2E1 Inhibitors;Cytochrome P-450 CYP2E1 Inhibitors (moderate);Cytochrome P-450 CYP2E1 Substrates;Cytochrome P-450 CYP3A Inhibitors;Drugs for Treatment of Tuberculosis;Fatty Acid Synthesis Inhibitors;Heterocyclic Compounds;Heterocyclic Compounds, 1-Ring;Hydrazides;Hydrazines;Hypolipidemic Agents;Isonicotinic Acids;Lipid Regulating Agents;Molecular Mechanisms of Pharmacological Action;Noxae;Organic Chemicals;Pharmacologic Actions;Pyridines;Therapeutic Uses;Toxic Actions","approved","DB00951","Arachidonic acid metabolism"
"CHEBI:15846","ENPP1","CHEBI:63580","NAD(+)","ribavirin","Anti-Infective Agents;Antiinfectives for Systemic Use;Antimetabolites;Antiviral Agents;Antivirals for Systemic Use;Carbohydrates;Chemical Actions and Uses;Direct Acting Antivirals;Glycosides;Molecular Mechanisms of Pharmacological Action;Noxae;Nucleic Acids, Nucleotides, and Nucleosides;Nucleosides;Nucleosides and Nucleotides Excl. Reverse Transcriptase Inhibitors;Pharmacologic Actions;Ribonucleosides;Therapeutic Uses;Toxic Actions","approved","DB00811","Nicotinate and nicotinamide metabolism"
"CHEBI:15927","PNP","CHEBI:490877","N-ribosylnicotinamide","didanosine","Anti-HIV Agents;Anti-Infective Agents;Anti-Retroviral Agents;Antiinfectives for Systemic Use;Antimetabolites;Antiviral Agents;Antivirals for Systemic Use;Carbohydrates;Chemical Actions and Uses;Deoxyribonucleosides;Dideoxynucleosides;Direct Acting Antivirals;Enzyme Inhibitors;Glycosides;Heterocyclic Compounds;Heterocyclic Compounds, 2-Ring;Inosine;Molecular Mechanisms of Pharmacological Action;Noxae;Nucleic Acid Synthesis Inhibitors;Nucleic Acids, Nucleotides, and Nucleosides;Nucleoside and Nucleotide Reverse Transcriptase Inhibitors;Nucleoside Reverse Transcriptase Inhibitors;Nucleosides;OAT3 Substrates;Pharmacologic Actions;Purine Nucleosides;Purines;Reverse Transcriptase Inhibitors;Ribonucleosides;Therapeutic Uses;Toxic Actions","approved","DB00900","Nicotinate and nicotinamide metabolism"
"CHEBI:15927","PNP","CHEBI:567361","N-ribosylnicotinamide","cladribine","2-Chloroadenosine;Adenosine;Antimetabolites;Antineoplastic Agents;Antineoplastic and Immunomodulating Agents;BCRP/ABCG2 Substrates;Carbohydrates;Chemical Actions and Uses;Deoxyadenosines;Deoxyribonucleosides;Glycosides;Heterocyclic Compounds;Heterocyclic Compounds, 2-Ring;Immunologic Factors;Immunosuppressive Agents;Myelosuppressive Agents;Nucleic Acids, Nucleotides, and Nucleosides;Nucleosides;OCT2 Substrates;Pharmacologic Actions;Physiological Effects of Drugs;Purine Analogues;Purine Nucleosides;Purines;Ribonucleosides;Therapeutic Uses","approved;investigational","DB00242","Nicotinate and nicotinamide metabolism"
"CHEBI:15940","PNP","CHEBI:490877","nicotinic acid","didanosine","Anti-HIV Agents;Anti-Infective Agents;Anti-Retroviral Agents;Antiinfectives for Systemic Use;Antimetabolites;Antiviral Agents;Antivirals for Systemic Use;Carbohydrates;Chemical Actions and Uses;Deoxyribonucleosides;Dideoxynucleosides;Direct Acting Antivirals;Enzyme Inhibitors;Glycosides;Heterocyclic Compounds;Heterocyclic Compounds, 2-Ring;Inosine;Molecular Mechanisms of Pharmacological Action;Noxae;Nucleic Acid Synthesis Inhibitors;Nucleic Acids, Nucleotides, and Nucleosides;Nucleoside and Nucleotide Reverse Transcriptase Inhibitors;Nucleoside Reverse Transcriptase Inhibitors;Nucleosides;OAT3 Substrates;Pharmacologic Actions;Purine Nucleosides;Purines;Reverse Transcriptase Inhibitors;Ribonucleosides;Therapeutic Uses;Toxic Actions","approved","DB00900","Nicotinate and nicotinamide metabolism"
"CHEBI:15940","PNP","CHEBI:567361","nicotinic acid","cladribine","2-Chloroadenosine;Adenosine;Antimetabolites;Antineoplastic Agents;Antineoplastic and Immunomodulating Agents;BCRP/ABCG2 Substrates;Carbohydrates;Chemical Actions and Uses;Deoxyadenosines;Deoxyribonucleosides;Glycosides;Heterocyclic Compounds;Heterocyclic Compounds, 2-Ring;Immunologic Factors;Immunosuppressive Agents;Myelosuppressive Agents;Nucleic Acids, Nucleotides, and Nucleosides;Nucleosides;OCT2 Substrates;Pharmacologic Actions;Physiological Effects of Drugs;Purine Analogues;Purine Nucleosides;Purines;Ribonucleosides;Therapeutic Uses","approved;investigational","DB00242","Nicotinate and nicotinamide metabolism"
"CHEBI:15999","HPD","CHEBI:50378","(4-hydroxyphenyl)pyruvic acid","nitisinone","4-Hydroxyphenylpyruvate Dioxygenase, antagonists & inhibitors;Alimentary Tract and Metabolism;Chemical Actions and Uses;Enzyme Inhibitors;Molecular Mechanisms of Pharmacological Action;Pharmacologic Actions;Various Alimentary Tract and Metabolism Products","approved;investigational","DB00348","Tyrosine metabolism;Ubiquinone and other terpenoid-quinone biosynthesis"
"CHEBI:16015","ABAT","CHEBI:39867","L-glutamic acid","valproic acid","Acids, Acyclic;Anticonvulsants;Antimanic Agents;Carboxylic Acids;Central Nervous System Agents;Central Nervous System Depressants;Chemical Actions and Uses;Cytochrome P-450 CYP1A2 Inhibitors;Cytochrome P-450 CYP2A6 Inducers;Cytochrome P-450 CYP2A6 Substrates;Cytochrome P-450 CYP2B6 Substrates;Cytochrome P-450 CYP2C19 Inhibitors;Cytochrome P-450 CYP2C19 Substrates;Cytochrome P-450 CYP2C8 Inhibitors;Cytochrome P-450 CYP2C9 Inhibitors;Cytochrome P-450 CYP2C9 Inhibitors (moderate);Cytochrome P-450 CYP2C9 Substrates;Cytochrome P-450 CYP3A Inhibitors;Enzyme Inhibitors;Fatty Acid Derivatives;Fatty Acids;Fatty Acids, Volatile;GABA Agents;Lipids;Molecular Mechanisms of Pharmacological Action;Nervous System;Neurotransmitter Agents;Organic Chemicals;Pentanoic Acids;Pharmacologic Actions;Physiological Effects of Drugs;Psychotropic Drugs;Therapeutic Uses;Tranquilizing Agents;Valerates","approved;investigational","DB00313","Propanoate metabolism;Valine, leucine and isoleucine degradation;beta-Alanine metabolism"
"CHEBI:16015","ABAT","CHEBI:63638","L-glutamic acid","vigabatrin","Acids, Acyclic;Amino Acids;Amino Acids, Peptides, and Proteins;Aminobutyrates;Anticonvulsants;Butyrates;Carboxylic Acids;Central Nervous System Agents;Central Nervous System Depressants;Chemical Actions and Uses;Enzyme Inhibitors;Fatty Acid Derivatives;Fatty Acids;Fatty Acids, Volatile;GABA Agents;gamma-Aminobutyric Acid;Lipids;Molecular Mechanisms of Pharmacological Action;Nervous System;Neurotransmitter Agents;Organic Chemicals;Pharmacologic Actions;Physiological Effects of Drugs;Therapeutic Uses","approved","DB01080","Propanoate metabolism;Valine, leucine and isoleucine degradation;beta-Alanine metabolism"
"CHEBI:16027","ADK","CHEBI:63580","AMP","ribavirin","Anti-Infective Agents;Antiinfectives for Systemic Use;Antimetabolites;Antiviral Agents;Antivirals for Systemic Use;Carbohydrates;Chemical Actions and Uses;Direct Acting Antivirals;Glycosides;Molecular Mechanisms of Pharmacological Action;Noxae;Nucleic Acids, Nucleotides, and Nucleosides;Nucleosides;Nucleosides and Nucleotides Excl. Reverse Transcriptase Inhibitors;Pharmacologic Actions;Ribonucleosides;Therapeutic Uses;Toxic Actions","approved","DB00811","Purine metabolism"
"CHEBI:16027","DCK","CHEBI:63599","AMP","fludarabine phosphate","Antimetabolites;Antimetabolites, Antineoplastic;Antineoplastic Agents;Antineoplastic and Immunomodulating Agents;Chemical Actions and Uses;DNA (Cytosine-5-)-Methyltransferase, antagonists & inhibitors;Enzyme Inhibitors;Immunologic Factors;Immunosuppressive Agents;Molecular Mechanisms of Pharmacological Action;Myeloablative Agonists;Myelosuppressive Agents;Noxae;Pharmacologic Actions;Physiological Effects of Drugs;Purine Analogues;Therapeutic Uses;Toxic Actions","approved","DB01073","Purine metabolism"
"CHEBI:16113","SOAT1","CHEBI:49040","cholesterol","ezetimibe","Anticholesteremic Agents;Antimetabolites;Azetidines;Azetines;BCRP/ABCG2 Substrates;Cardiovascular System;Chemical Actions and Uses;Cytochrome P-450 CYP3A Inhibitors;Heterocyclic Compounds;Heterocyclic Compounds, 1-Ring;Hypolipidemic Agents;Lipid Modifying Agents;Lipid Modifying Agents, Plain;Lipid Regulating Agents;Molecular Mechanisms of Pharmacological Action;Noxae;OATP1B1/SLCO1B1 Substrates;P-glycoprotein/ABCB1 Substrates;Pharmacologic Actions;Therapeutic Uses;Toxic Actions","approved","DB00973","Steroid biosynthesis"
"CHEBI:16113","CYP11A1","CHEBI:2654","cholesterol","Aminoglutethimide;aminoglutethimide","Antineoplastic Agents;Antineoplastic Agents, Hormonal;Antineoplastic and Immunomodulating Agents;Aromatase Inhibitors;Chemical Actions and Uses;Cytochrome P-450 CYP1A2 Inducers;Cytochrome P-450 CYP2C19 Inducers;Cytochrome P-450 CYP3A Inducers;Endocrine Therapy;Enzyme Inhibitors;Estrogen Antagonists;Glutethimide;Heterocyclic Compounds;Heterocyclic Compounds, 1-Ring;Hormone Antagonists;Hormone Antagonists and Related Agents;Hormones, Hormone Substitutes, and Hormone Antagonists;Molecular Mechanisms of Pharmacological Action;Pharmacologic Actions;Physiological Effects of Drugs;Piperidines;Piperidones;Steroid Synthesis Inhibitors;Therapeutic Uses","approved","DB00357","Steroid hormone biosynthesis"
"CHEBI:16235","HPRT1","CHEBI:2948","guanine","azathioprine","6-Mercaptopurine;Antimetabolites;Antimetabolites, Antineoplastic;Antineoplastic Agents;Antineoplastic and Immunomodulating Agents;Antirheumatic Agents;Carbohydrates;Chemical Actions and Uses;Glycosides;Heterocyclic Compounds;Heterocyclic Compounds, 2-Ring;Immunologic Factors;Immunosuppressive Agents;Inorganic Chemicals;Molecular Mechanisms of Pharmacological Action;Noxae;Nucleic Acids, Nucleotides, and Nucleosides;Nucleosides;Organic Chemicals;Pharmacologic Actions;Physiological Effects of Drugs;Purines;Sulfhydryl Compounds;Sulfur Compounds;Therapeutic Uses;Thionucleosides;Thiopurine Analogs;Toxic Actions","approved","DB00993","Purine metabolism"
"CHEBI:16235","HPRT1","CHEBI:50667","guanine","Mercaptopurine;mercaptopurine","Antimetabolites;Antimetabolites, Antineoplastic;Antineoplastic Agents;Antineoplastic and Immunomodulating Agents;Chemical Actions and Uses;Enzyme Inhibitors;Heterocyclic Compounds;Heterocyclic Compounds, 2-Ring;Immunologic Factors;Immunosuppressive Agents;Inorganic Chemicals;Molecular Mechanisms of Pharmacological Action;Myelosuppressive Agents;Noxae;Nucleic Acid Synthesis Inhibitors;Organic Chemicals;Pharmacologic Actions;Physiological Effects of Drugs;Purine Analogues;Purines;Sulfhydryl Compounds;Sulfur Compounds;Therapeutic Uses;Thiopurine Analogs;Toxic Actions","approved","DB01033","Purine metabolism"
"CHEBI:16235","PNP","CHEBI:490877","guanine","didanosine","Anti-HIV Agents;Anti-Infective Agents;Anti-Retroviral Agents;Antiinfectives for Systemic Use;Antimetabolites;Antiviral Agents;Antivirals for Systemic Use;Carbohydrates;Chemical Actions and Uses;Deoxyribonucleosides;Dideoxynucleosides;Direct Acting Antivirals;Enzyme Inhibitors;Glycosides;Heterocyclic Compounds;Heterocyclic Compounds, 2-Ring;Inosine;Molecular Mechanisms of Pharmacological Action;Noxae;Nucleic Acid Synthesis Inhibitors;Nucleic Acids, Nucleotides, and Nucleosides;Nucleoside and Nucleotide Reverse Transcriptase Inhibitors;Nucleoside Reverse Transcriptase Inhibitors;Nucleosides;OAT3 Substrates;Pharmacologic Actions;Purine Nucleosides;Purines;Reverse Transcriptase Inhibitors;Ribonucleosides;Therapeutic Uses;Toxic Actions","approved","DB00900","Purine metabolism"
"CHEBI:16235","HPRT1","CHEBI:2208","guanine","Mercaptopurine;purine-6-thiol","Antimetabolites;Antimetabolites, Antineoplastic;Antineoplastic Agents;Antineoplastic and Immunomodulating Agents;Chemical Actions and Uses;Enzyme Inhibitors;Heterocyclic Compounds;Heterocyclic Compounds, 2-Ring;Immunologic Factors;Immunosuppressive Agents;Inorganic Chemicals;Molecular Mechanisms of Pharmacological Action;Myelosuppressive Agents;Noxae;Nucleic Acid Synthesis Inhibitors;Organic Chemicals;Pharmacologic Actions;Physiological Effects of Drugs;Purine Analogues;Purines;Sulfhydryl Compounds;Sulfur Compounds;Therapeutic Uses;Thiopurine Analogs;Toxic Actions","approved","DB01033","Purine metabolism"
"CHEBI:16235","PNP","CHEBI:567361","guanine","cladribine","2-Chloroadenosine;Adenosine;Antimetabolites;Antineoplastic Agents;Antineoplastic and Immunomodulating Agents;BCRP/ABCG2 Substrates;Carbohydrates;Chemical Actions and Uses;Deoxyadenosines;Deoxyribonucleosides;Glycosides;Heterocyclic Compounds;Heterocyclic Compounds, 2-Ring;Immunologic Factors;Immunosuppressive Agents;Myelosuppressive Agents;Nucleic Acids, Nucleotides, and Nucleosides;Nucleosides;OCT2 Substrates;Pharmacologic Actions;Physiological Effects of Drugs;Purine Analogues;Purine Nucleosides;Purines;Ribonucleosides;Therapeutic Uses","approved;investigational","DB00242","Purine metabolism"
"CHEBI:16238","ACADSB","CHEBI:39867","FAD","valproic acid","Acids, Acyclic;Anticonvulsants;Antimanic Agents;Carboxylic Acids;Central Nervous System Agents;Central Nervous System Depressants;Chemical Actions and Uses;Cytochrome P-450 CYP1A2 Inhibitors;Cytochrome P-450 CYP2A6 Inducers;Cytochrome P-450 CYP2A6 Substrates;Cytochrome P-450 CYP2B6 Substrates;Cytochrome P-450 CYP2C19 Inhibitors;Cytochrome P-450 CYP2C19 Substrates;Cytochrome P-450 CYP2C8 Inhibitors;Cytochrome P-450 CYP2C9 Inhibitors;Cytochrome P-450 CYP2C9 Inhibitors (moderate);Cytochrome P-450 CYP2C9 Substrates;Cytochrome P-450 CYP3A Inhibitors;Enzyme Inhibitors;Fatty Acid Derivatives;Fatty Acids;Fatty Acids, Volatile;GABA Agents;Lipids;Molecular Mechanisms of Pharmacological Action;Nervous System;Neurotransmitter Agents;Organic Chemicals;Pentanoic Acids;Pharmacologic Actions;Physiological Effects of Drugs;Psychotropic Drugs;Therapeutic Uses;Tranquilizing Agents;Valerates","approved;investigational","DB00313","Fatty acid degradation"
"CHEBI:16238","ENPP1","CHEBI:63580","FAD","ribavirin","Anti-Infective Agents;Antiinfectives for Systemic Use;Antimetabolites;Antiviral Agents;Antivirals for Systemic Use;Carbohydrates;Chemical Actions and Uses;Direct Acting Antivirals;Glycosides;Molecular Mechanisms of Pharmacological Action;Noxae;Nucleic Acids, Nucleotides, and Nucleosides;Nucleosides;Nucleosides and Nucleotides Excl. Reverse Transcriptase Inhibitors;Pharmacologic Actions;Ribonucleosides;Therapeutic Uses;Toxic Actions","approved","DB00811","Riboflavin metabolism"
"CHEBI:16335","PNP","CHEBI:567361","adenosine","cladribine","2-Chloroadenosine;Adenosine;Antimetabolites;Antineoplastic Agents;Antineoplastic and Immunomodulating Agents;BCRP/ABCG2 Substrates;Carbohydrates;Chemical Actions and Uses;Deoxyadenosines;Deoxyribonucleosides;Glycosides;Heterocyclic Compounds;Heterocyclic Compounds, 2-Ring;Immunologic Factors;Immunosuppressive Agents;Myelosuppressive Agents;Nucleic Acids, Nucleotides, and Nucleosides;Nucleosides;OCT2 Substrates;Pharmacologic Actions;Physiological Effects of Drugs;Purine Analogues;Purine Nucleosides;Purines;Ribonucleosides;Therapeutic Uses","approved;investigational","DB00242","Purine metabolism"
"CHEBI:16335","PNP","CHEBI:490877","adenosine","didanosine","Anti-HIV Agents;Anti-Infective Agents;Anti-Retroviral Agents;Antiinfectives for Systemic Use;Antimetabolites;Antiviral Agents;Antivirals for Systemic Use;Carbohydrates;Chemical Actions and Uses;Deoxyribonucleosides;Dideoxynucleosides;Direct Acting Antivirals;Enzyme Inhibitors;Glycosides;Heterocyclic Compounds;Heterocyclic Compounds, 2-Ring;Inosine;Molecular Mechanisms of Pharmacological Action;Noxae;Nucleic Acid Synthesis Inhibitors;Nucleic Acids, Nucleotides, and Nucleosides;Nucleoside and Nucleotide Reverse Transcriptase Inhibitors;Nucleoside Reverse Transcriptase Inhibitors;Nucleosides;OAT3 Substrates;Pharmacologic Actions;Purine Nucleosides;Purines;Reverse Transcriptase Inhibitors;Ribonucleosides;Therapeutic Uses;Toxic Actions","approved","DB00900","Purine metabolism"
"CHEBI:16335","ADK","CHEBI:63580","adenosine","ribavirin","Anti-Infective Agents;Antiinfectives for Systemic Use;Antimetabolites;Antiviral Agents;Antivirals for Systemic Use;Carbohydrates;Chemical Actions and Uses;Direct Acting Antivirals;Glycosides;Molecular Mechanisms of Pharmacological Action;Noxae;Nucleic Acids, Nucleotides, and Nucleosides;Nucleosides;Nucleosides and Nucleotides Excl. Reverse Transcriptase Inhibitors;Pharmacologic Actions;Ribonucleosides;Therapeutic Uses;Toxic Actions","approved","DB00811","Purine metabolism"
"CHEBI:16335","DCK","CHEBI:63599","adenosine","fludarabine phosphate","Antimetabolites;Antimetabolites, Antineoplastic;Antineoplastic Agents;Antineoplastic and Immunomodulating Agents;Chemical Actions and Uses;DNA (Cytosine-5-)-Methyltransferase, antagonists & inhibitors;Enzyme Inhibitors;Immunologic Factors;Immunosuppressive Agents;Molecular Mechanisms of Pharmacological Action;Myeloablative Agonists;Myelosuppressive Agents;Noxae;Pharmacologic Actions;Physiological Effects of Drugs;Purine Analogues;Therapeutic Uses;Toxic Actions","approved","DB01073","Purine metabolism"
"CHEBI:16335","ADA","CHEBI:4653","adenosine","dipyridamole","Blood and Blood Forming Organs;Cardiovascular Agents;Chemical Actions and Uses;Enzyme Inhibitors;Fibrinolytic Agents;Hematologic Agents;Heterocyclic Compounds;Heterocyclic Compounds, 1-Ring;Hypotensive Agents;Molecular Mechanisms of Pharmacological Action;P-glycoprotein/ABCB1 Inhibitors;P-glycoprotein/ABCB1 Substrates;Pharmacologic Actions;Phosphodiesterase Inhibitors;Platelet Aggregation Inhibitors;Platelet Aggregation Inhibitors Excl. Heparin;Pyrimidines;Therapeutic Uses;Vasodilator Agents","approved","DB00975","Purine metabolism"
"CHEBI:16349","NOS3","CHEBI:6923","L-citrulline","Miconazole;miconazole","14-alpha Demethylase Inhibitors;Alimentary Tract and Metabolism;Anti-Infective Agents;Antidiarrheals, Intestinal Antiinflammatory/antiinfective Agents;Antifungal Agents;Antifungal Agents (Vaginal);Antifungals for Dermatological Use;Antifungals for Topical Use;Antiinfectives;Antiinfectives and Antiseptics for Local Oral Treatment;Antiinfectives for Systemic Use;Antimycotics for Systemic Use;Azoles;Chemical Actions and Uses;Chemically-Induced Disorders;Combined Inhibitors of CYP3A4 and P-glycoprotein;Cytochrome P-450 CYP1A2 Inhibitors;Cytochrome P-450 CYP2A6 Inhibitors;Cytochrome P-450 CYP2B6 Inhibitors;Cytochrome P-450 CYP2C19 Inhibitors;Cytochrome P-450 CYP2C9 Inhibitors;Cytochrome P-450 CYP2D6 Inhibitors;Cytochrome P-450 CYP2E1 Inhibitors;Cytochrome P-450 CYP3A Inhibitors;Cytochrome P-450 CYP3A4 Substrates;Cytochrome P-450 Enzyme Inhibitors;Dermatologicals;Drug-Related Side Effects and Adverse Reactions;Enzyme Inhibitors;Genito Urinary System and Sex Hormones;Gynecological Antiinfectives and Antiseptics;Heterocyclic Compounds;Heterocyclic Compounds, 1-Ring;Hormone Antagonists;Hormones, Hormone Substitutes, and Hormone Antagonists;Imidazole and Triazole Derivatives;Imidazole Derivatives;Imidazoles;Intestinal Antiinfectives;Metabolic Side Effects of Drugs and Substances;Molecular Mechanisms of Pharmacological Action;Otologicals;P-glycoprotein/ABCB1 Inhibitors;Pharmacologic Actions;Physiological Effects of Drugs;Sensory Organs;Steroid Synthesis Inhibitors;Stomatological Preparations;Therapeutic Uses","approved;investigational;vet_approved","DB01110","Arginine and proline metabolism"
"CHEBI:16467","NOS3","CHEBI:6923","L-arginine","Miconazole;miconazole","14-alpha Demethylase Inhibitors;Alimentary Tract and Metabolism;Anti-Infective Agents;Antidiarrheals, Intestinal Antiinflammatory/antiinfective Agents;Antifungal Agents;Antifungal Agents (Vaginal);Antifungals for Dermatological Use;Antifungals for Topical Use;Antiinfectives;Antiinfectives and Antiseptics for Local Oral Treatment;Antiinfectives for Systemic Use;Antimycotics for Systemic Use;Azoles;Chemical Actions and Uses;Chemically-Induced Disorders;Combined Inhibitors of CYP3A4 and P-glycoprotein;Cytochrome P-450 CYP1A2 Inhibitors;Cytochrome P-450 CYP2A6 Inhibitors;Cytochrome P-450 CYP2B6 Inhibitors;Cytochrome P-450 CYP2C19 Inhibitors;Cytochrome P-450 CYP2C9 Inhibitors;Cytochrome P-450 CYP2D6 Inhibitors;Cytochrome P-450 CYP2E1 Inhibitors;Cytochrome P-450 CYP3A Inhibitors;Cytochrome P-450 CYP3A4 Substrates;Cytochrome P-450 Enzyme Inhibitors;Dermatologicals;Drug-Related Side Effects and Adverse Reactions;Enzyme Inhibitors;Genito Urinary System and Sex Hormones;Gynecological Antiinfectives and Antiseptics;Heterocyclic Compounds;Heterocyclic Compounds, 1-Ring;Hormone Antagonists;Hormones, Hormone Substitutes, and Hormone Antagonists;Imidazole and Triazole Derivatives;Imidazole Derivatives;Imidazoles;Intestinal Antiinfectives;Metabolic Side Effects of Drugs and Substances;Molecular Mechanisms of Pharmacological Action;Otologicals;P-glycoprotein/ABCB1 Inhibitors;Pharmacologic Actions;Physiological Effects of Drugs;Sensory Organs;Steroid Synthesis Inhibitors;Stomatological Preparations;Therapeutic Uses","approved;investigational;vet_approved","DB01110","Arginine and proline metabolism"
"CHEBI:16497","POLE2","CHEBI:567361","dGTP","cladribine","2-Chloroadenosine;Adenosine;Antimetabolites;Antineoplastic Agents;Antineoplastic and Immunomodulating Agents;BCRP/ABCG2 Substrates;Carbohydrates;Chemical Actions and Uses;Deoxyadenosines;Deoxyribonucleosides;Glycosides;Heterocyclic Compounds;Heterocyclic Compounds, 2-Ring;Immunologic Factors;Immunosuppressive Agents;Myelosuppressive Agents;Nucleic Acids, Nucleotides, and Nucleosides;Nucleosides;OCT2 Substrates;Pharmacologic Actions;Physiological Effects of Drugs;Purine Analogues;Purine Nucleosides;Purines;Ribonucleosides;Therapeutic Uses","approved;investigational","DB00242","Purine metabolism"
"CHEBI:16497","POLA1","CHEBI:567361","dGTP","cladribine","2-Chloroadenosine;Adenosine;Antimetabolites;Antineoplastic Agents;Antineoplastic and Immunomodulating Agents;BCRP/ABCG2 Substrates;Carbohydrates;Chemical Actions and Uses;Deoxyadenosines;Deoxyribonucleosides;Glycosides;Heterocyclic Compounds;Heterocyclic Compounds, 2-Ring;Immunologic Factors;Immunosuppressive Agents;Myelosuppressive Agents;Nucleic Acids, Nucleotides, and Nucleosides;Nucleosides;OCT2 Substrates;Pharmacologic Actions;Physiological Effects of Drugs;Purine Analogues;Purine Nucleosides;Purines;Ribonucleosides;Therapeutic Uses","approved;investigational","DB00242","Purine metabolism"
"CHEBI:16497","POLE4","CHEBI:567361","dGTP","cladribine","2-Chloroadenosine;Adenosine;Antimetabolites;Antineoplastic Agents;Antineoplastic and Immunomodulating Agents;BCRP/ABCG2 Substrates;Carbohydrates;Chemical Actions and Uses;Deoxyadenosines;Deoxyribonucleosides;Glycosides;Heterocyclic Compounds;Heterocyclic Compounds, 2-Ring;Immunologic Factors;Immunosuppressive Agents;Myelosuppressive Agents;Nucleic Acids, Nucleotides, and Nucleosides;Nucleosides;OCT2 Substrates;Pharmacologic Actions;Physiological Effects of Drugs;Purine Analogues;Purine Nucleosides;Purines;Ribonucleosides;Therapeutic Uses","approved;investigational","DB00242","Purine metabolism"
"CHEBI:16497","POLE3","CHEBI:567361","dGTP","cladribine","2-Chloroadenosine;Adenosine;Antimetabolites;Antineoplastic Agents;Antineoplastic and Immunomodulating Agents;BCRP/ABCG2 Substrates;Carbohydrates;Chemical Actions and Uses;Deoxyadenosines;Deoxyribonucleosides;Glycosides;Heterocyclic Compounds;Heterocyclic Compounds, 2-Ring;Immunologic Factors;Immunosuppressive Agents;Myelosuppressive Agents;Nucleic Acids, Nucleotides, and Nucleosides;Nucleosides;OCT2 Substrates;Pharmacologic Actions;Physiological Effects of Drugs;Purine Analogues;Purine Nucleosides;Purines;Ribonucleosides;Therapeutic Uses","approved;investigational","DB00242","Purine metabolism"
"CHEBI:16497","POLA1","CHEBI:63599","dGTP","fludarabine phosphate","Antimetabolites;Antimetabolites, Antineoplastic;Antineoplastic Agents;Antineoplastic and Immunomodulating Agents;Chemical Actions and Uses;DNA (Cytosine-5-)-Methyltransferase, antagonists & inhibitors;Enzyme Inhibitors;Immunologic Factors;Immunosuppressive Agents;Molecular Mechanisms of Pharmacological Action;Myeloablative Agonists;Myelosuppressive Agents;Noxae;Pharmacologic Actions;Physiological Effects of Drugs;Purine Analogues;Therapeutic Uses;Toxic Actions","approved","DB01073","Purine metabolism"
"CHEBI:16497","POLA1","CHEBI:681569","dGTP","clofarabine","Antimetabolites;Antimetabolites, Antineoplastic;Antineoplastic Agents;Antineoplastic and Immunomodulating Agents;BCRP/ABCG2 Substrates;Chemical Actions and Uses;Immunosuppressive Agents;Molecular Mechanisms of Pharmacological Action;Myelosuppressive Agents;Noxae;Pharmacologic Actions;Purine Analogues;Therapeutic Uses;Toxic Actions","approved;investigational","DB00631","Purine metabolism"
"CHEBI:16497","POLA1","CHEBI:63612","dGTP","nelarabine","Antimetabolites;Antineoplastic Agents;Antineoplastic and Immunomodulating Agents;Immunosuppressive Agents;Myelosuppressive Agents;Purine Analogues","approved;investigational","DB01280","Purine metabolism"
"CHEBI:16497","POLE","CHEBI:567361","dGTP","cladribine","2-Chloroadenosine;Adenosine;Antimetabolites;Antineoplastic Agents;Antineoplastic and Immunomodulating Agents;BCRP/ABCG2 Substrates;Carbohydrates;Chemical Actions and Uses;Deoxyadenosines;Deoxyribonucleosides;Glycosides;Heterocyclic Compounds;Heterocyclic Compounds, 2-Ring;Immunologic Factors;Immunosuppressive Agents;Myelosuppressive Agents;Nucleic Acids, Nucleotides, and Nucleosides;Nucleosides;OCT2 Substrates;Pharmacologic Actions;Physiological Effects of Drugs;Purine Analogues;Purine Nucleosides;Purines;Ribonucleosides;Therapeutic Uses","approved;investigational","DB00242","Purine metabolism"
"CHEBI:16680","COMT","CHEBI:4798","S-adenosyl-L-homocysteine","entacapone","Anti-Dyskinesia Agents;Anti-Parkinson Drugs;Catechol O-Methyltransferase Inhibitors;Central Nervous System Agents;Central Nervous System Depressants;Chemical Actions and Uses;COMT Inhibitors;CYP2D6 Inhibitors (Weak);Dopamine Agents;Enzyme Inhibitors;Molecular Mechanisms of Pharmacological Action;Nervous System;Pharmacologic Actions;Therapeutic Uses","approved;investigational","DB00494","Tyrosine metabolism"
"CHEBI:16708","PNP","CHEBI:490877","adenine","didanosine","Anti-HIV Agents;Anti-Infective Agents;Anti-Retroviral Agents;Antiinfectives for Systemic Use;Antimetabolites;Antiviral Agents;Antivirals for Systemic Use;Carbohydrates;Chemical Actions and Uses;Deoxyribonucleosides;Dideoxynucleosides;Direct Acting Antivirals;Enzyme Inhibitors;Glycosides;Heterocyclic Compounds;Heterocyclic Compounds, 2-Ring;Inosine;Molecular Mechanisms of Pharmacological Action;Noxae;Nucleic Acid Synthesis Inhibitors;Nucleic Acids, Nucleotides, and Nucleosides;Nucleoside and Nucleotide Reverse Transcriptase Inhibitors;Nucleoside Reverse Transcriptase Inhibitors;Nucleosides;OAT3 Substrates;Pharmacologic Actions;Purine Nucleosides;Purines;Reverse Transcriptase Inhibitors;Ribonucleosides;Therapeutic Uses;Toxic Actions","approved","DB00900","Purine metabolism"
"CHEBI:16708","PNP","CHEBI:567361","adenine","cladribine","2-Chloroadenosine;Adenosine;Antimetabolites;Antineoplastic Agents;Antineoplastic and Immunomodulating Agents;BCRP/ABCG2 Substrates;Carbohydrates;Chemical Actions and Uses;Deoxyadenosines;Deoxyribonucleosides;Glycosides;Heterocyclic Compounds;Heterocyclic Compounds, 2-Ring;Immunologic Factors;Immunosuppressive Agents;Myelosuppressive Agents;Nucleic Acids, Nucleotides, and Nucleosides;Nucleosides;OCT2 Substrates;Pharmacologic Actions;Physiological Effects of Drugs;Purine Analogues;Purine Nucleosides;Purines;Ribonucleosides;Therapeutic Uses","approved;investigational","DB00242","Purine metabolism"
"CHEBI:16750","PNP","CHEBI:490877","guanosine","didanosine","Anti-HIV Agents;Anti-Infective Agents;Anti-Retroviral Agents;Antiinfectives for Systemic Use;Antimetabolites;Antiviral Agents;Antivirals for Systemic Use;Carbohydrates;Chemical Actions and Uses;Deoxyribonucleosides;Dideoxynucleosides;Direct Acting Antivirals;Enzyme Inhibitors;Glycosides;Heterocyclic Compounds;Heterocyclic Compounds, 2-Ring;Inosine;Molecular Mechanisms of Pharmacological Action;Noxae;Nucleic Acid Synthesis Inhibitors;Nucleic Acids, Nucleotides, and Nucleosides;Nucleoside and Nucleotide Reverse Transcriptase Inhibitors;Nucleoside Reverse Transcriptase Inhibitors;Nucleosides;OAT3 Substrates;Pharmacologic Actions;Purine Nucleosides;Purines;Reverse Transcriptase Inhibitors;Ribonucleosides;Therapeutic Uses;Toxic Actions","approved","DB00900","Purine metabolism"
"CHEBI:16750","PNP","CHEBI:567361","guanosine","cladribine","2-Chloroadenosine;Adenosine;Antimetabolites;Antineoplastic Agents;Antineoplastic and Immunomodulating Agents;BCRP/ABCG2 Substrates;Carbohydrates;Chemical Actions and Uses;Deoxyadenosines;Deoxyribonucleosides;Glycosides;Heterocyclic Compounds;Heterocyclic Compounds, 2-Ring;Immunologic Factors;Immunosuppressive Agents;Myelosuppressive Agents;Nucleic Acids, Nucleotides, and Nucleosides;Nucleosides;OCT2 Substrates;Pharmacologic Actions;Physiological Effects of Drugs;Purine Analogues;Purine Nucleosides;Purines;Ribonucleosides;Therapeutic Uses","approved;investigational","DB00242","Purine metabolism"
"CHEBI:16761","DCK","CHEBI:63599","ADP","fludarabine phosphate","Antimetabolites;Antimetabolites, Antineoplastic;Antineoplastic Agents;Antineoplastic and Immunomodulating Agents;Chemical Actions and Uses;DNA (Cytosine-5-)-Methyltransferase, antagonists & inhibitors;Enzyme Inhibitors;Immunologic Factors;Immunosuppressive Agents;Molecular Mechanisms of Pharmacological Action;Myeloablative Agonists;Myelosuppressive Agents;Noxae;Pharmacologic Actions;Physiological Effects of Drugs;Purine Analogues;Therapeutic Uses;Toxic Actions","approved","DB01073","Purine metabolism"
"CHEBI:16761","ADK","CHEBI:63580","ADP","ribavirin","Anti-Infective Agents;Antiinfectives for Systemic Use;Antimetabolites;Antiviral Agents;Antivirals for Systemic Use;Carbohydrates;Chemical Actions and Uses;Direct Acting Antivirals;Glycosides;Molecular Mechanisms of Pharmacological Action;Noxae;Nucleic Acids, Nucleotides, and Nucleosides;Nucleosides;Nucleosides and Nucleotides Excl. Reverse Transcriptase Inhibitors;Pharmacologic Actions;Ribonucleosides;Therapeutic Uses;Toxic Actions","approved","DB00811","Purine metabolism"
"CHEBI:16856","GLO1","CHEBI:49662","glutathione","indometacin","Acetic Acid Derivatives and Related Substances;Analgesics;Analgesics, Non-Narcotic;Anti-Inflammatory Agents;Anti-Inflammatory Agents, Non-Steroidal;Antiinflammatory Agents, Non-Steroids;Antiinflammatory and Antirheumatic Products;Antiinflammatory and Antirheumatic Products, Non-Steroids;Antiinflammatory Preparations, Non-Steroids for Topical Use;Antirheumatic Agents;Cardiac Therapy;Cardiovascular Agents;Cardiovascular System;Central Nervous System Agents;Chemical Actions and Uses;Cyclooxygenase Inhibitors;Cytochrome P-450 CYP2C19 Inhibitors;Cytochrome P-450 CYP2C19 Substrates;Cytochrome P-450 CYP2C9 Substrates;Enzyme Inhibitors;Gout Suppressants;Heterocyclic Compounds;Heterocyclic Compounds, 2-Ring;Indoles;Molecular Mechanisms of Pharmacological Action;Musculo-Skeletal System;Ophthalmologicals;P-glycoprotein/ABCB1 Inhibitors;P-glycoprotein/ABCB1 Substrates;Peripheral Nervous System Agents;Pharmacologic Actions;Physiological Effects of Drugs;Reproductive Control Agents;Sensory Organs;Sensory System Agents;Therapeutic Uses;Tocolytic Agents;Topical Products for Joint and Muscular Pain;UGT1A1 Inhibitors","approved;investigational","DB00328","Pyruvate metabolism"
"CHEBI:16958","ABAT","CHEBI:63638","beta-alanine","vigabatrin","Acids, Acyclic;Amino Acids;Amino Acids, Peptides, and Proteins;Aminobutyrates;Anticonvulsants;Butyrates;Carboxylic Acids;Central Nervous System Agents;Central Nervous System Depressants;Chemical Actions and Uses;Enzyme Inhibitors;Fatty Acid Derivatives;Fatty Acids;Fatty Acids, Volatile;GABA Agents;gamma-Aminobutyric Acid;Lipids;Molecular Mechanisms of Pharmacological Action;Nervous System;Neurotransmitter Agents;Organic Chemicals;Pharmacologic Actions;Physiological Effects of Drugs;Therapeutic Uses","approved","DB01080","Propanoate metabolism;beta-Alanine metabolism"
"CHEBI:16958","ABAT","CHEBI:39867","beta-alanine","valproic acid","Acids, Acyclic;Anticonvulsants;Antimanic Agents;Carboxylic Acids;Central Nervous System Agents;Central Nervous System Depressants;Chemical Actions and Uses;Cytochrome P-450 CYP1A2 Inhibitors;Cytochrome P-450 CYP2A6 Inducers;Cytochrome P-450 CYP2A6 Substrates;Cytochrome P-450 CYP2B6 Substrates;Cytochrome P-450 CYP2C19 Inhibitors;Cytochrome P-450 CYP2C19 Substrates;Cytochrome P-450 CYP2C8 Inhibitors;Cytochrome P-450 CYP2C9 Inhibitors;Cytochrome P-450 CYP2C9 Inhibitors (moderate);Cytochrome P-450 CYP2C9 Substrates;Cytochrome P-450 CYP3A Inhibitors;Enzyme Inhibitors;Fatty Acid Derivatives;Fatty Acids;Fatty Acids, Volatile;GABA Agents;Lipids;Molecular Mechanisms of Pharmacological Action;Nervous System;Neurotransmitter Agents;Organic Chemicals;Pentanoic Acids;Pharmacologic Actions;Physiological Effects of Drugs;Psychotropic Drugs;Therapeutic Uses;Tranquilizing Agents;Valerates","approved;investigational","DB00313","Propanoate metabolism;beta-Alanine metabolism"
"CHEBI:16962","AKR1D1","CHEBI:5062","cortisone","finasteride","5-alpha Reductase Inhibitors;Alpha-Adrenoreceptor Antagonists;Androstanes;Androstenes;Azasteroids;Chemical Actions and Uses;Cytochrome P-450 CYP3A4 Substrates;Dermatologicals;Drugs Used in Benign Prostatic Hypertrophy;Enzyme Inhibitors;Genito Urinary System and Sex Hormones;Hormone Antagonists;Hormones, Hormone Substitutes, and Hormone Antagonists;Molecular Mechanisms of Pharmacological Action;Pharmacologic Actions;Physiological Effects of Drugs;Polycyclic Compounds;Steroid Synthesis Inhibitors;Steroids;Steroids, Heterocyclic;Testosterone-5-Alpha Reductase Inhibitors;Therapeutic Uses;Urological Agents;Urologicals","approved","DB01216","Steroid hormone biosynthesis"
"CHEBI:16977","ABAT","CHEBI:39867","L-alanine","valproic acid","Acids, Acyclic;Anticonvulsants;Antimanic Agents;Carboxylic Acids;Central Nervous System Agents;Central Nervous System Depressants;Chemical Actions and Uses;Cytochrome P-450 CYP1A2 Inhibitors;Cytochrome P-450 CYP2A6 Inducers;Cytochrome P-450 CYP2A6 Substrates;Cytochrome P-450 CYP2B6 Substrates;Cytochrome P-450 CYP2C19 Inhibitors;Cytochrome P-450 CYP2C19 Substrates;Cytochrome P-450 CYP2C8 Inhibitors;Cytochrome P-450 CYP2C9 Inhibitors;Cytochrome P-450 CYP2C9 Inhibitors (moderate);Cytochrome P-450 CYP2C9 Substrates;Cytochrome P-450 CYP3A Inhibitors;Enzyme Inhibitors;Fatty Acid Derivatives;Fatty Acids;Fatty Acids, Volatile;GABA Agents;Lipids;Molecular Mechanisms of Pharmacological Action;Nervous System;Neurotransmitter Agents;Organic Chemicals;Pentanoic Acids;Pharmacologic Actions;Physiological Effects of Drugs;Psychotropic Drugs;Therapeutic Uses;Tranquilizing Agents;Valerates","approved;investigational","DB00313",""
"CHEBI:16977","ABAT","CHEBI:63638","L-alanine","vigabatrin","Acids, Acyclic;Amino Acids;Amino Acids, Peptides, and Proteins;Aminobutyrates;Anticonvulsants;Butyrates;Carboxylic Acids;Central Nervous System Agents;Central Nervous System Depressants;Chemical Actions and Uses;Enzyme Inhibitors;Fatty Acid Derivatives;Fatty Acids;Fatty Acids, Volatile;GABA Agents;gamma-Aminobutyric Acid;Lipids;Molecular Mechanisms of Pharmacological Action;Nervous System;Neurotransmitter Agents;Organic Chemicals;Pharmacologic Actions;Physiological Effects of Drugs;Therapeutic Uses","approved","DB01080",""
"CHEBI:17154","PNP","CHEBI:490877","nicotinamide","didanosine","Anti-HIV Agents;Anti-Infective Agents;Anti-Retroviral Agents;Antiinfectives for Systemic Use;Antimetabolites;Antiviral Agents;Antivirals for Systemic Use;Carbohydrates;Chemical Actions and Uses;Deoxyribonucleosides;Dideoxynucleosides;Direct Acting Antivirals;Enzyme Inhibitors;Glycosides;Heterocyclic Compounds;Heterocyclic Compounds, 2-Ring;Inosine;Molecular Mechanisms of Pharmacological Action;Noxae;Nucleic Acid Synthesis Inhibitors;Nucleic Acids, Nucleotides, and Nucleosides;Nucleoside and Nucleotide Reverse Transcriptase Inhibitors;Nucleoside Reverse Transcriptase Inhibitors;Nucleosides;OAT3 Substrates;Pharmacologic Actions;Purine Nucleosides;Purines;Reverse Transcriptase Inhibitors;Ribonucleosides;Therapeutic Uses;Toxic Actions","approved","DB00900","Nicotinate and nicotinamide metabolism"
"CHEBI:17154","PNP","CHEBI:567361","nicotinamide","cladribine","2-Chloroadenosine;Adenosine;Antimetabolites;Antineoplastic Agents;Antineoplastic and Immunomodulating Agents;BCRP/ABCG2 Substrates;Carbohydrates;Chemical Actions and Uses;Deoxyadenosines;Deoxyribonucleosides;Glycosides;Heterocyclic Compounds;Heterocyclic Compounds, 2-Ring;Immunologic Factors;Immunosuppressive Agents;Myelosuppressive Agents;Nucleic Acids, Nucleotides, and Nucleosides;Nucleosides;OCT2 Substrates;Pharmacologic Actions;Physiological Effects of Drugs;Purine Analogues;Purine Nucleosides;Purines;Ribonucleosides;Therapeutic Uses","approved;investigational","DB00242","Nicotinate and nicotinamide metabolism"
"CHEBI:17172","PNP","CHEBI:490877","2'-deoxyguanosine","didanosine","Anti-HIV Agents;Anti-Infective Agents;Anti-Retroviral Agents;Antiinfectives for Systemic Use;Antimetabolites;Antiviral Agents;Antivirals for Systemic Use;Carbohydrates;Chemical Actions and Uses;Deoxyribonucleosides;Dideoxynucleosides;Direct Acting Antivirals;Enzyme Inhibitors;Glycosides;Heterocyclic Compounds;Heterocyclic Compounds, 2-Ring;Inosine;Molecular Mechanisms of Pharmacological Action;Noxae;Nucleic Acid Synthesis Inhibitors;Nucleic Acids, Nucleotides, and Nucleosides;Nucleoside and Nucleotide Reverse Transcriptase Inhibitors;Nucleoside Reverse Transcriptase Inhibitors;Nucleosides;OAT3 Substrates;Pharmacologic Actions;Purine Nucleosides;Purines;Reverse Transcriptase Inhibitors;Ribonucleosides;Therapeutic Uses;Toxic Actions","approved","DB00900","Purine metabolism"
"CHEBI:17172","PNP","CHEBI:567361","2'-deoxyguanosine","cladribine","2-Chloroadenosine;Adenosine;Antimetabolites;Antineoplastic Agents;Antineoplastic and Immunomodulating Agents;BCRP/ABCG2 Substrates;Carbohydrates;Chemical Actions and Uses;Deoxyadenosines;Deoxyribonucleosides;Glycosides;Heterocyclic Compounds;Heterocyclic Compounds, 2-Ring;Immunologic Factors;Immunosuppressive Agents;Myelosuppressive Agents;Nucleic Acids, Nucleotides, and Nucleosides;Nucleosides;OCT2 Substrates;Pharmacologic Actions;Physiological Effects of Drugs;Purine Analogues;Purine Nucleosides;Purines;Ribonucleosides;Therapeutic Uses","approved;investigational","DB00242","Purine metabolism"
"CHEBI:17172","NT5C2","CHEBI:63580","2'-deoxyguanosine","ribavirin","Anti-Infective Agents;Antiinfectives for Systemic Use;Antimetabolites;Antiviral Agents;Antivirals for Systemic Use;Carbohydrates;Chemical Actions and Uses;Direct Acting Antivirals;Glycosides;Molecular Mechanisms of Pharmacological Action;Noxae;Nucleic Acids, Nucleotides, and Nucleosides;Nucleosides;Nucleosides and Nucleotides Excl. Reverse Transcriptase Inhibitors;Pharmacologic Actions;Ribonucleosides;Therapeutic Uses;Toxic Actions","approved","DB00811","Purine metabolism"
"CHEBI:17202","IMPDH2","CHEBI:168396","IMP","mycophenolic acid","Acids, Acyclic;Anti-Inflammatory Agents, Non-Steroidal;Antibiotics, Antineoplastic;Antineoplastic Agents;Antineoplastic and Immunomodulating Agents;Caproates;Carboxylic Acids;Chemical Actions and Uses;Enzyme Inhibitors;Fatty Acids;Fatty Acids, Volatile;Immunologic Factors;Immunosuppressive Agents;IMP Dehydrogenase, antagonists & inhibitors;Lipids;Molecular Mechanisms of Pharmacological Action;Organic Chemicals;Pharmacologic Actions;Physiological Effects of Drugs;Selective Immunosuppressants;Therapeutic Uses","approved","DB01024","Purine metabolism"
"CHEBI:17202","IMPDH1","CHEBI:8764","IMP","mycophenolate mofetil","Anti-Inflammatory Agents, Non-Steroidal;BCRP/ABCG2 Substrates;Chemical Actions and Uses;Cytochrome P-450 CYP2C8 Substrates;Cytochrome P-450 CYP3A4 Substrates;Enzyme Inhibitors;Immunologic Factors;Immunosuppressive Agents;IMP Dehydrogenase, antagonists & inhibitors;Molecular Mechanisms of Pharmacological Action;OATP1B1/SLCO1B1 Substrates;P-glycoprotein/ABCB1 Substrates;Pharmacologic Actions;Physiological Effects of Drugs","approved;investigational","DB00688","Purine metabolism"
"CHEBI:17202","IMPDH1","CHEBI:63580","IMP","ribavirin","Anti-Infective Agents;Antiinfectives for Systemic Use;Antimetabolites;Antiviral Agents;Antivirals for Systemic Use;Carbohydrates;Chemical Actions and Uses;Direct Acting Antivirals;Glycosides;Molecular Mechanisms of Pharmacological Action;Noxae;Nucleic Acids, Nucleotides, and Nucleosides;Nucleosides;Nucleosides and Nucleotides Excl. Reverse Transcriptase Inhibitors;Pharmacologic Actions;Ribonucleosides;Therapeutic Uses;Toxic Actions","approved","DB00811","Purine metabolism"
"CHEBI:17202","IMPDH1","CHEBI:168396","IMP","mycophenolic acid","Acids, Acyclic;Anti-Inflammatory Agents, Non-Steroidal;Antibiotics, Antineoplastic;Antineoplastic Agents;Antineoplastic and Immunomodulating Agents;Caproates;Carboxylic Acids;Chemical Actions and Uses;Enzyme Inhibitors;Fatty Acids;Fatty Acids, Volatile;Immunologic Factors;Immunosuppressive Agents;IMP Dehydrogenase, antagonists & inhibitors;Lipids;Molecular Mechanisms of Pharmacological Action;Organic Chemicals;Pharmacologic Actions;Physiological Effects of Drugs;Selective Immunosuppressants;Therapeutic Uses","approved","DB01024","Purine metabolism"
"CHEBI:17202","IMPDH1","CHEBI:50667","IMP","Mercaptopurine;mercaptopurine","Antimetabolites;Antimetabolites, Antineoplastic;Antineoplastic Agents;Antineoplastic and Immunomodulating Agents;Chemical Actions and Uses;Enzyme Inhibitors;Heterocyclic Compounds;Heterocyclic Compounds, 2-Ring;Immunologic Factors;Immunosuppressive Agents;Inorganic Chemicals;Molecular Mechanisms of Pharmacological Action;Myelosuppressive Agents;Noxae;Nucleic Acid Synthesis Inhibitors;Organic Chemicals;Pharmacologic Actions;Physiological Effects of Drugs;Purine Analogues;Purines;Sulfhydryl Compounds;Sulfur Compounds;Therapeutic Uses;Thiopurine Analogs;Toxic Actions","approved","DB01033","Purine metabolism"
"CHEBI:17202","IMPDH1","CHEBI:2208","IMP","Mercaptopurine;purine-6-thiol","Antimetabolites;Antimetabolites, Antineoplastic;Antineoplastic Agents;Antineoplastic and Immunomodulating Agents;Chemical Actions and Uses;Enzyme Inhibitors;Heterocyclic Compounds;Heterocyclic Compounds, 2-Ring;Immunologic Factors;Immunosuppressive Agents;Inorganic Chemicals;Molecular Mechanisms of Pharmacological Action;Myelosuppressive Agents;Noxae;Nucleic Acid Synthesis Inhibitors;Organic Chemicals;Pharmacologic Actions;Physiological Effects of Drugs;Purine Analogues;Purines;Sulfhydryl Compounds;Sulfur Compounds;Therapeutic Uses;Thiopurine Analogs;Toxic Actions","approved","DB01033","Purine metabolism"
"CHEBI:17202","IMPDH2","CHEBI:50667","IMP","Mercaptopurine;mercaptopurine","Antimetabolites;Antimetabolites, Antineoplastic;Antineoplastic Agents;Antineoplastic and Immunomodulating Agents;Chemical Actions and Uses;Enzyme Inhibitors;Heterocyclic Compounds;Heterocyclic Compounds, 2-Ring;Immunologic Factors;Immunosuppressive Agents;Inorganic Chemicals;Molecular Mechanisms of Pharmacological Action;Myelosuppressive Agents;Noxae;Nucleic Acid Synthesis Inhibitors;Organic Chemicals;Pharmacologic Actions;Physiological Effects of Drugs;Purine Analogues;Purines;Sulfhydryl Compounds;Sulfur Compounds;Therapeutic Uses;Thiopurine Analogs;Toxic Actions","approved","DB01033","Purine metabolism"
"CHEBI:17202","HPRT1","CHEBI:50667","IMP","Mercaptopurine;mercaptopurine","Antimetabolites;Antimetabolites, Antineoplastic;Antineoplastic Agents;Antineoplastic and Immunomodulating Agents;Chemical Actions and Uses;Enzyme Inhibitors;Heterocyclic Compounds;Heterocyclic Compounds, 2-Ring;Immunologic Factors;Immunosuppressive Agents;Inorganic Chemicals;Molecular Mechanisms of Pharmacological Action;Myelosuppressive Agents;Noxae;Nucleic Acid Synthesis Inhibitors;Organic Chemicals;Pharmacologic Actions;Physiological Effects of Drugs;Purine Analogues;Purines;Sulfhydryl Compounds;Sulfur Compounds;Therapeutic Uses;Thiopurine Analogs;Toxic Actions","approved","DB01033","Purine metabolism"
"CHEBI:17202","HPRT1","CHEBI:2948","IMP","azathioprine","6-Mercaptopurine;Antimetabolites;Antimetabolites, Antineoplastic;Antineoplastic Agents;Antineoplastic and Immunomodulating Agents;Antirheumatic Agents;Carbohydrates;Chemical Actions and Uses;Glycosides;Heterocyclic Compounds;Heterocyclic Compounds, 2-Ring;Immunologic Factors;Immunosuppressive Agents;Inorganic Chemicals;Molecular Mechanisms of Pharmacological Action;Noxae;Nucleic Acids, Nucleotides, and Nucleosides;Nucleosides;Organic Chemicals;Pharmacologic Actions;Physiological Effects of Drugs;Purines;Sulfhydryl Compounds;Sulfur Compounds;Therapeutic Uses;Thionucleosides;Thiopurine Analogs;Toxic Actions","approved","DB00993","Purine metabolism"
"CHEBI:17202","HPRT1","CHEBI:2208","IMP","Mercaptopurine;purine-6-thiol","Antimetabolites;Antimetabolites, Antineoplastic;Antineoplastic Agents;Antineoplastic and Immunomodulating Agents;Chemical Actions and Uses;Enzyme Inhibitors;Heterocyclic Compounds;Heterocyclic Compounds, 2-Ring;Immunologic Factors;Immunosuppressive Agents;Inorganic Chemicals;Molecular Mechanisms of Pharmacological Action;Myelosuppressive Agents;Noxae;Nucleic Acid Synthesis Inhibitors;Organic Chemicals;Pharmacologic Actions;Physiological Effects of Drugs;Purine Analogues;Purines;Sulfhydryl Compounds;Sulfur Compounds;Therapeutic Uses;Thiopurine Analogs;Toxic Actions","approved","DB01033","Purine metabolism"
"CHEBI:17202","IMPDH2","CHEBI:2208","IMP","Mercaptopurine;purine-6-thiol","Antimetabolites;Antimetabolites, Antineoplastic;Antineoplastic Agents;Antineoplastic and Immunomodulating Agents;Chemical Actions and Uses;Enzyme Inhibitors;Heterocyclic Compounds;Heterocyclic Compounds, 2-Ring;Immunologic Factors;Immunosuppressive Agents;Inorganic Chemicals;Molecular Mechanisms of Pharmacological Action;Myelosuppressive Agents;Noxae;Nucleic Acid Synthesis Inhibitors;Organic Chemicals;Pharmacologic Actions;Physiological Effects of Drugs;Purine Analogues;Purines;Sulfhydryl Compounds;Sulfur Compounds;Therapeutic Uses;Thiopurine Analogs;Toxic Actions","approved","DB01033","Purine metabolism"
"CHEBI:17202","IMPDH2","CHEBI:8764","IMP","mycophenolate mofetil","Anti-Inflammatory Agents, Non-Steroidal;BCRP/ABCG2 Substrates;Chemical Actions and Uses;Cytochrome P-450 CYP2C8 Substrates;Cytochrome P-450 CYP3A4 Substrates;Enzyme Inhibitors;Immunologic Factors;Immunosuppressive Agents;IMP Dehydrogenase, antagonists & inhibitors;Molecular Mechanisms of Pharmacological Action;OATP1B1/SLCO1B1 Substrates;P-glycoprotein/ABCB1 Substrates;Pharmacologic Actions;Physiological Effects of Drugs","approved;investigational","DB00688","Purine metabolism"
"CHEBI:17239","RRM1","CHEBI:175901","CDP","Gemcitabine;gemcitabine","Anti-Infective Agents;Antimetabolites;Antimetabolites, Antineoplastic;Antineoplastic Agents;Antineoplastic and Immunomodulating Agents;Antiviral Agents;Chemical Actions and Uses;Enzyme Inhibitors;Immunologic Factors;Immunosuppressive Agents;Molecular Mechanisms of Pharmacological Action;Myelosuppressive Agents;Noxae;P-glycoprotein/ABCB1 Substrates;Pharmacologic Actions;Physiological Effects of Drugs;Pyrimidine Analogues;Radiation-Sensitizing Agents;Ribonucleotide Reductases, antagonists & inhibitors;Therapeutic Uses;Toxic Actions","approved","DB00441","Pyrimidine metabolism"
"CHEBI:17239","RRM1","CHEBI:44423","CDP","hydroxyurea","Antineoplastic Agents;Antineoplastic and Immunomodulating Agents;Antisickling Agents;Chemical Actions and Uses;Cytochrome P-450 CYP2D6 Inhibitors;Enzyme Inhibitors;Hematologic Agents;Immunosuppressive Agents;Molecular Mechanisms of Pharmacological Action;Myelosuppressive Agents;Nucleic Acid Synthesis Inhibitors;Organic Chemicals;Pharmacologic Actions;Therapeutic Uses;Urea","approved","DB01005","Pyrimidine metabolism"
"CHEBI:17239","RRM1","CHEBI:681569","CDP","clofarabine","Antimetabolites;Antimetabolites, Antineoplastic;Antineoplastic Agents;Antineoplastic and Immunomodulating Agents;BCRP/ABCG2 Substrates;Chemical Actions and Uses;Immunosuppressive Agents;Molecular Mechanisms of Pharmacological Action;Myelosuppressive Agents;Noxae;Pharmacologic Actions;Purine Analogues;Therapeutic Uses;Toxic Actions","approved;investigational","DB00631","Pyrimidine metabolism"
"CHEBI:17239","RRM1","CHEBI:567361","CDP","cladribine","2-Chloroadenosine;Adenosine;Antimetabolites;Antineoplastic Agents;Antineoplastic and Immunomodulating Agents;BCRP/ABCG2 Substrates;Carbohydrates;Chemical Actions and Uses;Deoxyadenosines;Deoxyribonucleosides;Glycosides;Heterocyclic Compounds;Heterocyclic Compounds, 2-Ring;Immunologic Factors;Immunosuppressive Agents;Myelosuppressive Agents;Nucleic Acids, Nucleotides, and Nucleosides;Nucleosides;OCT2 Substrates;Pharmacologic Actions;Physiological Effects of Drugs;Purine Analogues;Purine Nucleosides;Purines;Ribonucleosides;Therapeutic Uses","approved;investigational","DB00242","Pyrimidine metabolism"
"CHEBI:17239","RRM1","CHEBI:63599","CDP","fludarabine phosphate","Antimetabolites;Antimetabolites, Antineoplastic;Antineoplastic Agents;Antineoplastic and Immunomodulating Agents;Chemical Actions and Uses;DNA (Cytosine-5-)-Methyltransferase, antagonists & inhibitors;Enzyme Inhibitors;Immunologic Factors;Immunosuppressive Agents;Molecular Mechanisms of Pharmacological Action;Myeloablative Agonists;Myelosuppressive Agents;Noxae;Pharmacologic Actions;Physiological Effects of Drugs;Purine Analogues;Therapeutic Uses;Toxic Actions","approved","DB01073","Pyrimidine metabolism"
"CHEBI:17345","HPRT1","CHEBI:50667","GMP","Mercaptopurine;mercaptopurine","Antimetabolites;Antimetabolites, Antineoplastic;Antineoplastic Agents;Antineoplastic and Immunomodulating Agents;Chemical Actions and Uses;Enzyme Inhibitors;Heterocyclic Compounds;Heterocyclic Compounds, 2-Ring;Immunologic Factors;Immunosuppressive Agents;Inorganic Chemicals;Molecular Mechanisms of Pharmacological Action;Myelosuppressive Agents;Noxae;Nucleic Acid Synthesis Inhibitors;Organic Chemicals;Pharmacologic Actions;Physiological Effects of Drugs;Purine Analogues;Purines;Sulfhydryl Compounds;Sulfur Compounds;Therapeutic Uses;Thiopurine Analogs;Toxic Actions","approved","DB01033","Purine metabolism"
"CHEBI:17345","HPRT1","CHEBI:2948","GMP","azathioprine","6-Mercaptopurine;Antimetabolites;Antimetabolites, Antineoplastic;Antineoplastic Agents;Antineoplastic and Immunomodulating Agents;Antirheumatic Agents;Carbohydrates;Chemical Actions and Uses;Glycosides;Heterocyclic Compounds;Heterocyclic Compounds, 2-Ring;Immunologic Factors;Immunosuppressive Agents;Inorganic Chemicals;Molecular Mechanisms of Pharmacological Action;Noxae;Nucleic Acids, Nucleotides, and Nucleosides;Nucleosides;Organic Chemicals;Pharmacologic Actions;Physiological Effects of Drugs;Purines;Sulfhydryl Compounds;Sulfur Compounds;Therapeutic Uses;Thionucleosides;Thiopurine Analogs;Toxic Actions","approved","DB00993","Purine metabolism"
"CHEBI:17345","HPRT1","CHEBI:2208","GMP","Mercaptopurine;purine-6-thiol","Antimetabolites;Antimetabolites, Antineoplastic;Antineoplastic Agents;Antineoplastic and Immunomodulating Agents;Chemical Actions and Uses;Enzyme Inhibitors;Heterocyclic Compounds;Heterocyclic Compounds, 2-Ring;Immunologic Factors;Immunosuppressive Agents;Inorganic Chemicals;Molecular Mechanisms of Pharmacological Action;Myelosuppressive Agents;Noxae;Nucleic Acid Synthesis Inhibitors;Organic Chemicals;Pharmacologic Actions;Physiological Effects of Drugs;Purine Analogues;Purines;Sulfhydryl Compounds;Sulfur Compounds;Therapeutic Uses;Thiopurine Analogs;Toxic Actions","approved","DB01033","Purine metabolism"
"CHEBI:17347","AKR1D1","CHEBI:5062","testosterone","finasteride","5-alpha Reductase Inhibitors;Alpha-Adrenoreceptor Antagonists;Androstanes;Androstenes;Azasteroids;Chemical Actions and Uses;Cytochrome P-450 CYP3A4 Substrates;Dermatologicals;Drugs Used in Benign Prostatic Hypertrophy;Enzyme Inhibitors;Genito Urinary System and Sex Hormones;Hormone Antagonists;Hormones, Hormone Substitutes, and Hormone Antagonists;Molecular Mechanisms of Pharmacological Action;Pharmacologic Actions;Physiological Effects of Drugs;Polycyclic Compounds;Steroid Synthesis Inhibitors;Steroids;Steroids, Heterocyclic;Testosterone-5-Alpha Reductase Inhibitors;Therapeutic Uses;Urological Agents;Urologicals","approved","DB01216","Steroid hormone biosynthesis"
"CHEBI:17368","HPRT1","CHEBI:2208","hypoxanthine","Mercaptopurine;purine-6-thiol","Antimetabolites;Antimetabolites, Antineoplastic;Antineoplastic Agents;Antineoplastic and Immunomodulating Agents;Chemical Actions and Uses;Enzyme Inhibitors;Heterocyclic Compounds;Heterocyclic Compounds, 2-Ring;Immunologic Factors;Immunosuppressive Agents;Inorganic Chemicals;Molecular Mechanisms of Pharmacological Action;Myelosuppressive Agents;Noxae;Nucleic Acid Synthesis Inhibitors;Organic Chemicals;Pharmacologic Actions;Physiological Effects of Drugs;Purine Analogues;Purines;Sulfhydryl Compounds;Sulfur Compounds;Therapeutic Uses;Thiopurine Analogs;Toxic Actions","approved","DB01033","Purine metabolism"
"CHEBI:17368","HPRT1","CHEBI:2948","hypoxanthine","azathioprine","6-Mercaptopurine;Antimetabolites;Antimetabolites, Antineoplastic;Antineoplastic Agents;Antineoplastic and Immunomodulating Agents;Antirheumatic Agents;Carbohydrates;Chemical Actions and Uses;Glycosides;Heterocyclic Compounds;Heterocyclic Compounds, 2-Ring;Immunologic Factors;Immunosuppressive Agents;Inorganic Chemicals;Molecular Mechanisms of Pharmacological Action;Noxae;Nucleic Acids, Nucleotides, and Nucleosides;Nucleosides;Organic Chemicals;Pharmacologic Actions;Physiological Effects of Drugs;Purines;Sulfhydryl Compounds;Sulfur Compounds;Therapeutic Uses;Thionucleosides;Thiopurine Analogs;Toxic Actions","approved","DB00993","Purine metabolism"
"CHEBI:17368","PNP","CHEBI:567361","hypoxanthine","cladribine","2-Chloroadenosine;Adenosine;Antimetabolites;Antineoplastic Agents;Antineoplastic and Immunomodulating Agents;BCRP/ABCG2 Substrates;Carbohydrates;Chemical Actions and Uses;Deoxyadenosines;Deoxyribonucleosides;Glycosides;Heterocyclic Compounds;Heterocyclic Compounds, 2-Ring;Immunologic Factors;Immunosuppressive Agents;Myelosuppressive Agents;Nucleic Acids, Nucleotides, and Nucleosides;Nucleosides;OCT2 Substrates;Pharmacologic Actions;Physiological Effects of Drugs;Purine Analogues;Purine Nucleosides;Purines;Ribonucleosides;Therapeutic Uses","approved;investigational","DB00242","Purine metabolism"
"CHEBI:17368","XDH","CHEBI:40279","hypoxanthine","allopurinol","Antigout Preparations;Antimetabolites;Antioxidants;Antirheumatic Agents;Chemical Actions and Uses;Enzyme Inhibitors;Free Radical Scavengers;Gout Suppressants;Heterocyclic Compounds;Heterocyclic Compounds, 2-Ring;Molecular Mechanisms of Pharmacological Action;Musculo-Skeletal System;Noxae;Pharmacologic Actions;Physiological Effects of Drugs;Preparations Inhibiting Uric Acid Production;Protective Agents;Purines;Specialty Uses of Chemicals;Therapeutic Uses;Toxic Actions;Xanthine Oxidase Inhibitors Inhibitors","approved","DB00437","Purine metabolism"
"CHEBI:17368","HPRT1","CHEBI:50667","hypoxanthine","Mercaptopurine;mercaptopurine","Antimetabolites;Antimetabolites, Antineoplastic;Antineoplastic Agents;Antineoplastic and Immunomodulating Agents;Chemical Actions and Uses;Enzyme Inhibitors;Heterocyclic Compounds;Heterocyclic Compounds, 2-Ring;Immunologic Factors;Immunosuppressive Agents;Inorganic Chemicals;Molecular Mechanisms of Pharmacological Action;Myelosuppressive Agents;Noxae;Nucleic Acid Synthesis Inhibitors;Organic Chemicals;Pharmacologic Actions;Physiological Effects of Drugs;Purine Analogues;Purines;Sulfhydryl Compounds;Sulfur Compounds;Therapeutic Uses;Thiopurine Analogs;Toxic Actions","approved","DB01033","Purine metabolism"
"CHEBI:17368","PNP","CHEBI:490877","hypoxanthine","didanosine","Anti-HIV Agents;Anti-Infective Agents;Anti-Retroviral Agents;Antiinfectives for Systemic Use;Antimetabolites;Antiviral Agents;Antivirals for Systemic Use;Carbohydrates;Chemical Actions and Uses;Deoxyribonucleosides;Dideoxynucleosides;Direct Acting Antivirals;Enzyme Inhibitors;Glycosides;Heterocyclic Compounds;Heterocyclic Compounds, 2-Ring;Inosine;Molecular Mechanisms of Pharmacological Action;Noxae;Nucleic Acid Synthesis Inhibitors;Nucleic Acids, Nucleotides, and Nucleosides;Nucleoside and Nucleotide Reverse Transcriptase Inhibitors;Nucleoside Reverse Transcriptase Inhibitors;Nucleosides;OAT3 Substrates;Pharmacologic Actions;Purine Nucleosides;Purines;Reverse Transcriptase Inhibitors;Ribonucleosides;Therapeutic Uses;Toxic Actions","approved","DB00900","Purine metabolism"
"CHEBI:17489","PDE3A","CHEBI:31401","3',5'-cyclic AMP","cilostazol","Anti-Asthmatic Agents;Autonomic Agents;Blood and Blood Forming Organs;Bronchodilator Agents;Cardiovascular Agents;Central Nervous System Agents;Chemical Actions and Uses;CYP3A4 Inhibitors (Weak);Cytochrome P-450 CYP1A2 Substrates;Cytochrome P-450 CYP2C19 Substrates;Cytochrome P-450 CYP2D6 Substrates;Cytochrome P-450 CYP3A4 Substrates;Enzyme Inhibitors;Fibrin Modulating Agents;Fibrinolytic Agents;Hematologic Agents;Molecular Mechanisms of Pharmacological Action;Neuroprotective Agents;Peripheral Nervous System Agents;Pharmacologic Actions;Phosphodiesterase 3 Inhibitors;Phosphodiesterase Inhibitors;Physiological Effects of Drugs;Platelet Aggregation Inhibitors;Platelet Aggregation Inhibitors Excl. Heparin;Protective Agents;Respiratory System Agents;Specialty Uses of Chemicals;Therapeutic Uses;Vasodilator Agents","approved","DB01166","Purine metabolism"
"CHEBI:17489","PDE5A","CHEBI:71940","3',5'-cyclic AMP","tadalafil","Carbolines;Cardiovascular Agents;Chemical Actions and Uses;Cytochrome P-450 CYP3A Inhibitors;Cytochrome P-450 CYP3A4 Substrates;Drugs Used in Erectile Dysfunction;Enzyme Inhibitors;Genito Urinary System and Sex Hormones;Heterocyclic Compounds;Heterocyclic Compounds, 1-Ring;Heterocyclic Compounds, 2-Ring;Heterocyclic Compounds, 3-Ring;Indoles;Molecular Mechanisms of Pharmacological Action;Pharmacologic Actions;Phosphodiesterase 5 Inhibitors;Phosphodiesterase Inhibitors;Pyridines;Therapeutic Uses;Urological Agents;Urologicals;Vasodilator Agents","approved;investigational","DB00820","Purine metabolism"
"CHEBI:17489","PDE1A","CHEBI:27732","3',5'-cyclic AMP","Caffeine;caffeine","Alkaloids;Apnea;Caffeine and Caffeine Containing Products;Central Nervous System Agents;Central Nervous System Stimulants;Chemical Actions and Uses;Combined Inhibitors of CYP3A4 and P-glycoprotein;Cytochrome P-450 CYP1A2 Inhibitors;Cytochrome P-450 CYP1A2 Inhibitors (moderate);Cytochrome P-450 CYP1A2 Substrates;Cytochrome P-450 CYP2C8 Substrates;Cytochrome P-450 CYP2C9 Substrates;Cytochrome P-450 CYP2D6 Substrates;Cytochrome P-450 CYP2E1 Substrates;Cytochrome P-450 CYP3A Inhibitors;Cytochrome P-450 CYP3A4 Substrates;Diagnostic Agents;Enzyme Inhibitors;Heterocyclic Compounds;Heterocyclic Compounds, 2-Ring;Molecular Mechanisms of Pharmacological Action;Nervous System;Neurotransmitter Agents;P-glycoprotein/ABCB1 Inhibitors;P-glycoprotein/ABCB1 Substrates;Pharmacologic Actions;Phosphodiesterase Inhibitors;Physiological Effects of Drugs;Psychoanaleptics;Psychostimulants, Agents Used for Adhd and Nootropics;Purinergic Agents;Purinergic Antagonists;Purinergic P1 Receptor Antagonists;Purines;Purinones;Tests for Gastric Secretion;Therapeutic Uses;Xanthine Derivatives;Xanthines","approved","DB00201","Purine metabolism"
"CHEBI:17489","PDE6G","CHEBI:46295","3',5'-cyclic AMP","vardenafil","Azoles;Cardiovascular Agents;Chemical Actions and Uses;Cytochrome P-450 CYP3A4 Substrates;Drugs Used in Erectile Dysfunction;Enzyme Inhibitors;Genito Urinary System and Sex Hormones;Heterocyclic Compounds;Heterocyclic Compounds, 1-Ring;Imidazoles;Molecular Mechanisms of Pharmacological Action;Pharmacologic Actions;Phosphodiesterase 5 Inhibitors;Phosphodiesterase Inhibitors;Piperazines;QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying);Therapeutic Uses;Urological Agents;Urologicals;Vasodilator Agents","approved","DB00862","Purine metabolism"
"CHEBI:17489","PDE11A","CHEBI:71940","3',5'-cyclic AMP","tadalafil","Carbolines;Cardiovascular Agents;Chemical Actions and Uses;Cytochrome P-450 CYP3A Inhibitors;Cytochrome P-450 CYP3A4 Substrates;Drugs Used in Erectile Dysfunction;Enzyme Inhibitors;Genito Urinary System and Sex Hormones;Heterocyclic Compounds;Heterocyclic Compounds, 1-Ring;Heterocyclic Compounds, 2-Ring;Heterocyclic Compounds, 3-Ring;Indoles;Molecular Mechanisms of Pharmacological Action;Pharmacologic Actions;Phosphodiesterase 5 Inhibitors;Phosphodiesterase Inhibitors;Pyridines;Therapeutic Uses;Urological Agents;Urologicals;Vasodilator Agents","approved;investigational","DB00820","Purine metabolism"
"CHEBI:17489","PDE6A","CHEBI:27732","3',5'-cyclic AMP","Caffeine;caffeine","Alkaloids;Apnea;Caffeine and Caffeine Containing Products;Central Nervous System Agents;Central Nervous System Stimulants;Chemical Actions and Uses;Combined Inhibitors of CYP3A4 and P-glycoprotein;Cytochrome P-450 CYP1A2 Inhibitors;Cytochrome P-450 CYP1A2 Inhibitors (moderate);Cytochrome P-450 CYP1A2 Substrates;Cytochrome P-450 CYP2C8 Substrates;Cytochrome P-450 CYP2C9 Substrates;Cytochrome P-450 CYP2D6 Substrates;Cytochrome P-450 CYP2E1 Substrates;Cytochrome P-450 CYP3A Inhibitors;Cytochrome P-450 CYP3A4 Substrates;Diagnostic Agents;Enzyme Inhibitors;Heterocyclic Compounds;Heterocyclic Compounds, 2-Ring;Molecular Mechanisms of Pharmacological Action;Nervous System;Neurotransmitter Agents;P-glycoprotein/ABCB1 Inhibitors;P-glycoprotein/ABCB1 Substrates;Pharmacologic Actions;Phosphodiesterase Inhibitors;Physiological Effects of Drugs;Psychoanaleptics;Psychostimulants, Agents Used for Adhd and Nootropics;Purinergic Agents;Purinergic Antagonists;Purinergic P1 Receptor Antagonists;Purines;Purinones;Tests for Gastric Secretion;Therapeutic Uses;Xanthine Derivatives;Xanthines","approved","DB00201","Purine metabolism"
"CHEBI:17489","PDE6H","CHEBI:46295","3',5'-cyclic AMP","vardenafil","Azoles;Cardiovascular Agents;Chemical Actions and Uses;Cytochrome P-450 CYP3A4 Substrates;Drugs Used in Erectile Dysfunction;Enzyme Inhibitors;Genito Urinary System and Sex Hormones;Heterocyclic Compounds;Heterocyclic Compounds, 1-Ring;Imidazoles;Molecular Mechanisms of Pharmacological Action;Pharmacologic Actions;Phosphodiesterase 5 Inhibitors;Phosphodiesterase Inhibitors;Piperazines;QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying);Therapeutic Uses;Urological Agents;Urologicals;Vasodilator Agents","approved","DB00862","Purine metabolism"
"CHEBI:17489","PDE6B","CHEBI:27732","3',5'-cyclic AMP","Caffeine;caffeine","Alkaloids;Apnea;Caffeine and Caffeine Containing Products;Central Nervous System Agents;Central Nervous System Stimulants;Chemical Actions and Uses;Combined Inhibitors of CYP3A4 and P-glycoprotein;Cytochrome P-450 CYP1A2 Inhibitors;Cytochrome P-450 CYP1A2 Inhibitors (moderate);Cytochrome P-450 CYP1A2 Substrates;Cytochrome P-450 CYP2C8 Substrates;Cytochrome P-450 CYP2C9 Substrates;Cytochrome P-450 CYP2D6 Substrates;Cytochrome P-450 CYP2E1 Substrates;Cytochrome P-450 CYP3A Inhibitors;Cytochrome P-450 CYP3A4 Substrates;Diagnostic Agents;Enzyme Inhibitors;Heterocyclic Compounds;Heterocyclic Compounds, 2-Ring;Molecular Mechanisms of Pharmacological Action;Nervous System;Neurotransmitter Agents;P-glycoprotein/ABCB1 Inhibitors;P-glycoprotein/ABCB1 Substrates;Pharmacologic Actions;Phosphodiesterase Inhibitors;Physiological Effects of Drugs;Psychoanaleptics;Psychostimulants, Agents Used for Adhd and Nootropics;Purinergic Agents;Purinergic Antagonists;Purinergic P1 Receptor Antagonists;Purines;Purinones;Tests for Gastric Secretion;Therapeutic Uses;Xanthine Derivatives;Xanthines","approved","DB00201","Purine metabolism"
"CHEBI:17489","PDE9A","CHEBI:27732","3',5'-cyclic AMP","Caffeine;caffeine","Alkaloids;Apnea;Caffeine and Caffeine Containing Products;Central Nervous System Agents;Central Nervous System Stimulants;Chemical Actions and Uses;Combined Inhibitors of CYP3A4 and P-glycoprotein;Cytochrome P-450 CYP1A2 Inhibitors;Cytochrome P-450 CYP1A2 Inhibitors (moderate);Cytochrome P-450 CYP1A2 Substrates;Cytochrome P-450 CYP2C8 Substrates;Cytochrome P-450 CYP2C9 Substrates;Cytochrome P-450 CYP2D6 Substrates;Cytochrome P-450 CYP2E1 Substrates;Cytochrome P-450 CYP3A Inhibitors;Cytochrome P-450 CYP3A4 Substrates;Diagnostic Agents;Enzyme Inhibitors;Heterocyclic Compounds;Heterocyclic Compounds, 2-Ring;Molecular Mechanisms of Pharmacological Action;Nervous System;Neurotransmitter Agents;P-glycoprotein/ABCB1 Inhibitors;P-glycoprotein/ABCB1 Substrates;Pharmacologic Actions;Phosphodiesterase Inhibitors;Physiological Effects of Drugs;Psychoanaleptics;Psychostimulants, Agents Used for Adhd and Nootropics;Purinergic Agents;Purinergic Antagonists;Purinergic P1 Receptor Antagonists;Purines;Purinones;Tests for Gastric Secretion;Therapeutic Uses;Xanthine Derivatives;Xanthines","approved","DB00201","Purine metabolism"
"CHEBI:17489","PDE4D","CHEBI:4728","3',5'-cyclic AMP","dyphylline","Alkaloids;Anti-Asthmatic Agents;Autonomic Agents;Bronchodilator Agents;Cardiovascular Agents;Chemical Actions and Uses;Drugs for Obstructive Airway Diseases;Enzyme Inhibitors;Heterocyclic Compounds;Heterocyclic Compounds, 2-Ring;Molecular Mechanisms of Pharmacological Action;Peripheral Nervous System Agents;Pharmacologic Actions;Phosphodiesterase Inhibitors;Physiological Effects of Drugs;Purines;Purinones;Respiratory System;Respiratory System Agents;Theophylline;Theophylline Derivatives;Therapeutic Uses;Vasodilator Agents;Xanthines;Xanthines and Adrenergics","approved","DB00651","Purine metabolism"
"CHEBI:17489","PDE5A","CHEBI:4653","3',5'-cyclic AMP","dipyridamole","Blood and Blood Forming Organs;Cardiovascular Agents;Chemical Actions and Uses;Enzyme Inhibitors;Fibrinolytic Agents;Hematologic Agents;Heterocyclic Compounds;Heterocyclic Compounds, 1-Ring;Hypotensive Agents;Molecular Mechanisms of Pharmacological Action;P-glycoprotein/ABCB1 Inhibitors;P-glycoprotein/ABCB1 Substrates;Pharmacologic Actions;Phosphodiesterase Inhibitors;Platelet Aggregation Inhibitors;Platelet Aggregation Inhibitors Excl. Heparin;Pyrimidines;Therapeutic Uses;Vasodilator Agents","approved","DB00975","Purine metabolism"
"CHEBI:17489","PDE4B","CHEBI:27732","3',5'-cyclic AMP","Caffeine;caffeine","Alkaloids;Apnea;Caffeine and Caffeine Containing Products;Central Nervous System Agents;Central Nervous System Stimulants;Chemical Actions and Uses;Combined Inhibitors of CYP3A4 and P-glycoprotein;Cytochrome P-450 CYP1A2 Inhibitors;Cytochrome P-450 CYP1A2 Inhibitors (moderate);Cytochrome P-450 CYP1A2 Substrates;Cytochrome P-450 CYP2C8 Substrates;Cytochrome P-450 CYP2C9 Substrates;Cytochrome P-450 CYP2D6 Substrates;Cytochrome P-450 CYP2E1 Substrates;Cytochrome P-450 CYP3A Inhibitors;Cytochrome P-450 CYP3A4 Substrates;Diagnostic Agents;Enzyme Inhibitors;Heterocyclic Compounds;Heterocyclic Compounds, 2-Ring;Molecular Mechanisms of Pharmacological Action;Nervous System;Neurotransmitter Agents;P-glycoprotein/ABCB1 Inhibitors;P-glycoprotein/ABCB1 Substrates;Pharmacologic Actions;Phosphodiesterase Inhibitors;Physiological Effects of Drugs;Psychoanaleptics;Psychostimulants, Agents Used for Adhd and Nootropics;Purinergic Agents;Purinergic Antagonists;Purinergic P1 Receptor Antagonists;Purines;Purinones;Tests for Gastric Secretion;Therapeutic Uses;Xanthine Derivatives;Xanthines","approved","DB00201","Purine metabolism"
"CHEBI:17489","PDE4B","CHEBI:28177","3',5'-cyclic AMP","theophylline","Alkaloids;Anti-Asthmatic Agents;Autonomic Agents;Bronchodilator Agents;Cardiovascular Agents;Chemical Actions and Uses;Cytochrome P-450 CYP1A2 Inhibitors;Cytochrome P-450 CYP1A2 Inhibitors (moderate);Cytochrome P-450 CYP1A2 Substrates;Cytochrome P-450 CYP2C8 Substrates;Cytochrome P-450 CYP2C9 Substrates;Cytochrome P-450 CYP2D6 Substrates;Cytochrome P-450 CYP2E1 Substrates;Cytochrome P-450 CYP3A4 Substrates;Drugs for Obstructive Airway Diseases;Enzyme Inhibitors;Heterocyclic Compounds;Heterocyclic Compounds, 2-Ring;Molecular Mechanisms of Pharmacological Action;Neurotransmitter Agents;Peripheral Nervous System Agents;Pharmacologic Actions;Phosphodiesterase Inhibitors;Physiological Effects of Drugs;Purinergic Agents;Purinergic Antagonists;Purinergic P1 Receptor Antagonists;Purines;Purinones;Respiratory System;Respiratory System Agents;Theophylline Derivatives;Therapeutic Uses;Vasodilator Agents;Xanthines;Xanthines and Adrenergics","approved","DB00277","Purine metabolism"
"CHEBI:17489","PDE4A","CHEBI:28177","3',5'-cyclic AMP","theophylline","Alkaloids;Anti-Asthmatic Agents;Autonomic Agents;Bronchodilator Agents;Cardiovascular Agents;Chemical Actions and Uses;Cytochrome P-450 CYP1A2 Inhibitors;Cytochrome P-450 CYP1A2 Inhibitors (moderate);Cytochrome P-450 CYP1A2 Substrates;Cytochrome P-450 CYP2C8 Substrates;Cytochrome P-450 CYP2C9 Substrates;Cytochrome P-450 CYP2D6 Substrates;Cytochrome P-450 CYP2E1 Substrates;Cytochrome P-450 CYP3A4 Substrates;Drugs for Obstructive Airway Diseases;Enzyme Inhibitors;Heterocyclic Compounds;Heterocyclic Compounds, 2-Ring;Molecular Mechanisms of Pharmacological Action;Neurotransmitter Agents;Peripheral Nervous System Agents;Pharmacologic Actions;Phosphodiesterase Inhibitors;Physiological Effects of Drugs;Purinergic Agents;Purinergic Antagonists;Purinergic P1 Receptor Antagonists;Purines;Purinones;Respiratory System;Respiratory System Agents;Theophylline Derivatives;Therapeutic Uses;Vasodilator Agents;Xanthines;Xanthines and Adrenergics","approved","DB00277","Purine metabolism"
"CHEBI:17489","PDE10A","CHEBI:27732","3',5'-cyclic AMP","Caffeine;caffeine","Alkaloids;Apnea;Caffeine and Caffeine Containing Products;Central Nervous System Agents;Central Nervous System Stimulants;Chemical Actions and Uses;Combined Inhibitors of CYP3A4 and P-glycoprotein;Cytochrome P-450 CYP1A2 Inhibitors;Cytochrome P-450 CYP1A2 Inhibitors (moderate);Cytochrome P-450 CYP1A2 Substrates;Cytochrome P-450 CYP2C8 Substrates;Cytochrome P-450 CYP2C9 Substrates;Cytochrome P-450 CYP2D6 Substrates;Cytochrome P-450 CYP2E1 Substrates;Cytochrome P-450 CYP3A Inhibitors;Cytochrome P-450 CYP3A4 Substrates;Diagnostic Agents;Enzyme Inhibitors;Heterocyclic Compounds;Heterocyclic Compounds, 2-Ring;Molecular Mechanisms of Pharmacological Action;Nervous System;Neurotransmitter Agents;P-glycoprotein/ABCB1 Inhibitors;P-glycoprotein/ABCB1 Substrates;Pharmacologic Actions;Phosphodiesterase Inhibitors;Physiological Effects of Drugs;Psychoanaleptics;Psychostimulants, Agents Used for Adhd and Nootropics;Purinergic Agents;Purinergic Antagonists;Purinergic P1 Receptor Antagonists;Purines;Purinones;Tests for Gastric Secretion;Therapeutic Uses;Xanthine Derivatives;Xanthines","approved","DB00201","Purine metabolism"
"CHEBI:17489","PDE3A","CHEBI:50567","3',5'-cyclic AMP","levosimendan","Anti-Arrhythmia Agents;Cardiac Stimulants Excl. Cardiac Glycosides;Cardiac Therapy;Cardiotonic Agents;Cardiovascular Agents;Cardiovascular System;Chemical Actions and Uses;Enzyme Inhibitors;Molecular Mechanisms of Pharmacological Action;Pharmacologic Actions;Phosphodiesterase Inhibitors;Physiological Effects of Drugs;Protective Agents;Specialty Uses of Chemicals;Therapeutic Uses;Vasodilator Agents","approved;investigational","DB00922","Purine metabolism"
"CHEBI:17489","PDE7B","CHEBI:4728","3',5'-cyclic AMP","dyphylline","Alkaloids;Anti-Asthmatic Agents;Autonomic Agents;Bronchodilator Agents;Cardiovascular Agents;Chemical Actions and Uses;Drugs for Obstructive Airway Diseases;Enzyme Inhibitors;Heterocyclic Compounds;Heterocyclic Compounds, 2-Ring;Molecular Mechanisms of Pharmacological Action;Peripheral Nervous System Agents;Pharmacologic Actions;Phosphodiesterase Inhibitors;Physiological Effects of Drugs;Purines;Purinones;Respiratory System;Respiratory System Agents;Theophylline;Theophylline Derivatives;Therapeutic Uses;Vasodilator Agents;Xanthines;Xanthines and Adrenergics","approved","DB00651","Purine metabolism"
"CHEBI:17489","PDE2A","CHEBI:27732","3',5'-cyclic AMP","Caffeine;caffeine","Alkaloids;Apnea;Caffeine and Caffeine Containing Products;Central Nervous System Agents;Central Nervous System Stimulants;Chemical Actions and Uses;Combined Inhibitors of CYP3A4 and P-glycoprotein;Cytochrome P-450 CYP1A2 Inhibitors;Cytochrome P-450 CYP1A2 Inhibitors (moderate);Cytochrome P-450 CYP1A2 Substrates;Cytochrome P-450 CYP2C8 Substrates;Cytochrome P-450 CYP2C9 Substrates;Cytochrome P-450 CYP2D6 Substrates;Cytochrome P-450 CYP2E1 Substrates;Cytochrome P-450 CYP3A Inhibitors;Cytochrome P-450 CYP3A4 Substrates;Diagnostic Agents;Enzyme Inhibitors;Heterocyclic Compounds;Heterocyclic Compounds, 2-Ring;Molecular Mechanisms of Pharmacological Action;Nervous System;Neurotransmitter Agents;P-glycoprotein/ABCB1 Inhibitors;P-glycoprotein/ABCB1 Substrates;Pharmacologic Actions;Phosphodiesterase Inhibitors;Physiological Effects of Drugs;Psychoanaleptics;Psychostimulants, Agents Used for Adhd and Nootropics;Purinergic Agents;Purinergic Antagonists;Purinergic P1 Receptor Antagonists;Purines;Purinones;Tests for Gastric Secretion;Therapeutic Uses;Xanthine Derivatives;Xanthines","approved","DB00201","Purine metabolism"
"CHEBI:17489","PDE7A","CHEBI:27732","3',5'-cyclic AMP","Caffeine;caffeine","Alkaloids;Apnea;Caffeine and Caffeine Containing Products;Central Nervous System Agents;Central Nervous System Stimulants;Chemical Actions and Uses;Combined Inhibitors of CYP3A4 and P-glycoprotein;Cytochrome P-450 CYP1A2 Inhibitors;Cytochrome P-450 CYP1A2 Inhibitors (moderate);Cytochrome P-450 CYP1A2 Substrates;Cytochrome P-450 CYP2C8 Substrates;Cytochrome P-450 CYP2C9 Substrates;Cytochrome P-450 CYP2D6 Substrates;Cytochrome P-450 CYP2E1 Substrates;Cytochrome P-450 CYP3A Inhibitors;Cytochrome P-450 CYP3A4 Substrates;Diagnostic Agents;Enzyme Inhibitors;Heterocyclic Compounds;Heterocyclic Compounds, 2-Ring;Molecular Mechanisms of Pharmacological Action;Nervous System;Neurotransmitter Agents;P-glycoprotein/ABCB1 Inhibitors;P-glycoprotein/ABCB1 Substrates;Pharmacologic Actions;Phosphodiesterase Inhibitors;Physiological Effects of Drugs;Psychoanaleptics;Psychostimulants, Agents Used for Adhd and Nootropics;Purinergic Agents;Purinergic Antagonists;Purinergic P1 Receptor Antagonists;Purines;Purinones;Tests for Gastric Secretion;Therapeutic Uses;Xanthine Derivatives;Xanthines","approved","DB00201","Purine metabolism"
"CHEBI:17489","PDE4C","CHEBI:27732","3',5'-cyclic AMP","Caffeine;caffeine","Alkaloids;Apnea;Caffeine and Caffeine Containing Products;Central Nervous System Agents;Central Nervous System Stimulants;Chemical Actions and Uses;Combined Inhibitors of CYP3A4 and P-glycoprotein;Cytochrome P-450 CYP1A2 Inhibitors;Cytochrome P-450 CYP1A2 Inhibitors (moderate);Cytochrome P-450 CYP1A2 Substrates;Cytochrome P-450 CYP2C8 Substrates;Cytochrome P-450 CYP2C9 Substrates;Cytochrome P-450 CYP2D6 Substrates;Cytochrome P-450 CYP2E1 Substrates;Cytochrome P-450 CYP3A Inhibitors;Cytochrome P-450 CYP3A4 Substrates;Diagnostic Agents;Enzyme Inhibitors;Heterocyclic Compounds;Heterocyclic Compounds, 2-Ring;Molecular Mechanisms of Pharmacological Action;Nervous System;Neurotransmitter Agents;P-glycoprotein/ABCB1 Inhibitors;P-glycoprotein/ABCB1 Substrates;Pharmacologic Actions;Phosphodiesterase Inhibitors;Physiological Effects of Drugs;Psychoanaleptics;Psychostimulants, Agents Used for Adhd and Nootropics;Purinergic Agents;Purinergic Antagonists;Purinergic P1 Receptor Antagonists;Purines;Purinones;Tests for Gastric Secretion;Therapeutic Uses;Xanthine Derivatives;Xanthines","approved","DB00201","Purine metabolism"
"CHEBI:17489","PDE1C","CHEBI:27732","3',5'-cyclic AMP","Caffeine;caffeine","Alkaloids;Apnea;Caffeine and Caffeine Containing Products;Central Nervous System Agents;Central Nervous System Stimulants;Chemical Actions and Uses;Combined Inhibitors of CYP3A4 and P-glycoprotein;Cytochrome P-450 CYP1A2 Inhibitors;Cytochrome P-450 CYP1A2 Inhibitors (moderate);Cytochrome P-450 CYP1A2 Substrates;Cytochrome P-450 CYP2C8 Substrates;Cytochrome P-450 CYP2C9 Substrates;Cytochrome P-450 CYP2D6 Substrates;Cytochrome P-450 CYP2E1 Substrates;Cytochrome P-450 CYP3A Inhibitors;Cytochrome P-450 CYP3A4 Substrates;Diagnostic Agents;Enzyme Inhibitors;Heterocyclic Compounds;Heterocyclic Compounds, 2-Ring;Molecular Mechanisms of Pharmacological Action;Nervous System;Neurotransmitter Agents;P-glycoprotein/ABCB1 Inhibitors;P-glycoprotein/ABCB1 Substrates;Pharmacologic Actions;Phosphodiesterase Inhibitors;Physiological Effects of Drugs;Psychoanaleptics;Psychostimulants, Agents Used for Adhd and Nootropics;Purinergic Agents;Purinergic Antagonists;Purinergic P1 Receptor Antagonists;Purines;Purinones;Tests for Gastric Secretion;Therapeutic Uses;Xanthine Derivatives;Xanthines","approved","DB00201","Purine metabolism"
"CHEBI:17489","PDE4C","CHEBI:4728","3',5'-cyclic AMP","dyphylline","Alkaloids;Anti-Asthmatic Agents;Autonomic Agents;Bronchodilator Agents;Cardiovascular Agents;Chemical Actions and Uses;Drugs for Obstructive Airway Diseases;Enzyme Inhibitors;Heterocyclic Compounds;Heterocyclic Compounds, 2-Ring;Molecular Mechanisms of Pharmacological Action;Peripheral Nervous System Agents;Pharmacologic Actions;Phosphodiesterase Inhibitors;Physiological Effects of Drugs;Purines;Purinones;Respiratory System;Respiratory System Agents;Theophylline;Theophylline Derivatives;Therapeutic Uses;Vasodilator Agents;Xanthines;Xanthines and Adrenergics","approved","DB00651","Purine metabolism"
"CHEBI:17489","PDE8B","CHEBI:27732","3',5'-cyclic AMP","Caffeine;caffeine","Alkaloids;Apnea;Caffeine and Caffeine Containing Products;Central Nervous System Agents;Central Nervous System Stimulants;Chemical Actions and Uses;Combined Inhibitors of CYP3A4 and P-glycoprotein;Cytochrome P-450 CYP1A2 Inhibitors;Cytochrome P-450 CYP1A2 Inhibitors (moderate);Cytochrome P-450 CYP1A2 Substrates;Cytochrome P-450 CYP2C8 Substrates;Cytochrome P-450 CYP2C9 Substrates;Cytochrome P-450 CYP2D6 Substrates;Cytochrome P-450 CYP2E1 Substrates;Cytochrome P-450 CYP3A Inhibitors;Cytochrome P-450 CYP3A4 Substrates;Diagnostic Agents;Enzyme Inhibitors;Heterocyclic Compounds;Heterocyclic Compounds, 2-Ring;Molecular Mechanisms of Pharmacological Action;Nervous System;Neurotransmitter Agents;P-glycoprotein/ABCB1 Inhibitors;P-glycoprotein/ABCB1 Substrates;Pharmacologic Actions;Phosphodiesterase Inhibitors;Physiological Effects of Drugs;Psychoanaleptics;Psychostimulants, Agents Used for Adhd and Nootropics;Purinergic Agents;Purinergic Antagonists;Purinergic P1 Receptor Antagonists;Purines;Purinones;Tests for Gastric Secretion;Therapeutic Uses;Xanthine Derivatives;Xanthines","approved","DB00201","Purine metabolism"
"CHEBI:17489","PDE7A","CHEBI:4728","3',5'-cyclic AMP","dyphylline","Alkaloids;Anti-Asthmatic Agents;Autonomic Agents;Bronchodilator Agents;Cardiovascular Agents;Chemical Actions and Uses;Drugs for Obstructive Airway Diseases;Enzyme Inhibitors;Heterocyclic Compounds;Heterocyclic Compounds, 2-Ring;Molecular Mechanisms of Pharmacological Action;Peripheral Nervous System Agents;Pharmacologic Actions;Phosphodiesterase Inhibitors;Physiological Effects of Drugs;Purines;Purinones;Respiratory System;Respiratory System Agents;Theophylline;Theophylline Derivatives;Therapeutic Uses;Vasodilator Agents;Xanthines;Xanthines and Adrenergics","approved","DB00651","Purine metabolism"
"CHEBI:17489","PDE4D","CHEBI:27732","3',5'-cyclic AMP","Caffeine;caffeine","Alkaloids;Apnea;Caffeine and Caffeine Containing Products;Central Nervous System Agents;Central Nervous System Stimulants;Chemical Actions and Uses;Combined Inhibitors of CYP3A4 and P-glycoprotein;Cytochrome P-450 CYP1A2 Inhibitors;Cytochrome P-450 CYP1A2 Inhibitors (moderate);Cytochrome P-450 CYP1A2 Substrates;Cytochrome P-450 CYP2C8 Substrates;Cytochrome P-450 CYP2C9 Substrates;Cytochrome P-450 CYP2D6 Substrates;Cytochrome P-450 CYP2E1 Substrates;Cytochrome P-450 CYP3A Inhibitors;Cytochrome P-450 CYP3A4 Substrates;Diagnostic Agents;Enzyme Inhibitors;Heterocyclic Compounds;Heterocyclic Compounds, 2-Ring;Molecular Mechanisms of Pharmacological Action;Nervous System;Neurotransmitter Agents;P-glycoprotein/ABCB1 Inhibitors;P-glycoprotein/ABCB1 Substrates;Pharmacologic Actions;Phosphodiesterase Inhibitors;Physiological Effects of Drugs;Psychoanaleptics;Psychostimulants, Agents Used for Adhd and Nootropics;Purinergic Agents;Purinergic Antagonists;Purinergic P1 Receptor Antagonists;Purines;Purinones;Tests for Gastric Secretion;Therapeutic Uses;Xanthine Derivatives;Xanthines","approved","DB00201","Purine metabolism"
"CHEBI:17489","PDE11A","CHEBI:27732","3',5'-cyclic AMP","Caffeine;caffeine","Alkaloids;Apnea;Caffeine and Caffeine Containing Products;Central Nervous System Agents;Central Nervous System Stimulants;Chemical Actions and Uses;Combined Inhibitors of CYP3A4 and P-glycoprotein;Cytochrome P-450 CYP1A2 Inhibitors;Cytochrome P-450 CYP1A2 Inhibitors (moderate);Cytochrome P-450 CYP1A2 Substrates;Cytochrome P-450 CYP2C8 Substrates;Cytochrome P-450 CYP2C9 Substrates;Cytochrome P-450 CYP2D6 Substrates;Cytochrome P-450 CYP2E1 Substrates;Cytochrome P-450 CYP3A Inhibitors;Cytochrome P-450 CYP3A4 Substrates;Diagnostic Agents;Enzyme Inhibitors;Heterocyclic Compounds;Heterocyclic Compounds, 2-Ring;Molecular Mechanisms of Pharmacological Action;Nervous System;Neurotransmitter Agents;P-glycoprotein/ABCB1 Inhibitors;P-glycoprotein/ABCB1 Substrates;Pharmacologic Actions;Phosphodiesterase Inhibitors;Physiological Effects of Drugs;Psychoanaleptics;Psychostimulants, Agents Used for Adhd and Nootropics;Purinergic Agents;Purinergic Antagonists;Purinergic P1 Receptor Antagonists;Purines;Purinones;Tests for Gastric Secretion;Therapeutic Uses;Xanthine Derivatives;Xanthines","approved","DB00201","Purine metabolism"
"CHEBI:17489","PDE5A","CHEBI:27732","3',5'-cyclic AMP","Caffeine;caffeine","Alkaloids;Apnea;Caffeine and Caffeine Containing Products;Central Nervous System Agents;Central Nervous System Stimulants;Chemical Actions and Uses;Combined Inhibitors of CYP3A4 and P-glycoprotein;Cytochrome P-450 CYP1A2 Inhibitors;Cytochrome P-450 CYP1A2 Inhibitors (moderate);Cytochrome P-450 CYP1A2 Substrates;Cytochrome P-450 CYP2C8 Substrates;Cytochrome P-450 CYP2C9 Substrates;Cytochrome P-450 CYP2D6 Substrates;Cytochrome P-450 CYP2E1 Substrates;Cytochrome P-450 CYP3A Inhibitors;Cytochrome P-450 CYP3A4 Substrates;Diagnostic Agents;Enzyme Inhibitors;Heterocyclic Compounds;Heterocyclic Compounds, 2-Ring;Molecular Mechanisms of Pharmacological Action;Nervous System;Neurotransmitter Agents;P-glycoprotein/ABCB1 Inhibitors;P-glycoprotein/ABCB1 Substrates;Pharmacologic Actions;Phosphodiesterase Inhibitors;Physiological Effects of Drugs;Psychoanaleptics;Psychostimulants, Agents Used for Adhd and Nootropics;Purinergic Agents;Purinergic Antagonists;Purinergic P1 Receptor Antagonists;Purines;Purinones;Tests for Gastric Secretion;Therapeutic Uses;Xanthine Derivatives;Xanthines","approved","DB00201","Purine metabolism"
"CHEBI:17489","PDE10A","CHEBI:28241","3',5'-cyclic AMP","papaverine","Alimentary Tract and Metabolism;Alkaloids;Benzylisoquinolines;Cardiovascular Agents;Chemical Actions and Uses;Drugs for Functional Gastrointestinal Disorders;Drugs Used in Erectile Dysfunction;Enzyme Inhibitors;Genito Urinary System and Sex Hormones;Heterocyclic Compounds;Heterocyclic Compounds, 2-Ring;Hypotensive Agents;Isoquinolines;Molecular Mechanisms of Pharmacological Action;Opiate Alkaloids;Papaverine and Derivatives;Pharmacologic Actions;Phosphodiesterase Inhibitors;Therapeutic Uses;Urological Agents;Urologicals;Vasodilator Agents","approved","DB01113","Purine metabolism"
"CHEBI:17489","PDE5A","CHEBI:28177","3',5'-cyclic AMP","theophylline","Alkaloids;Anti-Asthmatic Agents;Autonomic Agents;Bronchodilator Agents;Cardiovascular Agents;Chemical Actions and Uses;Cytochrome P-450 CYP1A2 Inhibitors;Cytochrome P-450 CYP1A2 Inhibitors (moderate);Cytochrome P-450 CYP1A2 Substrates;Cytochrome P-450 CYP2C8 Substrates;Cytochrome P-450 CYP2C9 Substrates;Cytochrome P-450 CYP2D6 Substrates;Cytochrome P-450 CYP2E1 Substrates;Cytochrome P-450 CYP3A4 Substrates;Drugs for Obstructive Airway Diseases;Enzyme Inhibitors;Heterocyclic Compounds;Heterocyclic Compounds, 2-Ring;Molecular Mechanisms of Pharmacological Action;Neurotransmitter Agents;Peripheral Nervous System Agents;Pharmacologic Actions;Phosphodiesterase Inhibitors;Physiological Effects of Drugs;Purinergic Agents;Purinergic Antagonists;Purinergic P1 Receptor Antagonists;Purines;Purinones;Respiratory System;Respiratory System Agents;Theophylline Derivatives;Therapeutic Uses;Vasodilator Agents;Xanthines;Xanthines and Adrenergics","approved","DB00277","Purine metabolism"
"CHEBI:17489","PDE4A","CHEBI:27732","3',5'-cyclic AMP","Caffeine;caffeine","Alkaloids;Apnea;Caffeine and Caffeine Containing Products;Central Nervous System Agents;Central Nervous System Stimulants;Chemical Actions and Uses;Combined Inhibitors of CYP3A4 and P-glycoprotein;Cytochrome P-450 CYP1A2 Inhibitors;Cytochrome P-450 CYP1A2 Inhibitors (moderate);Cytochrome P-450 CYP1A2 Substrates;Cytochrome P-450 CYP2C8 Substrates;Cytochrome P-450 CYP2C9 Substrates;Cytochrome P-450 CYP2D6 Substrates;Cytochrome P-450 CYP2E1 Substrates;Cytochrome P-450 CYP3A Inhibitors;Cytochrome P-450 CYP3A4 Substrates;Diagnostic Agents;Enzyme Inhibitors;Heterocyclic Compounds;Heterocyclic Compounds, 2-Ring;Molecular Mechanisms of Pharmacological Action;Nervous System;Neurotransmitter Agents;P-glycoprotein/ABCB1 Inhibitors;P-glycoprotein/ABCB1 Substrates;Pharmacologic Actions;Phosphodiesterase Inhibitors;Physiological Effects of Drugs;Psychoanaleptics;Psychostimulants, Agents Used for Adhd and Nootropics;Purinergic Agents;Purinergic Antagonists;Purinergic P1 Receptor Antagonists;Purines;Purinones;Tests for Gastric Secretion;Therapeutic Uses;Xanthine Derivatives;Xanthines","approved","DB00201","Purine metabolism"
"CHEBI:17489","PDE4A","CHEBI:4728","3',5'-cyclic AMP","dyphylline","Alkaloids;Anti-Asthmatic Agents;Autonomic Agents;Bronchodilator Agents;Cardiovascular Agents;Chemical Actions and Uses;Drugs for Obstructive Airway Diseases;Enzyme Inhibitors;Heterocyclic Compounds;Heterocyclic Compounds, 2-Ring;Molecular Mechanisms of Pharmacological Action;Peripheral Nervous System Agents;Pharmacologic Actions;Phosphodiesterase Inhibitors;Physiological Effects of Drugs;Purines;Purinones;Respiratory System;Respiratory System Agents;Theophylline;Theophylline Derivatives;Therapeutic Uses;Vasodilator Agents;Xanthines;Xanthines and Adrenergics","approved","DB00651","Purine metabolism"
"CHEBI:17489","PDE7B","CHEBI:27732","3',5'-cyclic AMP","Caffeine;caffeine","Alkaloids;Apnea;Caffeine and Caffeine Containing Products;Central Nervous System Agents;Central Nervous System Stimulants;Chemical Actions and Uses;Combined Inhibitors of CYP3A4 and P-glycoprotein;Cytochrome P-450 CYP1A2 Inhibitors;Cytochrome P-450 CYP1A2 Inhibitors (moderate);Cytochrome P-450 CYP1A2 Substrates;Cytochrome P-450 CYP2C8 Substrates;Cytochrome P-450 CYP2C9 Substrates;Cytochrome P-450 CYP2D6 Substrates;Cytochrome P-450 CYP2E1 Substrates;Cytochrome P-450 CYP3A Inhibitors;Cytochrome P-450 CYP3A4 Substrates;Diagnostic Agents;Enzyme Inhibitors;Heterocyclic Compounds;Heterocyclic Compounds, 2-Ring;Molecular Mechanisms of Pharmacological Action;Nervous System;Neurotransmitter Agents;P-glycoprotein/ABCB1 Inhibitors;P-glycoprotein/ABCB1 Substrates;Pharmacologic Actions;Phosphodiesterase Inhibitors;Physiological Effects of Drugs;Psychoanaleptics;Psychostimulants, Agents Used for Adhd and Nootropics;Purinergic Agents;Purinergic Antagonists;Purinergic P1 Receptor Antagonists;Purines;Purinones;Tests for Gastric Secretion;Therapeutic Uses;Xanthine Derivatives;Xanthines","approved","DB00201","Purine metabolism"
"CHEBI:17489","PDE3A","CHEBI:28177","3',5'-cyclic AMP","theophylline","Alkaloids;Anti-Asthmatic Agents;Autonomic Agents;Bronchodilator Agents;Cardiovascular Agents;Chemical Actions and Uses;Cytochrome P-450 CYP1A2 Inhibitors;Cytochrome P-450 CYP1A2 Inhibitors (moderate);Cytochrome P-450 CYP1A2 Substrates;Cytochrome P-450 CYP2C8 Substrates;Cytochrome P-450 CYP2C9 Substrates;Cytochrome P-450 CYP2D6 Substrates;Cytochrome P-450 CYP2E1 Substrates;Cytochrome P-450 CYP3A4 Substrates;Drugs for Obstructive Airway Diseases;Enzyme Inhibitors;Heterocyclic Compounds;Heterocyclic Compounds, 2-Ring;Molecular Mechanisms of Pharmacological Action;Neurotransmitter Agents;Peripheral Nervous System Agents;Pharmacologic Actions;Phosphodiesterase Inhibitors;Physiological Effects of Drugs;Purinergic Agents;Purinergic Antagonists;Purinergic P1 Receptor Antagonists;Purines;Purinones;Respiratory System;Respiratory System Agents;Theophylline Derivatives;Therapeutic Uses;Vasodilator Agents;Xanthines;Xanthines and Adrenergics","approved","DB00277","Purine metabolism"
"CHEBI:17489","PDE4B","CHEBI:4728","3',5'-cyclic AMP","dyphylline","Alkaloids;Anti-Asthmatic Agents;Autonomic Agents;Bronchodilator Agents;Cardiovascular Agents;Chemical Actions and Uses;Drugs for Obstructive Airway Diseases;Enzyme Inhibitors;Heterocyclic Compounds;Heterocyclic Compounds, 2-Ring;Molecular Mechanisms of Pharmacological Action;Peripheral Nervous System Agents;Pharmacologic Actions;Phosphodiesterase Inhibitors;Physiological Effects of Drugs;Purines;Purinones;Respiratory System;Respiratory System Agents;Theophylline;Theophylline Derivatives;Therapeutic Uses;Vasodilator Agents;Xanthines;Xanthines and Adrenergics","approved","DB00651","Purine metabolism"
"CHEBI:17489","PDE6C","CHEBI:27732","3',5'-cyclic AMP","Caffeine;caffeine","Alkaloids;Apnea;Caffeine and Caffeine Containing Products;Central Nervous System Agents;Central Nervous System Stimulants;Chemical Actions and Uses;Combined Inhibitors of CYP3A4 and P-glycoprotein;Cytochrome P-450 CYP1A2 Inhibitors;Cytochrome P-450 CYP1A2 Inhibitors (moderate);Cytochrome P-450 CYP1A2 Substrates;Cytochrome P-450 CYP2C8 Substrates;Cytochrome P-450 CYP2C9 Substrates;Cytochrome P-450 CYP2D6 Substrates;Cytochrome P-450 CYP2E1 Substrates;Cytochrome P-450 CYP3A Inhibitors;Cytochrome P-450 CYP3A4 Substrates;Diagnostic Agents;Enzyme Inhibitors;Heterocyclic Compounds;Heterocyclic Compounds, 2-Ring;Molecular Mechanisms of Pharmacological Action;Nervous System;Neurotransmitter Agents;P-glycoprotein/ABCB1 Inhibitors;P-glycoprotein/ABCB1 Substrates;Pharmacologic Actions;Phosphodiesterase Inhibitors;Physiological Effects of Drugs;Psychoanaleptics;Psychostimulants, Agents Used for Adhd and Nootropics;Purinergic Agents;Purinergic Antagonists;Purinergic P1 Receptor Antagonists;Purines;Purinones;Tests for Gastric Secretion;Therapeutic Uses;Xanthine Derivatives;Xanthines","approved","DB00201","Purine metabolism"
"CHEBI:17489","PDE5A","CHEBI:46295","3',5'-cyclic AMP","vardenafil","Azoles;Cardiovascular Agents;Chemical Actions and Uses;Cytochrome P-450 CYP3A4 Substrates;Drugs Used in Erectile Dysfunction;Enzyme Inhibitors;Genito Urinary System and Sex Hormones;Heterocyclic Compounds;Heterocyclic Compounds, 1-Ring;Imidazoles;Molecular Mechanisms of Pharmacological Action;Pharmacologic Actions;Phosphodiesterase 5 Inhibitors;Phosphodiesterase Inhibitors;Piperazines;QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying);Therapeutic Uses;Urological Agents;Urologicals;Vasodilator Agents","approved","DB00862","Purine metabolism"
"CHEBI:17489","PDE10A","CHEBI:4653","3',5'-cyclic AMP","dipyridamole","Blood and Blood Forming Organs;Cardiovascular Agents;Chemical Actions and Uses;Enzyme Inhibitors;Fibrinolytic Agents;Hematologic Agents;Heterocyclic Compounds;Heterocyclic Compounds, 1-Ring;Hypotensive Agents;Molecular Mechanisms of Pharmacological Action;P-glycoprotein/ABCB1 Inhibitors;P-glycoprotein/ABCB1 Substrates;Pharmacologic Actions;Phosphodiesterase Inhibitors;Platelet Aggregation Inhibitors;Platelet Aggregation Inhibitors Excl. Heparin;Pyrimidines;Therapeutic Uses;Vasodilator Agents","approved","DB00975","Purine metabolism"
"CHEBI:17489","PDE1B","CHEBI:27732","3',5'-cyclic AMP","Caffeine;caffeine","Alkaloids;Apnea;Caffeine and Caffeine Containing Products;Central Nervous System Agents;Central Nervous System Stimulants;Chemical Actions and Uses;Combined Inhibitors of CYP3A4 and P-glycoprotein;Cytochrome P-450 CYP1A2 Inhibitors;Cytochrome P-450 CYP1A2 Inhibitors (moderate);Cytochrome P-450 CYP1A2 Substrates;Cytochrome P-450 CYP2C8 Substrates;Cytochrome P-450 CYP2C9 Substrates;Cytochrome P-450 CYP2D6 Substrates;Cytochrome P-450 CYP2E1 Substrates;Cytochrome P-450 CYP3A Inhibitors;Cytochrome P-450 CYP3A4 Substrates;Diagnostic Agents;Enzyme Inhibitors;Heterocyclic Compounds;Heterocyclic Compounds, 2-Ring;Molecular Mechanisms of Pharmacological Action;Nervous System;Neurotransmitter Agents;P-glycoprotein/ABCB1 Inhibitors;P-glycoprotein/ABCB1 Substrates;Pharmacologic Actions;Phosphodiesterase Inhibitors;Physiological Effects of Drugs;Psychoanaleptics;Psychostimulants, Agents Used for Adhd and Nootropics;Purinergic Agents;Purinergic Antagonists;Purinergic P1 Receptor Antagonists;Purines;Purinones;Tests for Gastric Secretion;Therapeutic Uses;Xanthine Derivatives;Xanthines","approved","DB00201","Purine metabolism"
"CHEBI:17489","PDE4B","CHEBI:28241","3',5'-cyclic AMP","papaverine","Alimentary Tract and Metabolism;Alkaloids;Benzylisoquinolines;Cardiovascular Agents;Chemical Actions and Uses;Drugs for Functional Gastrointestinal Disorders;Drugs Used in Erectile Dysfunction;Enzyme Inhibitors;Genito Urinary System and Sex Hormones;Heterocyclic Compounds;Heterocyclic Compounds, 2-Ring;Hypotensive Agents;Isoquinolines;Molecular Mechanisms of Pharmacological Action;Opiate Alkaloids;Papaverine and Derivatives;Pharmacologic Actions;Phosphodiesterase Inhibitors;Therapeutic Uses;Urological Agents;Urologicals;Vasodilator Agents","approved","DB01113","Purine metabolism"
"CHEBI:17489","PDE3A","CHEBI:27732","3',5'-cyclic AMP","Caffeine;caffeine","Alkaloids;Apnea;Caffeine and Caffeine Containing Products;Central Nervous System Agents;Central Nervous System Stimulants;Chemical Actions and Uses;Combined Inhibitors of CYP3A4 and P-glycoprotein;Cytochrome P-450 CYP1A2 Inhibitors;Cytochrome P-450 CYP1A2 Inhibitors (moderate);Cytochrome P-450 CYP1A2 Substrates;Cytochrome P-450 CYP2C8 Substrates;Cytochrome P-450 CYP2C9 Substrates;Cytochrome P-450 CYP2D6 Substrates;Cytochrome P-450 CYP2E1 Substrates;Cytochrome P-450 CYP3A Inhibitors;Cytochrome P-450 CYP3A4 Substrates;Diagnostic Agents;Enzyme Inhibitors;Heterocyclic Compounds;Heterocyclic Compounds, 2-Ring;Molecular Mechanisms of Pharmacological Action;Nervous System;Neurotransmitter Agents;P-glycoprotein/ABCB1 Inhibitors;P-glycoprotein/ABCB1 Substrates;Pharmacologic Actions;Phosphodiesterase Inhibitors;Physiological Effects of Drugs;Psychoanaleptics;Psychostimulants, Agents Used for Adhd and Nootropics;Purinergic Agents;Purinergic Antagonists;Purinergic P1 Receptor Antagonists;Purines;Purinones;Tests for Gastric Secretion;Therapeutic Uses;Xanthine Derivatives;Xanthines","approved","DB00201","Purine metabolism"
"CHEBI:17489","PDE3B","CHEBI:27732","3',5'-cyclic AMP","Caffeine;caffeine","Alkaloids;Apnea;Caffeine and Caffeine Containing Products;Central Nervous System Agents;Central Nervous System Stimulants;Chemical Actions and Uses;Combined Inhibitors of CYP3A4 and P-glycoprotein;Cytochrome P-450 CYP1A2 Inhibitors;Cytochrome P-450 CYP1A2 Inhibitors (moderate);Cytochrome P-450 CYP1A2 Substrates;Cytochrome P-450 CYP2C8 Substrates;Cytochrome P-450 CYP2C9 Substrates;Cytochrome P-450 CYP2D6 Substrates;Cytochrome P-450 CYP2E1 Substrates;Cytochrome P-450 CYP3A Inhibitors;Cytochrome P-450 CYP3A4 Substrates;Diagnostic Agents;Enzyme Inhibitors;Heterocyclic Compounds;Heterocyclic Compounds, 2-Ring;Molecular Mechanisms of Pharmacological Action;Nervous System;Neurotransmitter Agents;P-glycoprotein/ABCB1 Inhibitors;P-glycoprotein/ABCB1 Substrates;Pharmacologic Actions;Phosphodiesterase Inhibitors;Physiological Effects of Drugs;Psychoanaleptics;Psychostimulants, Agents Used for Adhd and Nootropics;Purinergic Agents;Purinergic Antagonists;Purinergic P1 Receptor Antagonists;Purines;Purinones;Tests for Gastric Secretion;Therapeutic Uses;Xanthine Derivatives;Xanthines","approved","DB00201","Purine metabolism"
"CHEBI:17489","PDE8A","CHEBI:27732","3',5'-cyclic AMP","Caffeine;caffeine","Alkaloids;Apnea;Caffeine and Caffeine Containing Products;Central Nervous System Agents;Central Nervous System Stimulants;Chemical Actions and Uses;Combined Inhibitors of CYP3A4 and P-glycoprotein;Cytochrome P-450 CYP1A2 Inhibitors;Cytochrome P-450 CYP1A2 Inhibitors (moderate);Cytochrome P-450 CYP1A2 Substrates;Cytochrome P-450 CYP2C8 Substrates;Cytochrome P-450 CYP2C9 Substrates;Cytochrome P-450 CYP2D6 Substrates;Cytochrome P-450 CYP2E1 Substrates;Cytochrome P-450 CYP3A Inhibitors;Cytochrome P-450 CYP3A4 Substrates;Diagnostic Agents;Enzyme Inhibitors;Heterocyclic Compounds;Heterocyclic Compounds, 2-Ring;Molecular Mechanisms of Pharmacological Action;Nervous System;Neurotransmitter Agents;P-glycoprotein/ABCB1 Inhibitors;P-glycoprotein/ABCB1 Substrates;Pharmacologic Actions;Phosphodiesterase Inhibitors;Physiological Effects of Drugs;Psychoanaleptics;Psychostimulants, Agents Used for Adhd and Nootropics;Purinergic Agents;Purinergic Antagonists;Purinergic P1 Receptor Antagonists;Purines;Purinones;Tests for Gastric Secretion;Therapeutic Uses;Xanthine Derivatives;Xanthines","approved","DB00201","Purine metabolism"
"CHEBI:17489","PDE4A","CHEBI:4653","3',5'-cyclic AMP","dipyridamole","Blood and Blood Forming Organs;Cardiovascular Agents;Chemical Actions and Uses;Enzyme Inhibitors;Fibrinolytic Agents;Hematologic Agents;Heterocyclic Compounds;Heterocyclic Compounds, 1-Ring;Hypotensive Agents;Molecular Mechanisms of Pharmacological Action;P-glycoprotein/ABCB1 Inhibitors;P-glycoprotein/ABCB1 Substrates;Pharmacologic Actions;Phosphodiesterase Inhibitors;Platelet Aggregation Inhibitors;Platelet Aggregation Inhibitors Excl. Heparin;Pyrimidines;Therapeutic Uses;Vasodilator Agents","approved","DB00975","Purine metabolism"
"CHEBI:17596","ADA","CHEBI:4653","inosine","dipyridamole","Blood and Blood Forming Organs;Cardiovascular Agents;Chemical Actions and Uses;Enzyme Inhibitors;Fibrinolytic Agents;Hematologic Agents;Heterocyclic Compounds;Heterocyclic Compounds, 1-Ring;Hypotensive Agents;Molecular Mechanisms of Pharmacological Action;P-glycoprotein/ABCB1 Inhibitors;P-glycoprotein/ABCB1 Substrates;Pharmacologic Actions;Phosphodiesterase Inhibitors;Platelet Aggregation Inhibitors;Platelet Aggregation Inhibitors Excl. Heparin;Pyrimidines;Therapeutic Uses;Vasodilator Agents","approved","DB00975","Purine metabolism"
"CHEBI:17596","PNP","CHEBI:490877","inosine","didanosine","Anti-HIV Agents;Anti-Infective Agents;Anti-Retroviral Agents;Antiinfectives for Systemic Use;Antimetabolites;Antiviral Agents;Antivirals for Systemic Use;Carbohydrates;Chemical Actions and Uses;Deoxyribonucleosides;Dideoxynucleosides;Direct Acting Antivirals;Enzyme Inhibitors;Glycosides;Heterocyclic Compounds;Heterocyclic Compounds, 2-Ring;Inosine;Molecular Mechanisms of Pharmacological Action;Noxae;Nucleic Acid Synthesis Inhibitors;Nucleic Acids, Nucleotides, and Nucleosides;Nucleoside and Nucleotide Reverse Transcriptase Inhibitors;Nucleoside Reverse Transcriptase Inhibitors;Nucleosides;OAT3 Substrates;Pharmacologic Actions;Purine Nucleosides;Purines;Reverse Transcriptase Inhibitors;Ribonucleosides;Therapeutic Uses;Toxic Actions","approved","DB00900","Purine metabolism"
"CHEBI:17596","PNP","CHEBI:567361","inosine","cladribine","2-Chloroadenosine;Adenosine;Antimetabolites;Antineoplastic Agents;Antineoplastic and Immunomodulating Agents;BCRP/ABCG2 Substrates;Carbohydrates;Chemical Actions and Uses;Deoxyadenosines;Deoxyribonucleosides;Glycosides;Heterocyclic Compounds;Heterocyclic Compounds, 2-Ring;Immunologic Factors;Immunosuppressive Agents;Myelosuppressive Agents;Nucleic Acids, Nucleotides, and Nucleosides;Nucleosides;OCT2 Substrates;Pharmacologic Actions;Physiological Effects of Drugs;Purine Analogues;Purine Nucleosides;Purines;Ribonucleosides;Therapeutic Uses","approved;investigational","DB00242","Purine metabolism"
"CHEBI:17650","CYP21A2","CHEBI:47519","cortisol","Ketoconazole;ketoconazole","14-alpha Demethylase Inhibitors;Anti-Infective Agents;Antifungal Agents;Antifungals for Dermatological Use;Antifungals for Topical Use;Antiinfectives for Systemic Use;Antimycotics for Systemic Use;BSEP/ABCB11 Inhibitors;Chemical Actions and Uses;Chemically-Induced Disorders;Combined Inhibitors of CYP3A4 and P-glycoprotein;Cytochrome P-450 CYP1A2 Inhibitors;Cytochrome P-450 CYP2A6 Inhibitors;Cytochrome P-450 CYP2B6 Inhibitors;Cytochrome P-450 CYP2C19 Inhibitors;Cytochrome P-450 CYP2C19 Inhibitors (moderate);Cytochrome P-450 CYP2C8 Inhibitors;Cytochrome P-450 CYP2C9 Inhibitors;Cytochrome P-450 CYP2C9 Inhibitors (moderate);Cytochrome P-450 CYP2D6 Inhibitors;Cytochrome P-450 CYP2D6 Inhibitors (moderate);Cytochrome P-450 CYP3A Inhibitors;Cytochrome P-450 CYP3A4 Inhibitors (strong);Cytochrome P-450 CYP3A4 Substrates;Cytochrome P-450 Enzyme Inhibitors;Dermatologicals;Drug-Related Side Effects and Adverse Reactions;Enzyme Inhibitors;Genito Urinary System and Sex Hormones;Gynecological Antiinfectives and Antiseptics;Heterocyclic Compounds;Heterocyclic Compounds, 1-Ring;Hormone Antagonists;Hormones, Hormone Substitutes, and Hormone Antagonists;Imidazole and Triazole Derivatives;Imidazole Derivatives;Metabolic Side Effects of Drugs and Substances;Molecular Mechanisms of Pharmacological Action;P-glycoprotein/ABCB1 Inhibitors;P-glycoprotein/ABCB1 Substrates;Pharmacologic Actions;Physiological Effects of Drugs;Piperazines;QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying);Steroid Synthesis Inhibitors;Therapeutic Uses","approved;investigational","DB01026","Steroid hormone biosynthesis"
"CHEBI:17650","AKR1D1","CHEBI:5062","cortisol","finasteride","5-alpha Reductase Inhibitors;Alpha-Adrenoreceptor Antagonists;Androstanes;Androstenes;Azasteroids;Chemical Actions and Uses;Cytochrome P-450 CYP3A4 Substrates;Dermatologicals;Drugs Used in Benign Prostatic Hypertrophy;Enzyme Inhibitors;Genito Urinary System and Sex Hormones;Hormone Antagonists;Hormones, Hormone Substitutes, and Hormone Antagonists;Molecular Mechanisms of Pharmacological Action;Pharmacologic Actions;Physiological Effects of Drugs;Polycyclic Compounds;Steroid Synthesis Inhibitors;Steroids;Steroids, Heterocyclic;Testosterone-5-Alpha Reductase Inhibitors;Therapeutic Uses;Urological Agents;Urologicals","approved","DB01216","Steroid hormone biosynthesis"
"CHEBI:17659","RRM1","CHEBI:44423","UDP","hydroxyurea","Antineoplastic Agents;Antineoplastic and Immunomodulating Agents;Antisickling Agents;Chemical Actions and Uses;Cytochrome P-450 CYP2D6 Inhibitors;Enzyme Inhibitors;Hematologic Agents;Immunosuppressive Agents;Molecular Mechanisms of Pharmacological Action;Myelosuppressive Agents;Nucleic Acid Synthesis Inhibitors;Organic Chemicals;Pharmacologic Actions;Therapeutic Uses;Urea","approved","DB01005","Pyrimidine metabolism"
"CHEBI:17659","RRM1","CHEBI:567361","UDP","cladribine","2-Chloroadenosine;Adenosine;Antimetabolites;Antineoplastic Agents;Antineoplastic and Immunomodulating Agents;BCRP/ABCG2 Substrates;Carbohydrates;Chemical Actions and Uses;Deoxyadenosines;Deoxyribonucleosides;Glycosides;Heterocyclic Compounds;Heterocyclic Compounds, 2-Ring;Immunologic Factors;Immunosuppressive Agents;Myelosuppressive Agents;Nucleic Acids, Nucleotides, and Nucleosides;Nucleosides;OCT2 Substrates;Pharmacologic Actions;Physiological Effects of Drugs;Purine Analogues;Purine Nucleosides;Purines;Ribonucleosides;Therapeutic Uses","approved;investigational","DB00242","Pyrimidine metabolism"
"CHEBI:17659","RRM1","CHEBI:175901","UDP","Gemcitabine;gemcitabine","Anti-Infective Agents;Antimetabolites;Antimetabolites, Antineoplastic;Antineoplastic Agents;Antineoplastic and Immunomodulating Agents;Antiviral Agents;Chemical Actions and Uses;Enzyme Inhibitors;Immunologic Factors;Immunosuppressive Agents;Molecular Mechanisms of Pharmacological Action;Myelosuppressive Agents;Noxae;P-glycoprotein/ABCB1 Substrates;Pharmacologic Actions;Physiological Effects of Drugs;Pyrimidine Analogues;Radiation-Sensitizing Agents;Ribonucleotide Reductases, antagonists & inhibitors;Therapeutic Uses;Toxic Actions","approved","DB00441","Pyrimidine metabolism"
"CHEBI:17659","RRM1","CHEBI:63599","UDP","fludarabine phosphate","Antimetabolites;Antimetabolites, Antineoplastic;Antineoplastic Agents;Antineoplastic and Immunomodulating Agents;Chemical Actions and Uses;DNA (Cytosine-5-)-Methyltransferase, antagonists & inhibitors;Enzyme Inhibitors;Immunologic Factors;Immunosuppressive Agents;Molecular Mechanisms of Pharmacological Action;Myeloablative Agonists;Myelosuppressive Agents;Noxae;Pharmacologic Actions;Physiological Effects of Drugs;Purine Analogues;Therapeutic Uses;Toxic Actions","approved","DB01073","Pyrimidine metabolism"
"CHEBI:17659","RRM1","CHEBI:681569","UDP","clofarabine","Antimetabolites;Antimetabolites, Antineoplastic;Antineoplastic Agents;Antineoplastic and Immunomodulating Agents;BCRP/ABCG2 Substrates;Chemical Actions and Uses;Immunosuppressive Agents;Molecular Mechanisms of Pharmacological Action;Myelosuppressive Agents;Noxae;Pharmacologic Actions;Purine Analogues;Therapeutic Uses;Toxic Actions","approved;investigational","DB00631","Pyrimidine metabolism"
"CHEBI:17712","PNP","CHEBI:490877","Xanthine","didanosine","Anti-HIV Agents;Anti-Infective Agents;Anti-Retroviral Agents;Antiinfectives for Systemic Use;Antimetabolites;Antiviral Agents;Antivirals for Systemic Use;Carbohydrates;Chemical Actions and Uses;Deoxyribonucleosides;Dideoxynucleosides;Direct Acting Antivirals;Enzyme Inhibitors;Glycosides;Heterocyclic Compounds;Heterocyclic Compounds, 2-Ring;Inosine;Molecular Mechanisms of Pharmacological Action;Noxae;Nucleic Acid Synthesis Inhibitors;Nucleic Acids, Nucleotides, and Nucleosides;Nucleoside and Nucleotide Reverse Transcriptase Inhibitors;Nucleoside Reverse Transcriptase Inhibitors;Nucleosides;OAT3 Substrates;Pharmacologic Actions;Purine Nucleosides;Purines;Reverse Transcriptase Inhibitors;Ribonucleosides;Therapeutic Uses;Toxic Actions","approved","DB00900","Purine metabolism"
"CHEBI:17712","PNP","CHEBI:567361","Xanthine","cladribine","2-Chloroadenosine;Adenosine;Antimetabolites;Antineoplastic Agents;Antineoplastic and Immunomodulating Agents;BCRP/ABCG2 Substrates;Carbohydrates;Chemical Actions and Uses;Deoxyadenosines;Deoxyribonucleosides;Glycosides;Heterocyclic Compounds;Heterocyclic Compounds, 2-Ring;Immunologic Factors;Immunosuppressive Agents;Myelosuppressive Agents;Nucleic Acids, Nucleotides, and Nucleosides;Nucleosides;OCT2 Substrates;Pharmacologic Actions;Physiological Effects of Drugs;Purine Analogues;Purine Nucleosides;Purines;Ribonucleosides;Therapeutic Uses","approved;investigational","DB00242","Purine metabolism"
"CHEBI:17712","HPRT1","CHEBI:2948","Xanthine","azathioprine","6-Mercaptopurine;Antimetabolites;Antimetabolites, Antineoplastic;Antineoplastic Agents;Antineoplastic and Immunomodulating Agents;Antirheumatic Agents;Carbohydrates;Chemical Actions and Uses;Glycosides;Heterocyclic Compounds;Heterocyclic Compounds, 2-Ring;Immunologic Factors;Immunosuppressive Agents;Inorganic Chemicals;Molecular Mechanisms of Pharmacological Action;Noxae;Nucleic Acids, Nucleotides, and Nucleosides;Nucleosides;Organic Chemicals;Pharmacologic Actions;Physiological Effects of Drugs;Purines;Sulfhydryl Compounds;Sulfur Compounds;Therapeutic Uses;Thionucleosides;Thiopurine Analogs;Toxic Actions","approved","DB00993","Purine metabolism"
"CHEBI:17712","HPRT1","CHEBI:50667","Xanthine","Mercaptopurine;mercaptopurine","Antimetabolites;Antimetabolites, Antineoplastic;Antineoplastic Agents;Antineoplastic and Immunomodulating Agents;Chemical Actions and Uses;Enzyme Inhibitors;Heterocyclic Compounds;Heterocyclic Compounds, 2-Ring;Immunologic Factors;Immunosuppressive Agents;Inorganic Chemicals;Molecular Mechanisms of Pharmacological Action;Myelosuppressive Agents;Noxae;Nucleic Acid Synthesis Inhibitors;Organic Chemicals;Pharmacologic Actions;Physiological Effects of Drugs;Purine Analogues;Purines;Sulfhydryl Compounds;Sulfur Compounds;Therapeutic Uses;Thiopurine Analogs;Toxic Actions","approved","DB01033","Purine metabolism"
"CHEBI:17712","HPRT1","CHEBI:2208","Xanthine","Mercaptopurine;purine-6-thiol","Antimetabolites;Antimetabolites, Antineoplastic;Antineoplastic Agents;Antineoplastic and Immunomodulating Agents;Chemical Actions and Uses;Enzyme Inhibitors;Heterocyclic Compounds;Heterocyclic Compounds, 2-Ring;Immunologic Factors;Immunosuppressive Agents;Inorganic Chemicals;Molecular Mechanisms of Pharmacological Action;Myelosuppressive Agents;Noxae;Nucleic Acid Synthesis Inhibitors;Organic Chemicals;Pharmacologic Actions;Physiological Effects of Drugs;Purine Analogues;Purines;Sulfhydryl Compounds;Sulfur Compounds;Therapeutic Uses;Thiopurine Analogs;Toxic Actions","approved","DB01033","Purine metabolism"
"CHEBI:17712","XDH","CHEBI:40279","Xanthine","allopurinol","Antigout Preparations;Antimetabolites;Antioxidants;Antirheumatic Agents;Chemical Actions and Uses;Enzyme Inhibitors;Free Radical Scavengers;Gout Suppressants;Heterocyclic Compounds;Heterocyclic Compounds, 2-Ring;Molecular Mechanisms of Pharmacological Action;Musculo-Skeletal System;Noxae;Pharmacologic Actions;Physiological Effects of Drugs;Preparations Inhibiting Uric Acid Production;Protective Agents;Purines;Specialty Uses of Chemicals;Therapeutic Uses;Toxic Actions;Xanthine Oxidase Inhibitors Inhibitors","approved","DB00437","Purine metabolism"
"CHEBI:17754","AKR1B1","CHEBI:9352","glycerol","sulindac","Acetic Acid Derivatives and Related Substances;Analgesics;Analgesics, Non-Narcotic;Anti-Inflammatory Agents;Anti-Inflammatory Agents, Non-Steroidal;Antiinflammatory and Antirheumatic Products;Antiinflammatory and Antirheumatic Products, Non-Steroids;Antineoplastic Agents;Antirheumatic Agents;Central Nervous System Agents;Chemical Actions and Uses;Cyclooxygenase Inhibitors;Cytochrome P-450 CYP1A2 Inhibitors;Enzyme Inhibitors;Hydrocarbons;Hydrocarbons, Aromatic;Hydrocarbons, Cyclic;Indenes;Molecular Mechanisms of Pharmacological Action;Musculo-Skeletal System;Organic Chemicals;Peripheral Nervous System Agents;Pharmacologic Actions;Physiological Effects of Drugs;Polycyclic Compounds;Polycyclic Hydrocarbons, Aromatic;Sensory System Agents;Therapeutic Uses","approved","DB00605","Glycerolipid metabolism"
"CHEBI:17768","MAOB","CHEBI:63620","N-acetylputrescine","rasagiline","Anti-Parkinson Drugs;Central Nervous System Agents;Chemical Actions and Uses;Cytochrome P-450 CYP1A2 Substrates;Dopamine Agents;Enzyme Inhibitors;Molecular Mechanisms of Pharmacological Action;Monoamine Oxidase B Inhibitors;Monoamine Oxidase Inhibitors;Nervous System;Neuroprotective Agents;Pharmacologic Actions;Physiological Effects of Drugs;Protective Agents;Serotonin Modulators;Specialty Uses of Chemicals;Therapeutic Uses","approved","DB01367","Arginine and proline metabolism"
"CHEBI:17768","MAOA","CHEBI:83531","N-acetylputrescine","moclobemide","Acids, Carbocyclic;Amides;Antidepressive Agents;Benzamides;Benzene Derivatives;Benzoates;Carboxylic Acids;Central Nervous System Agents;Chemical Actions and Uses;Chlorobenzoates;CYP2D6 Inhibitors (Weak);Cytochrome P-450 CYP1A2 Inhibitors;Cytochrome P-450 CYP2C19 Inhibitors;Cytochrome P-450 CYP2C19 Inhibitors (moderate);Cytochrome P-450 CYP2C19 Substrates;Cytochrome P-450 CYP2C9 Inhibitors;Cytochrome P-450 CYP2C9 Substrates;Cytochrome P-450 CYP2D6 Inducers;Cytochrome P-450 CYP2D6 Inhibitors;Cytochrome P-450 CYP2D6 Substrates;Enzyme Inhibitors;Hydrocarbons;Hydrocarbons, Aromatic;Hydrocarbons, Cyclic;Molecular Mechanisms of Pharmacological Action;Monoamine Oxidase a Inhibitors;Monoamine Oxidase Inhibitors;Nervous System;Organic Chemicals;Pharmacologic Actions;Psychoanaleptics;Psychotropic Drugs;Serotonin Modulators;Therapeutic Uses","approved","DB01171","Arginine and proline metabolism"
"CHEBI:17775","XDH","CHEBI:40279","7,9-dihydro-1H-purine-2,6,8(3H)-trione","allopurinol","Antigout Preparations;Antimetabolites;Antioxidants;Antirheumatic Agents;Chemical Actions and Uses;Enzyme Inhibitors;Free Radical Scavengers;Gout Suppressants;Heterocyclic Compounds;Heterocyclic Compounds, 2-Ring;Molecular Mechanisms of Pharmacological Action;Musculo-Skeletal System;Noxae;Pharmacologic Actions;Physiological Effects of Drugs;Preparations Inhibiting Uric Acid Production;Protective Agents;Purines;Specialty Uses of Chemicals;Therapeutic Uses;Toxic Actions;Xanthine Oxidase Inhibitors Inhibitors","approved","DB00437","Purine metabolism"
"CHEBI:17895","TH","CHEBI:6912","L-tyrosine","alpha-methyl-L-tyrosine","Amino Acids;Amino Acids, Aromatic;Amino Acids, Cyclic;Amino Acids, Peptides, and Proteins;Antihypertensive Agents;Cardiovascular System;Chemical Actions and Uses;Enzyme Inhibitors;Methyltyrosines;Molecular Mechanisms of Pharmacological Action;Pharmacologic Actions;Tyrosine;Tyrosine Hydroxylase Inhibitors","approved","DB00765","Tyrosine metabolism"
"CHEBI:17924","AKR1B1","CHEBI:9352","D-glucitol","sulindac","Acetic Acid Derivatives and Related Substances;Analgesics;Analgesics, Non-Narcotic;Anti-Inflammatory Agents;Anti-Inflammatory Agents, Non-Steroidal;Antiinflammatory and Antirheumatic Products;Antiinflammatory and Antirheumatic Products, Non-Steroids;Antineoplastic Agents;Antirheumatic Agents;Central Nervous System Agents;Chemical Actions and Uses;Cyclooxygenase Inhibitors;Cytochrome P-450 CYP1A2 Inhibitors;Enzyme Inhibitors;Hydrocarbons;Hydrocarbons, Aromatic;Hydrocarbons, Cyclic;Indenes;Molecular Mechanisms of Pharmacological Action;Musculo-Skeletal System;Organic Chemicals;Peripheral Nervous System Agents;Pharmacologic Actions;Physiological Effects of Drugs;Polycyclic Compounds;Polycyclic Hydrocarbons, Aromatic;Sensory System Agents;Therapeutic Uses","approved","DB00605","Fructose and mannose metabolism"
"CHEBI:17925","AKR1B1","CHEBI:9352","alpha-D-glucose","sulindac","Acetic Acid Derivatives and Related Substances;Analgesics;Analgesics, Non-Narcotic;Anti-Inflammatory Agents;Anti-Inflammatory Agents, Non-Steroidal;Antiinflammatory and Antirheumatic Products;Antiinflammatory and Antirheumatic Products, Non-Steroids;Antineoplastic Agents;Antirheumatic Agents;Central Nervous System Agents;Chemical Actions and Uses;Cyclooxygenase Inhibitors;Cytochrome P-450 CYP1A2 Inhibitors;Enzyme Inhibitors;Hydrocarbons;Hydrocarbons, Aromatic;Hydrocarbons, Cyclic;Indenes;Molecular Mechanisms of Pharmacological Action;Musculo-Skeletal System;Organic Chemicals;Peripheral Nervous System Agents;Pharmacologic Actions;Physiological Effects of Drugs;Polycyclic Compounds;Polycyclic Hydrocarbons, Aromatic;Sensory System Agents;Therapeutic Uses","approved","DB00605","Fructose and mannose metabolism"
"CHEBI:17992","SI","CHEBI:2376","sucrose","acarbose","Alimentary Tract and Metabolism;Blood Glucose Lowering Agents;Blood Glucose Lowering Drugs, Excl. Insulins;Carbohydrates;Chemical Actions and Uses;Drugs Used in Diabetes;Enzyme Inhibitors;Glycoside Hydrolase Inhibitors;Hypoglycemic Agents;Molecular Mechanisms of Pharmacological Action;Oligosaccharides;Pharmacologic Actions;Physiological Effects of Drugs;Polysaccharides;Trisaccharides","approved;investigational","DB00284","Galactose metabolism;Starch and sucrose metabolism"
"CHEBI:18012","DHODH","CHEBI:575568","fumaric acid","atovaquone","Anti-Infective Agents;Antimalarials;Antiparasitic Agents;Antiparasitic Products, Insecticides and Repellents;Antiprotozoals;Chemical Actions and Uses;Cytochrome P-450 CYP2C9 Inhibitors;Enzyme Inhibitors;Hydrocarbons;Hydrocarbons, Aromatic;Hydrocarbons, Cyclic;Molecular Mechanisms of Pharmacological Action;Naphthalenes;Naphthoquinones;Organic Chemicals;Pharmacologic Actions;Polycyclic Compounds;Polycyclic Hydrocarbons, Aromatic;Quinones;Therapeutic Uses","approved","DB01117",""
"CHEBI:18012","DHODH","CHEBI:6402","fumaric acid","leflunomide","Adjuvants;Adjuvants, Immunologic;Anti-Inflammatory Agents, Non-Steroidal;Antineoplastic Agents;Antineoplastic and Immunomodulating Agents;Antirheumatic Agents;Antiviral Agents;BCRP/ABCG2 Substrates;Chemical Actions and Uses;Cytochrome P-450 CYP1A2 Substrates;Cytochrome P-450 CYP2C9 Inhibitors;Cytochrome P-450 CYP2C9 Inhibitors (moderate);Cytochrome P-450 CYP2C9 Substrates;Enzyme Inhibitors;Immunologic Factors;Immunosuppressive Agents;Molecular Mechanisms of Pharmacological Action;Pharmacologic Actions;Physiological Effects of Drugs;Selective Immunosuppressants;Therapeutic Uses","approved;investigational","DB01097",""
"CHEBI:18107","PNP","CHEBI:567361","xanthosine","cladribine","2-Chloroadenosine;Adenosine;Antimetabolites;Antineoplastic Agents;Antineoplastic and Immunomodulating Agents;BCRP/ABCG2 Substrates;Carbohydrates;Chemical Actions and Uses;Deoxyadenosines;Deoxyribonucleosides;Glycosides;Heterocyclic Compounds;Heterocyclic Compounds, 2-Ring;Immunologic Factors;Immunosuppressive Agents;Myelosuppressive Agents;Nucleic Acids, Nucleotides, and Nucleosides;Nucleosides;OCT2 Substrates;Pharmacologic Actions;Physiological Effects of Drugs;Purine Analogues;Purine Nucleosides;Purines;Ribonucleosides;Therapeutic Uses","approved;investigational","DB00242","Purine metabolism"
"CHEBI:18107","PNP","CHEBI:490877","xanthosine","didanosine","Anti-HIV Agents;Anti-Infective Agents;Anti-Retroviral Agents;Antiinfectives for Systemic Use;Antimetabolites;Antiviral Agents;Antivirals for Systemic Use;Carbohydrates;Chemical Actions and Uses;Deoxyribonucleosides;Dideoxynucleosides;Direct Acting Antivirals;Enzyme Inhibitors;Glycosides;Heterocyclic Compounds;Heterocyclic Compounds, 2-Ring;Inosine;Molecular Mechanisms of Pharmacological Action;Noxae;Nucleic Acid Synthesis Inhibitors;Nucleic Acids, Nucleotides, and Nucleosides;Nucleoside and Nucleotide Reverse Transcriptase Inhibitors;Nucleoside Reverse Transcriptase Inhibitors;Nucleosides;OAT3 Substrates;Pharmacologic Actions;Purine Nucleosides;Purines;Reverse Transcriptase Inhibitors;Ribonucleosides;Therapeutic Uses;Toxic Actions","approved","DB00900","Purine metabolism"
"CHEBI:18169","IMPA2","CHEBI:49713","1D-myo-inositol 3-phosphate","lithium(1+)","Acids;Acids, Noncarboxylic;Alkalies;Anions;Antidepressive Agents;Antimanic Agents;Antipsychotic Agents;Carbon Compounds, Inorganic;Carbonates;Carbonic Acid;Central Nervous System Agents;Central Nervous System Depressants;Chemical Actions and Uses;Electrolytes;Elements;Enzyme Inhibitors;Inorganic Chemicals;Ions;Lithium;Lithium Compounds;Metals;Metals, Alkali;Metals, Light;Molecular Mechanisms of Pharmacological Action;Nervous System;Pharmacologic Actions;Physiological Effects of Drugs;Psycholeptics;Psychotropic Drugs;QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying);Serotonin Modulators;Therapeutic Uses;Tranquilizing Agents","approved","DB01356","Inositol phosphate metabolism"
"CHEBI:18297","IMPA2","CHEBI:49713","1D-myo-inositol 1-phosphate","lithium(1+)","Acids;Acids, Noncarboxylic;Alkalies;Anions;Antidepressive Agents;Antimanic Agents;Antipsychotic Agents;Carbon Compounds, Inorganic;Carbonates;Carbonic Acid;Central Nervous System Agents;Central Nervous System Depressants;Chemical Actions and Uses;Electrolytes;Elements;Enzyme Inhibitors;Inorganic Chemicals;Ions;Lithium;Lithium Compounds;Metals;Metals, Alkali;Metals, Light;Molecular Mechanisms of Pharmacological Action;Nervous System;Pharmacologic Actions;Physiological Effects of Drugs;Psycholeptics;Psychotropic Drugs;QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying);Serotonin Modulators;Therapeutic Uses;Tranquilizing Agents","approved","DB01356","Inositol phosphate metabolism"
"CHEBI:18304","ENPP1","CHEBI:63580","deamido-NAD(+)","ribavirin","Anti-Infective Agents;Antiinfectives for Systemic Use;Antimetabolites;Antiviral Agents;Antivirals for Systemic Use;Carbohydrates;Chemical Actions and Uses;Direct Acting Antivirals;Glycosides;Molecular Mechanisms of Pharmacological Action;Noxae;Nucleic Acids, Nucleotides, and Nucleosides;Nucleosides;Nucleosides and Nucleotides Excl. Reverse Transcriptase Inhibitors;Pharmacologic Actions;Ribonucleosides;Therapeutic Uses;Toxic Actions","approved","DB00811","Nicotinate and nicotinamide metabolism"
"CHEBI:18361","POLA1","CHEBI:63612","PPi","nelarabine","Antimetabolites;Antineoplastic Agents;Antineoplastic and Immunomodulating Agents;Immunosuppressive Agents;Myelosuppressive Agents;Purine Analogues","approved;investigational","DB01280","Purine metabolism;Pyrimidine metabolism"
"CHEBI:18361","POLA1","CHEBI:567361","PPi","cladribine","2-Chloroadenosine;Adenosine;Antimetabolites;Antineoplastic Agents;Antineoplastic and Immunomodulating Agents;BCRP/ABCG2 Substrates;Carbohydrates;Chemical Actions and Uses;Deoxyadenosines;Deoxyribonucleosides;Glycosides;Heterocyclic Compounds;Heterocyclic Compounds, 2-Ring;Immunologic Factors;Immunosuppressive Agents;Myelosuppressive Agents;Nucleic Acids, Nucleotides, and Nucleosides;Nucleosides;OCT2 Substrates;Pharmacologic Actions;Physiological Effects of Drugs;Purine Analogues;Purine Nucleosides;Purines;Ribonucleosides;Therapeutic Uses","approved;investigational","DB00242","Purine metabolism;Pyrimidine metabolism"
"CHEBI:18361","HPRT1","CHEBI:2948","PPi","azathioprine","6-Mercaptopurine;Antimetabolites;Antimetabolites, Antineoplastic;Antineoplastic Agents;Antineoplastic and Immunomodulating Agents;Antirheumatic Agents;Carbohydrates;Chemical Actions and Uses;Glycosides;Heterocyclic Compounds;Heterocyclic Compounds, 2-Ring;Immunologic Factors;Immunosuppressive Agents;Inorganic Chemicals;Molecular Mechanisms of Pharmacological Action;Noxae;Nucleic Acids, Nucleotides, and Nucleosides;Nucleosides;Organic Chemicals;Pharmacologic Actions;Physiological Effects of Drugs;Purines;Sulfhydryl Compounds;Sulfur Compounds;Therapeutic Uses;Thionucleosides;Thiopurine Analogs;Toxic Actions","approved","DB00993","Purine metabolism"
"CHEBI:18361","POLE2","CHEBI:567361","PPi","cladribine","2-Chloroadenosine;Adenosine;Antimetabolites;Antineoplastic Agents;Antineoplastic and Immunomodulating Agents;BCRP/ABCG2 Substrates;Carbohydrates;Chemical Actions and Uses;Deoxyadenosines;Deoxyribonucleosides;Glycosides;Heterocyclic Compounds;Heterocyclic Compounds, 2-Ring;Immunologic Factors;Immunosuppressive Agents;Myelosuppressive Agents;Nucleic Acids, Nucleotides, and Nucleosides;Nucleosides;OCT2 Substrates;Pharmacologic Actions;Physiological Effects of Drugs;Purine Analogues;Purine Nucleosides;Purines;Ribonucleosides;Therapeutic Uses","approved;investigational","DB00242","Purine metabolism;Pyrimidine metabolism"
"CHEBI:18361","POLE","CHEBI:567361","PPi","cladribine","2-Chloroadenosine;Adenosine;Antimetabolites;Antineoplastic Agents;Antineoplastic and Immunomodulating Agents;BCRP/ABCG2 Substrates;Carbohydrates;Chemical Actions and Uses;Deoxyadenosines;Deoxyribonucleosides;Glycosides;Heterocyclic Compounds;Heterocyclic Compounds, 2-Ring;Immunologic Factors;Immunosuppressive Agents;Myelosuppressive Agents;Nucleic Acids, Nucleotides, and Nucleosides;Nucleosides;OCT2 Substrates;Pharmacologic Actions;Physiological Effects of Drugs;Purine Analogues;Purine Nucleosides;Purines;Ribonucleosides;Therapeutic Uses","approved;investigational","DB00242","Purine metabolism;Pyrimidine metabolism"
"CHEBI:18361","ENPP1","CHEBI:63580","PPi","ribavirin","Anti-Infective Agents;Antiinfectives for Systemic Use;Antimetabolites;Antiviral Agents;Antivirals for Systemic Use;Carbohydrates;Chemical Actions and Uses;Direct Acting Antivirals;Glycosides;Molecular Mechanisms of Pharmacological Action;Noxae;Nucleic Acids, Nucleotides, and Nucleosides;Nucleosides;Nucleosides and Nucleotides Excl. Reverse Transcriptase Inhibitors;Pharmacologic Actions;Ribonucleosides;Therapeutic Uses;Toxic Actions","approved","DB00811","Pantothenate and CoA biosynthesis"
"CHEBI:18361","HPRT1","CHEBI:50667","PPi","Mercaptopurine;mercaptopurine","Antimetabolites;Antimetabolites, Antineoplastic;Antineoplastic Agents;Antineoplastic and Immunomodulating Agents;Chemical Actions and Uses;Enzyme Inhibitors;Heterocyclic Compounds;Heterocyclic Compounds, 2-Ring;Immunologic Factors;Immunosuppressive Agents;Inorganic Chemicals;Molecular Mechanisms of Pharmacological Action;Myelosuppressive Agents;Noxae;Nucleic Acid Synthesis Inhibitors;Organic Chemicals;Pharmacologic Actions;Physiological Effects of Drugs;Purine Analogues;Purines;Sulfhydryl Compounds;Sulfur Compounds;Therapeutic Uses;Thiopurine Analogs;Toxic Actions","approved","DB01033","Purine metabolism"
"CHEBI:18361","HPRT1","CHEBI:2208","PPi","Mercaptopurine;purine-6-thiol","Antimetabolites;Antimetabolites, Antineoplastic;Antineoplastic Agents;Antineoplastic and Immunomodulating Agents;Chemical Actions and Uses;Enzyme Inhibitors;Heterocyclic Compounds;Heterocyclic Compounds, 2-Ring;Immunologic Factors;Immunosuppressive Agents;Inorganic Chemicals;Molecular Mechanisms of Pharmacological Action;Myelosuppressive Agents;Noxae;Nucleic Acid Synthesis Inhibitors;Organic Chemicals;Pharmacologic Actions;Physiological Effects of Drugs;Purine Analogues;Purines;Sulfhydryl Compounds;Sulfur Compounds;Therapeutic Uses;Thiopurine Analogs;Toxic Actions","approved","DB01033","Purine metabolism"
"CHEBI:18361","POLE3","CHEBI:567361","PPi","cladribine","2-Chloroadenosine;Adenosine;Antimetabolites;Antineoplastic Agents;Antineoplastic and Immunomodulating Agents;BCRP/ABCG2 Substrates;Carbohydrates;Chemical Actions and Uses;Deoxyadenosines;Deoxyribonucleosides;Glycosides;Heterocyclic Compounds;Heterocyclic Compounds, 2-Ring;Immunologic Factors;Immunosuppressive Agents;Myelosuppressive Agents;Nucleic Acids, Nucleotides, and Nucleosides;Nucleosides;OCT2 Substrates;Pharmacologic Actions;Physiological Effects of Drugs;Purine Analogues;Purine Nucleosides;Purines;Ribonucleosides;Therapeutic Uses","approved;investigational","DB00242","Purine metabolism;Pyrimidine metabolism"
"CHEBI:18361","POLA1","CHEBI:63599","PPi","fludarabine phosphate","Antimetabolites;Antimetabolites, Antineoplastic;Antineoplastic Agents;Antineoplastic and Immunomodulating Agents;Chemical Actions and Uses;DNA (Cytosine-5-)-Methyltransferase, antagonists & inhibitors;Enzyme Inhibitors;Immunologic Factors;Immunosuppressive Agents;Molecular Mechanisms of Pharmacological Action;Myeloablative Agonists;Myelosuppressive Agents;Noxae;Pharmacologic Actions;Physiological Effects of Drugs;Purine Analogues;Therapeutic Uses;Toxic Actions","approved","DB01073","Purine metabolism;Pyrimidine metabolism"
"CHEBI:18361","POLE4","CHEBI:567361","PPi","cladribine","2-Chloroadenosine;Adenosine;Antimetabolites;Antineoplastic Agents;Antineoplastic and Immunomodulating Agents;BCRP/ABCG2 Substrates;Carbohydrates;Chemical Actions and Uses;Deoxyadenosines;Deoxyribonucleosides;Glycosides;Heterocyclic Compounds;Heterocyclic Compounds, 2-Ring;Immunologic Factors;Immunosuppressive Agents;Myelosuppressive Agents;Nucleic Acids, Nucleotides, and Nucleosides;Nucleosides;OCT2 Substrates;Pharmacologic Actions;Physiological Effects of Drugs;Purine Analogues;Purine Nucleosides;Purines;Ribonucleosides;Therapeutic Uses","approved;investigational","DB00242","Purine metabolism;Pyrimidine metabolism"
"CHEBI:18361","POLA1","CHEBI:681569","PPi","clofarabine","Antimetabolites;Antimetabolites, Antineoplastic;Antineoplastic Agents;Antineoplastic and Immunomodulating Agents;BCRP/ABCG2 Substrates;Chemical Actions and Uses;Immunosuppressive Agents;Molecular Mechanisms of Pharmacological Action;Myelosuppressive Agents;Noxae;Pharmacologic Actions;Purine Analogues;Therapeutic Uses;Toxic Actions","approved;investigational","DB00631","Purine metabolism;Pyrimidine metabolism"
"CHEBI:18367","PNP","CHEBI:567361","Phosphate","cladribine","2-Chloroadenosine;Adenosine;Antimetabolites;Antineoplastic Agents;Antineoplastic and Immunomodulating Agents;BCRP/ABCG2 Substrates;Carbohydrates;Chemical Actions and Uses;Deoxyadenosines;Deoxyribonucleosides;Glycosides;Heterocyclic Compounds;Heterocyclic Compounds, 2-Ring;Immunologic Factors;Immunosuppressive Agents;Myelosuppressive Agents;Nucleic Acids, Nucleotides, and Nucleosides;Nucleosides;OCT2 Substrates;Pharmacologic Actions;Physiological Effects of Drugs;Purine Analogues;Purine Nucleosides;Purines;Ribonucleosides;Therapeutic Uses","approved;investigational","DB00242","Nicotinate and nicotinamide metabolism;Purine metabolism;Pyrimidine metabolism"
"CHEBI:18367","NT5C2","CHEBI:63580","Phosphate","ribavirin","Anti-Infective Agents;Antiinfectives for Systemic Use;Antimetabolites;Antiviral Agents;Antivirals for Systemic Use;Carbohydrates;Chemical Actions and Uses;Direct Acting Antivirals;Glycosides;Molecular Mechanisms of Pharmacological Action;Noxae;Nucleic Acids, Nucleotides, and Nucleosides;Nucleosides;Nucleosides and Nucleotides Excl. Reverse Transcriptase Inhibitors;Pharmacologic Actions;Ribonucleosides;Therapeutic Uses;Toxic Actions","approved","DB00811","Purine metabolism"
"CHEBI:18367","PNP","CHEBI:490877","Phosphate","didanosine","Anti-HIV Agents;Anti-Infective Agents;Anti-Retroviral Agents;Antiinfectives for Systemic Use;Antimetabolites;Antiviral Agents;Antivirals for Systemic Use;Carbohydrates;Chemical Actions and Uses;Deoxyribonucleosides;Dideoxynucleosides;Direct Acting Antivirals;Enzyme Inhibitors;Glycosides;Heterocyclic Compounds;Heterocyclic Compounds, 2-Ring;Inosine;Molecular Mechanisms of Pharmacological Action;Noxae;Nucleic Acid Synthesis Inhibitors;Nucleic Acids, Nucleotides, and Nucleosides;Nucleoside and Nucleotide Reverse Transcriptase Inhibitors;Nucleoside Reverse Transcriptase Inhibitors;Nucleosides;OAT3 Substrates;Pharmacologic Actions;Purine Nucleosides;Purines;Reverse Transcriptase Inhibitors;Ribonucleosides;Therapeutic Uses;Toxic Actions","approved","DB00900","Nicotinate and nicotinamide metabolism;Purine metabolism;Pyrimidine metabolism"
"CHEBI:18403","AKR1B1","CHEBI:9352","L-arabinitol","sulindac","Acetic Acid Derivatives and Related Substances;Analgesics;Analgesics, Non-Narcotic;Anti-Inflammatory Agents;Anti-Inflammatory Agents, Non-Steroidal;Antiinflammatory and Antirheumatic Products;Antiinflammatory and Antirheumatic Products, Non-Steroids;Antineoplastic Agents;Antirheumatic Agents;Central Nervous System Agents;Chemical Actions and Uses;Cyclooxygenase Inhibitors;Cytochrome P-450 CYP1A2 Inhibitors;Enzyme Inhibitors;Hydrocarbons;Hydrocarbons, Aromatic;Hydrocarbons, Cyclic;Indenes;Molecular Mechanisms of Pharmacological Action;Musculo-Skeletal System;Organic Chemicals;Peripheral Nervous System Agents;Pharmacologic Actions;Physiological Effects of Drugs;Polycyclic Compounds;Polycyclic Hydrocarbons, Aromatic;Sensory System Agents;Therapeutic Uses","approved","DB00605","Pentose and glucuronate interconversions"
"CHEBI:20106","COMT","CHEBI:4798","Vanillylmandelic acid","entacapone","Anti-Dyskinesia Agents;Anti-Parkinson Drugs;Catechol O-Methyltransferase Inhibitors;Central Nervous System Agents;Central Nervous System Depressants;Chemical Actions and Uses;COMT Inhibitors;CYP2D6 Inhibitors (Weak);Dopamine Agents;Enzyme Inhibitors;Molecular Mechanisms of Pharmacological Action;Nervous System;Pharmacologic Actions;Therapeutic Uses","approved;investigational","DB00494","Tyrosine metabolism"
"CHEBI:25858","CYP1A2","CHEBI:6030","1,7-dimethylxanthine","isoniazide","Acids, Heterocyclic;Anti-Bacterial Agents;Anti-Infective Agents;Antiinfectives for Systemic Use;Antimetabolites;Antimycobacterials;Antitubercular Agents;Chemical Actions and Uses;CYP3A4 Inhibitors (Weak);Cytochrome P-450 CYP1A2 Inhibitors;Cytochrome P-450 CYP2A6 Inhibitors;Cytochrome P-450 CYP2C19 Inhibitors;Cytochrome P-450 CYP2C19 Inhibitors (moderate);Cytochrome P-450 CYP2C8 Inhibitors;Cytochrome P-450 CYP2C9 Inhibitors;Cytochrome P-450 CYP2D6 Inhibitors;Cytochrome P-450 CYP2D6 Inhibitors (moderate);Cytochrome P-450 CYP2E1 Inducers;Cytochrome P-450 CYP2E1 Inhibitors;Cytochrome P-450 CYP2E1 Inhibitors (moderate);Cytochrome P-450 CYP2E1 Substrates;Cytochrome P-450 CYP3A Inhibitors;Drugs for Treatment of Tuberculosis;Fatty Acid Synthesis Inhibitors;Heterocyclic Compounds;Heterocyclic Compounds, 1-Ring;Hydrazides;Hydrazines;Hypolipidemic Agents;Isonicotinic Acids;Lipid Regulating Agents;Molecular Mechanisms of Pharmacological Action;Noxae;Organic Chemicals;Pharmacologic Actions;Pyridines;Therapeutic Uses;Toxic Actions","approved","DB00951","Caffeine metabolism"
"CHEBI:25858","XDH","CHEBI:40279","1,7-dimethylxanthine","allopurinol","Antigout Preparations;Antimetabolites;Antioxidants;Antirheumatic Agents;Chemical Actions and Uses;Enzyme Inhibitors;Free Radical Scavengers;Gout Suppressants;Heterocyclic Compounds;Heterocyclic Compounds, 2-Ring;Molecular Mechanisms of Pharmacological Action;Musculo-Skeletal System;Noxae;Pharmacologic Actions;Physiological Effects of Drugs;Preparations Inhibiting Uric Acid Production;Protective Agents;Purines;Specialty Uses of Chemicals;Therapeutic Uses;Toxic Actions;Xanthine Oxidase Inhibitors Inhibitors","approved","DB00437","Caffeine metabolism"
"CHEBI:26078","PNP","CHEBI:567361","Phosphate","cladribine","2-Chloroadenosine;Adenosine;Antimetabolites;Antineoplastic Agents;Antineoplastic and Immunomodulating Agents;BCRP/ABCG2 Substrates;Carbohydrates;Chemical Actions and Uses;Deoxyadenosines;Deoxyribonucleosides;Glycosides;Heterocyclic Compounds;Heterocyclic Compounds, 2-Ring;Immunologic Factors;Immunosuppressive Agents;Myelosuppressive Agents;Nucleic Acids, Nucleotides, and Nucleosides;Nucleosides;OCT2 Substrates;Pharmacologic Actions;Physiological Effects of Drugs;Purine Analogues;Purine Nucleosides;Purines;Ribonucleosides;Therapeutic Uses","approved;investigational","DB00242","Nicotinate and nicotinamide metabolism;Purine metabolism;Pyrimidine metabolism"
"CHEBI:26078","NT5C2","CHEBI:63580","Phosphate","ribavirin","Anti-Infective Agents;Antiinfectives for Systemic Use;Antimetabolites;Antiviral Agents;Antivirals for Systemic Use;Carbohydrates;Chemical Actions and Uses;Direct Acting Antivirals;Glycosides;Molecular Mechanisms of Pharmacological Action;Noxae;Nucleic Acids, Nucleotides, and Nucleosides;Nucleosides;Nucleosides and Nucleotides Excl. Reverse Transcriptase Inhibitors;Pharmacologic Actions;Ribonucleosides;Therapeutic Uses;Toxic Actions","approved","DB00811","Purine metabolism"
"CHEBI:26078","PNP","CHEBI:490877","Phosphate","didanosine","Anti-HIV Agents;Anti-Infective Agents;Anti-Retroviral Agents;Antiinfectives for Systemic Use;Antimetabolites;Antiviral Agents;Antivirals for Systemic Use;Carbohydrates;Chemical Actions and Uses;Deoxyribonucleosides;Dideoxynucleosides;Direct Acting Antivirals;Enzyme Inhibitors;Glycosides;Heterocyclic Compounds;Heterocyclic Compounds, 2-Ring;Inosine;Molecular Mechanisms of Pharmacological Action;Noxae;Nucleic Acid Synthesis Inhibitors;Nucleic Acids, Nucleotides, and Nucleosides;Nucleoside and Nucleotide Reverse Transcriptase Inhibitors;Nucleoside Reverse Transcriptase Inhibitors;Nucleosides;OAT3 Substrates;Pharmacologic Actions;Purine Nucleosides;Purines;Reverse Transcriptase Inhibitors;Ribonucleosides;Therapeutic Uses;Toxic Actions","approved","DB00900","Nicotinate and nicotinamide metabolism;Purine metabolism;Pyrimidine metabolism"
"CHEBI:27432","PLA2G2A","CHEBI:49662","alpha-linolenic acid","indometacin","Acetic Acid Derivatives and Related Substances;Analgesics;Analgesics, Non-Narcotic;Anti-Inflammatory Agents;Anti-Inflammatory Agents, Non-Steroidal;Antiinflammatory Agents, Non-Steroids;Antiinflammatory and Antirheumatic Products;Antiinflammatory and Antirheumatic Products, Non-Steroids;Antiinflammatory Preparations, Non-Steroids for Topical Use;Antirheumatic Agents;Cardiac Therapy;Cardiovascular Agents;Cardiovascular System;Central Nervous System Agents;Chemical Actions and Uses;Cyclooxygenase Inhibitors;Cytochrome P-450 CYP2C19 Inhibitors;Cytochrome P-450 CYP2C19 Substrates;Cytochrome P-450 CYP2C9 Substrates;Enzyme Inhibitors;Gout Suppressants;Heterocyclic Compounds;Heterocyclic Compounds, 2-Ring;Indoles;Molecular Mechanisms of Pharmacological Action;Musculo-Skeletal System;Ophthalmologicals;P-glycoprotein/ABCB1 Inhibitors;P-glycoprotein/ABCB1 Substrates;Peripheral Nervous System Agents;Pharmacologic Actions;Physiological Effects of Drugs;Reproductive Control Agents;Sensory Organs;Sensory System Agents;Therapeutic Uses;Tocolytic Agents;Topical Products for Joint and Muscular Pain;UGT1A1 Inhibitors","approved;investigational","DB00328",""
"CHEBI:27432","PLA2G4A","CHEBI:8711","alpha-linolenic acid","quinacrine","Acridines;Aminoacridines;Anthelmintics;Anti-Infective Agents;Anticestodal Agents;Antimalarials;Antinematodal Agents;Antineoplastic Agents;Antiparasitic Agents;Antiparasitic Products, Insecticides and Repellents;Antiplatyhelmintic Agents;Antiprotozoals;Chemical Actions and Uses;Cytochrome P-450 CYP3A4 Substrates;Enzyme Inhibitors;Heterocyclic Compounds;Heterocyclic Compounds, 3-Ring;Molecular Mechanisms of Pharmacological Action;P-glycoprotein/ABCB1 Inhibitors;Pharmacologic Actions;Therapeutic Uses","approved","DB01103",""
"CHEBI:27432","PLA2G6","CHEBI:8711","alpha-linolenic acid","quinacrine","Acridines;Aminoacridines;Anthelmintics;Anti-Infective Agents;Anticestodal Agents;Antimalarials;Antinematodal Agents;Antineoplastic Agents;Antiparasitic Agents;Antiparasitic Products, Insecticides and Repellents;Antiplatyhelmintic Agents;Antiprotozoals;Chemical Actions and Uses;Cytochrome P-450 CYP3A4 Substrates;Enzyme Inhibitors;Heterocyclic Compounds;Heterocyclic Compounds, 3-Ring;Molecular Mechanisms of Pharmacological Action;P-glycoprotein/ABCB1 Inhibitors;Pharmacologic Actions;Therapeutic Uses","approved","DB01103",""
"CHEBI:27432","PLA2G2A","CHEBI:47381","alpha-linolenic acid","Diclofenac;diclofenac","Acetic Acid Derivatives and Related Substances;Acids, Carbocyclic;Analgesics;Analgesics, Non-Narcotic;Anti-Inflammatory Agents;Anti-Inflammatory Agents, Non-Steroidal;Antiinflammatory Agents, Non-Steroids;Antiinflammatory and Antirheumatic Products;Antiinflammatory and Antirheumatic Products, Non-Steroids;Antiinflammatory Preparations, Non-Steroids for Topical Use;Antirheumatic Agents;Carboxylic Acids;Central Nervous System Agents;Chemical Actions and Uses;Cyclooxygenase Inhibitors;Cytochrome P-450 CYP1A2 Inhibitors;Cytochrome P-450 CYP1A2 Substrates;Cytochrome P-450 CYP2B6 Substrates;Cytochrome P-450 CYP2C19 Substrates;Cytochrome P-450 CYP2C8 Substrates;Cytochrome P-450 CYP2C9 Inhibitors;Cytochrome P-450 CYP2C9 Substrates;Cytochrome P-450 CYP2E1 Inhibitors;Cytochrome P-450 CYP3A4 Substrates;Dermatologicals;Enzyme Inhibitors;Molecular Mechanisms of Pharmacological Action;Musculo-Skeletal System;Ophthalmologicals;Organic Chemicals;P-glycoprotein/ABCB1 Inhibitors;Peripheral Nervous System Agents;Pharmacologic Actions;Phenylacetates;Physiological Effects of Drugs;Sensory Organs;Sensory System Agents;Therapeutic Uses;Topical Products for Joint and Muscular Pain","approved;vet_approved","DB00586",""
"CHEBI:27470","DHFR","CHEBI:8455","folic acid","proguanil","Amidines;Anti-Infective Agents;Antimalarials;Antimetabolites;Antiparasitic Agents;Antiparasitic Products, Insecticides and Repellents;Antiprotozoals;Biguanides;Chemical Actions and Uses;Cytochrome P-450 CYP1A2 Substrates;Cytochrome P-450 CYP2C19 Substrates;Cytochrome P-450 CYP2C9 Substrates;Cytochrome P-450 CYP2D6 Inhibitors;Cytochrome P-450 CYP2E1 Substrates;Cytochrome P-450 CYP3A4 Substrates;Guanidines;Molecular Mechanisms of Pharmacological Action;Noxae;Organic Chemicals;Pharmacologic Actions;Therapeutic Uses;Toxic Actions","approved","DB01131","Folate biosynthesis;One carbon pool by folate"
"CHEBI:27470","DHFR","CHEBI:8673","folic acid","pyrimethamine","Anti-Infective Agents;Antimalarials;Antiparasitic Agents;Antiparasitic Products, Insecticides and Repellents;Antiprotozoals;Chemical Actions and Uses;Cytochrome P-450 CYP2C8 Inhibitors;Cytochrome P-450 CYP2C9 Inhibitors;Cytochrome P-450 CYP2C9 Inhibitors (moderate);Cytochrome P-450 CYP2D6 Inhibitors;Diaminopyrimidines;Enzyme Inhibitors;Folic Acid Antagonists;Heterocyclic Compounds;Heterocyclic Compounds, 1-Ring;Molecular Mechanisms of Pharmacological Action;Pharmacologic Actions;Pyrimidines;Therapeutic Uses","approved;vet_approved","DB00205","Folate biosynthesis;One carbon pool by folate"
"CHEBI:27470","DHFR","CHEBI:45924","folic acid","trimethoprim","Anti-Infective Agents;Anti-Infective Agents, Urinary;Antibacterials for Systemic Use;Antiinfectives for Systemic Use;Antimalarials;Antiparasitic Agents;Antiprotozoals;Chemical Actions and Uses;Chemically-Induced Disorders;Cytochrome P-450 CYP2C8 Inhibitors;Cytochrome P-450 CYP2C8 Inhibitors (moderate);Cytochrome P-450 CYP2C8 Substrates;Cytochrome P-450 CYP2C9 Inhibitors;Cytochrome P-450 CYP2C9 Inhibitors (moderate);Cytochrome P-450 CYP2C9 Substrates;Cytochrome P-450 CYP3A4 Substrates;Cytochrome P-450 Enzyme Inhibitors;Drug-Related Side Effects and Adverse Reactions;Enzyme Inhibitors;Folic Acid Antagonists;Heterocyclic Compounds;Heterocyclic Compounds, 1-Ring;Metabolic Side Effects of Drugs and Substances;Molecular Mechanisms of Pharmacological Action;P-glycoprotein/ABCB1 Inducers;P-glycoprotein/ABCB1 Inhibitors;Pharmacologic Actions;Pyrimidines;QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying);Renal Agents;Sulfonamides and Trimethoprim;Therapeutic Uses;Trimethoprim and Derivatives","approved;vet_approved","DB00440","Folate biosynthesis;One carbon pool by folate"
"CHEBI:27470","DHFR","CHEBI:17833","folic acid","gentamycin","Aminoglycoside Antibacterials;Aminoglycosides;Anti-Bacterial Agents;Anti-Infective Agents;Antibacterials for Systemic Use;Antibiotics for Topical Use;Antiinfectives;Antiinfectives for Systemic Use;Carbohydrates;Chemical Actions and Uses;Dermatologicals;Enzyme Inhibitors;Glycosides;Molecular Mechanisms of Pharmacological Action;Ophthalmological and Otological Preparations;Ophthalmologicals;Otologicals;Pharmacologic Actions;Protein Synthesis Inhibitors;Sensory Organs;Therapeutic Uses","approved;vet_approved","DB00798","Folate biosynthesis;One carbon pool by folate"
"CHEBI:27732","CYP1A2","CHEBI:6030","caffeine","isoniazide","Acids, Heterocyclic;Anti-Bacterial Agents;Anti-Infective Agents;Antiinfectives for Systemic Use;Antimetabolites;Antimycobacterials;Antitubercular Agents;Chemical Actions and Uses;CYP3A4 Inhibitors (Weak);Cytochrome P-450 CYP1A2 Inhibitors;Cytochrome P-450 CYP2A6 Inhibitors;Cytochrome P-450 CYP2C19 Inhibitors;Cytochrome P-450 CYP2C19 Inhibitors (moderate);Cytochrome P-450 CYP2C8 Inhibitors;Cytochrome P-450 CYP2C9 Inhibitors;Cytochrome P-450 CYP2D6 Inhibitors;Cytochrome P-450 CYP2D6 Inhibitors (moderate);Cytochrome P-450 CYP2E1 Inducers;Cytochrome P-450 CYP2E1 Inhibitors;Cytochrome P-450 CYP2E1 Inhibitors (moderate);Cytochrome P-450 CYP2E1 Substrates;Cytochrome P-450 CYP3A Inhibitors;Drugs for Treatment of Tuberculosis;Fatty Acid Synthesis Inhibitors;Heterocyclic Compounds;Heterocyclic Compounds, 1-Ring;Hydrazides;Hydrazines;Hypolipidemic Agents;Isonicotinic Acids;Lipid Regulating Agents;Molecular Mechanisms of Pharmacological Action;Noxae;Organic Chemicals;Pharmacologic Actions;Pyridines;Therapeutic Uses;Toxic Actions","approved","DB00951","Caffeine metabolism"
"CHEBI:28918","COMT","CHEBI:4798","(R)-adrenaline","entacapone","Anti-Dyskinesia Agents;Anti-Parkinson Drugs;Catechol O-Methyltransferase Inhibitors;Central Nervous System Agents;Central Nervous System Depressants;Chemical Actions and Uses;COMT Inhibitors;CYP2D6 Inhibitors (Weak);Dopamine Agents;Enzyme Inhibitors;Molecular Mechanisms of Pharmacological Action;Nervous System;Pharmacologic Actions;Therapeutic Uses","approved;investigational","DB00494","Tyrosine metabolism"
"CHEBI:28946","XDH","CHEBI:40279","theobromine","allopurinol","Antigout Preparations;Antimetabolites;Antioxidants;Antirheumatic Agents;Chemical Actions and Uses;Enzyme Inhibitors;Free Radical Scavengers;Gout Suppressants;Heterocyclic Compounds;Heterocyclic Compounds, 2-Ring;Molecular Mechanisms of Pharmacological Action;Musculo-Skeletal System;Noxae;Pharmacologic Actions;Physiological Effects of Drugs;Preparations Inhibiting Uric Acid Production;Protective Agents;Purines;Specialty Uses of Chemicals;Therapeutic Uses;Toxic Actions;Xanthine Oxidase Inhibitors Inhibitors","approved","DB00437","Caffeine metabolism"
"CHEBI:28997","ADA","CHEBI:4653","2'-deoxyinosine","dipyridamole","Blood and Blood Forming Organs;Cardiovascular Agents;Chemical Actions and Uses;Enzyme Inhibitors;Fibrinolytic Agents;Hematologic Agents;Heterocyclic Compounds;Heterocyclic Compounds, 1-Ring;Hypotensive Agents;Molecular Mechanisms of Pharmacological Action;P-glycoprotein/ABCB1 Inhibitors;P-glycoprotein/ABCB1 Substrates;Pharmacologic Actions;Phosphodiesterase Inhibitors;Platelet Aggregation Inhibitors;Platelet Aggregation Inhibitors Excl. Heparin;Pyrimidines;Therapeutic Uses;Vasodilator Agents","approved","DB00975","Purine metabolism"
"CHEBI:29009","MAOB","CHEBI:63620","N(tele)-methylhistamine","rasagiline","Anti-Parkinson Drugs;Central Nervous System Agents;Chemical Actions and Uses;Cytochrome P-450 CYP1A2 Substrates;Dopamine Agents;Enzyme Inhibitors;Molecular Mechanisms of Pharmacological Action;Monoamine Oxidase B Inhibitors;Monoamine Oxidase Inhibitors;Nervous System;Neuroprotective Agents;Pharmacologic Actions;Physiological Effects of Drugs;Protective Agents;Serotonin Modulators;Specialty Uses of Chemicals;Therapeutic Uses","approved","DB01367","Histidine metabolism"
"CHEBI:29009","MAOA","CHEBI:83531","N(tele)-methylhistamine","moclobemide","Acids, Carbocyclic;Amides;Antidepressive Agents;Benzamides;Benzene Derivatives;Benzoates;Carboxylic Acids;Central Nervous System Agents;Chemical Actions and Uses;Chlorobenzoates;CYP2D6 Inhibitors (Weak);Cytochrome P-450 CYP1A2 Inhibitors;Cytochrome P-450 CYP2C19 Inhibitors;Cytochrome P-450 CYP2C19 Inhibitors (moderate);Cytochrome P-450 CYP2C19 Substrates;Cytochrome P-450 CYP2C9 Inhibitors;Cytochrome P-450 CYP2C9 Substrates;Cytochrome P-450 CYP2D6 Inducers;Cytochrome P-450 CYP2D6 Inhibitors;Cytochrome P-450 CYP2D6 Substrates;Enzyme Inhibitors;Hydrocarbons;Hydrocarbons, Aromatic;Hydrocarbons, Cyclic;Molecular Mechanisms of Pharmacological Action;Monoamine Oxidase a Inhibitors;Monoamine Oxidase Inhibitors;Nervous System;Organic Chemicals;Pharmacologic Actions;Psychoanaleptics;Psychotropic Drugs;Serotonin Modulators;Therapeutic Uses","approved","DB01171","Histidine metabolism"
"CHEBI:29073","DBH","CHEBI:4659","Ascorbate","disulfiram","Acetaldehyde Dehydrogenase Inhibitors;Acids;Acids, Acyclic;Acids, Noncarboxylic;Alcohol Deterrents;Anions;Antiparasitic Products, Insecticides and Repellents;Carbamates;Carboxylic Acids;Central Nervous System Agents;Chemical Actions and Uses;CYP2D6 Inhibitors (Weak);CYP2E1 Inhibitors (Strong);Cytochrome P-450 CYP2C9 Inhibitors;Cytochrome P-450 CYP2E1 Inhibitors;Cytochrome P-450 CYP3A4 Substrates;Disulfides;Ditiocarb;Drugs Used in Addictive Disorders;Drugs Used in Alcohol Dependence;Ectoparasiticides, Incl. Scabicides;Ectoparasiticides, Incl. Scabicides, Insecticides and Repellents;Electrolytes;Enzyme Inhibitors;Gases;Hydrogen Sulfide;Inorganic Chemicals;Ions;Molecular Mechanisms of Pharmacological Action;Nervous System;Organic Chemicals;Pharmacologic Actions;Sulfides;Sulfur Compounds;Sulfur Containing Products;Therapeutic Uses;Thiocarbamates","approved","DB00822","Tyrosine metabolism"
"CHEBI:29888","POLA1","CHEBI:63599","PPi","fludarabine phosphate","Antimetabolites;Antimetabolites, Antineoplastic;Antineoplastic Agents;Antineoplastic and Immunomodulating Agents;Chemical Actions and Uses;DNA (Cytosine-5-)-Methyltransferase, antagonists & inhibitors;Enzyme Inhibitors;Immunologic Factors;Immunosuppressive Agents;Molecular Mechanisms of Pharmacological Action;Myeloablative Agonists;Myelosuppressive Agents;Noxae;Pharmacologic Actions;Physiological Effects of Drugs;Purine Analogues;Therapeutic Uses;Toxic Actions","approved","DB01073","Purine metabolism;Pyrimidine metabolism"
"CHEBI:29888","POLA1","CHEBI:63612","PPi","nelarabine","Antimetabolites;Antineoplastic Agents;Antineoplastic and Immunomodulating Agents;Immunosuppressive Agents;Myelosuppressive Agents;Purine Analogues","approved;investigational","DB01280","Purine metabolism;Pyrimidine metabolism"
"CHEBI:29888","POLE4","CHEBI:567361","PPi","cladribine","2-Chloroadenosine;Adenosine;Antimetabolites;Antineoplastic Agents;Antineoplastic and Immunomodulating Agents;BCRP/ABCG2 Substrates;Carbohydrates;Chemical Actions and Uses;Deoxyadenosines;Deoxyribonucleosides;Glycosides;Heterocyclic Compounds;Heterocyclic Compounds, 2-Ring;Immunologic Factors;Immunosuppressive Agents;Myelosuppressive Agents;Nucleic Acids, Nucleotides, and Nucleosides;Nucleosides;OCT2 Substrates;Pharmacologic Actions;Physiological Effects of Drugs;Purine Analogues;Purine Nucleosides;Purines;Ribonucleosides;Therapeutic Uses","approved;investigational","DB00242","Purine metabolism;Pyrimidine metabolism"
"CHEBI:29888","ENPP1","CHEBI:63580","PPi","ribavirin","Anti-Infective Agents;Antiinfectives for Systemic Use;Antimetabolites;Antiviral Agents;Antivirals for Systemic Use;Carbohydrates;Chemical Actions and Uses;Direct Acting Antivirals;Glycosides;Molecular Mechanisms of Pharmacological Action;Noxae;Nucleic Acids, Nucleotides, and Nucleosides;Nucleosides;Nucleosides and Nucleotides Excl. Reverse Transcriptase Inhibitors;Pharmacologic Actions;Ribonucleosides;Therapeutic Uses;Toxic Actions","approved","DB00811","Pantothenate and CoA biosynthesis"
"CHEBI:29888","POLE2","CHEBI:567361","PPi","cladribine","2-Chloroadenosine;Adenosine;Antimetabolites;Antineoplastic Agents;Antineoplastic and Immunomodulating Agents;BCRP/ABCG2 Substrates;Carbohydrates;Chemical Actions and Uses;Deoxyadenosines;Deoxyribonucleosides;Glycosides;Heterocyclic Compounds;Heterocyclic Compounds, 2-Ring;Immunologic Factors;Immunosuppressive Agents;Myelosuppressive Agents;Nucleic Acids, Nucleotides, and Nucleosides;Nucleosides;OCT2 Substrates;Pharmacologic Actions;Physiological Effects of Drugs;Purine Analogues;Purine Nucleosides;Purines;Ribonucleosides;Therapeutic Uses","approved;investigational","DB00242","Purine metabolism;Pyrimidine metabolism"
"CHEBI:29888","HPRT1","CHEBI:50667","PPi","Mercaptopurine;mercaptopurine","Antimetabolites;Antimetabolites, Antineoplastic;Antineoplastic Agents;Antineoplastic and Immunomodulating Agents;Chemical Actions and Uses;Enzyme Inhibitors;Heterocyclic Compounds;Heterocyclic Compounds, 2-Ring;Immunologic Factors;Immunosuppressive Agents;Inorganic Chemicals;Molecular Mechanisms of Pharmacological Action;Myelosuppressive Agents;Noxae;Nucleic Acid Synthesis Inhibitors;Organic Chemicals;Pharmacologic Actions;Physiological Effects of Drugs;Purine Analogues;Purines;Sulfhydryl Compounds;Sulfur Compounds;Therapeutic Uses;Thiopurine Analogs;Toxic Actions","approved","DB01033","Purine metabolism"
"CHEBI:29888","POLA1","CHEBI:681569","PPi","clofarabine","Antimetabolites;Antimetabolites, Antineoplastic;Antineoplastic Agents;Antineoplastic and Immunomodulating Agents;BCRP/ABCG2 Substrates;Chemical Actions and Uses;Immunosuppressive Agents;Molecular Mechanisms of Pharmacological Action;Myelosuppressive Agents;Noxae;Pharmacologic Actions;Purine Analogues;Therapeutic Uses;Toxic Actions","approved;investigational","DB00631","Purine metabolism;Pyrimidine metabolism"
"CHEBI:29888","HPRT1","CHEBI:2948","PPi","azathioprine","6-Mercaptopurine;Antimetabolites;Antimetabolites, Antineoplastic;Antineoplastic Agents;Antineoplastic and Immunomodulating Agents;Antirheumatic Agents;Carbohydrates;Chemical Actions and Uses;Glycosides;Heterocyclic Compounds;Heterocyclic Compounds, 2-Ring;Immunologic Factors;Immunosuppressive Agents;Inorganic Chemicals;Molecular Mechanisms of Pharmacological Action;Noxae;Nucleic Acids, Nucleotides, and Nucleosides;Nucleosides;Organic Chemicals;Pharmacologic Actions;Physiological Effects of Drugs;Purines;Sulfhydryl Compounds;Sulfur Compounds;Therapeutic Uses;Thionucleosides;Thiopurine Analogs;Toxic Actions","approved","DB00993","Purine metabolism"
"CHEBI:29888","HPRT1","CHEBI:2208","PPi","Mercaptopurine;purine-6-thiol","Antimetabolites;Antimetabolites, Antineoplastic;Antineoplastic Agents;Antineoplastic and Immunomodulating Agents;Chemical Actions and Uses;Enzyme Inhibitors;Heterocyclic Compounds;Heterocyclic Compounds, 2-Ring;Immunologic Factors;Immunosuppressive Agents;Inorganic Chemicals;Molecular Mechanisms of Pharmacological Action;Myelosuppressive Agents;Noxae;Nucleic Acid Synthesis Inhibitors;Organic Chemicals;Pharmacologic Actions;Physiological Effects of Drugs;Purine Analogues;Purines;Sulfhydryl Compounds;Sulfur Compounds;Therapeutic Uses;Thiopurine Analogs;Toxic Actions","approved","DB01033","Purine metabolism"
"CHEBI:29888","POLE","CHEBI:567361","PPi","cladribine","2-Chloroadenosine;Adenosine;Antimetabolites;Antineoplastic Agents;Antineoplastic and Immunomodulating Agents;BCRP/ABCG2 Substrates;Carbohydrates;Chemical Actions and Uses;Deoxyadenosines;Deoxyribonucleosides;Glycosides;Heterocyclic Compounds;Heterocyclic Compounds, 2-Ring;Immunologic Factors;Immunosuppressive Agents;Myelosuppressive Agents;Nucleic Acids, Nucleotides, and Nucleosides;Nucleosides;OCT2 Substrates;Pharmacologic Actions;Physiological Effects of Drugs;Purine Analogues;Purine Nucleosides;Purines;Ribonucleosides;Therapeutic Uses","approved;investigational","DB00242","Purine metabolism;Pyrimidine metabolism"
"CHEBI:29888","POLA1","CHEBI:567361","PPi","cladribine","2-Chloroadenosine;Adenosine;Antimetabolites;Antineoplastic Agents;Antineoplastic and Immunomodulating Agents;BCRP/ABCG2 Substrates;Carbohydrates;Chemical Actions and Uses;Deoxyadenosines;Deoxyribonucleosides;Glycosides;Heterocyclic Compounds;Heterocyclic Compounds, 2-Ring;Immunologic Factors;Immunosuppressive Agents;Myelosuppressive Agents;Nucleic Acids, Nucleotides, and Nucleosides;Nucleosides;OCT2 Substrates;Pharmacologic Actions;Physiological Effects of Drugs;Purine Analogues;Purine Nucleosides;Purines;Ribonucleosides;Therapeutic Uses","approved;investigational","DB00242","Purine metabolism;Pyrimidine metabolism"
"CHEBI:29888","POLE3","CHEBI:567361","PPi","cladribine","2-Chloroadenosine;Adenosine;Antimetabolites;Antineoplastic Agents;Antineoplastic and Immunomodulating Agents;BCRP/ABCG2 Substrates;Carbohydrates;Chemical Actions and Uses;Deoxyadenosines;Deoxyribonucleosides;Glycosides;Heterocyclic Compounds;Heterocyclic Compounds, 2-Ring;Immunologic Factors;Immunosuppressive Agents;Myelosuppressive Agents;Nucleic Acids, Nucleotides, and Nucleosides;Nucleosides;OCT2 Substrates;Pharmacologic Actions;Physiological Effects of Drugs;Purine Analogues;Purine Nucleosides;Purines;Ribonucleosides;Therapeutic Uses","approved;investigational","DB00242","Purine metabolism;Pyrimidine metabolism"
"CHEBI:30851","HPD","CHEBI:50378","keto-phenylpyruvic acid","nitisinone","4-Hydroxyphenylpyruvate Dioxygenase, antagonists & inhibitors;Alimentary Tract and Metabolism;Chemical Actions and Uses;Enzyme Inhibitors;Molecular Mechanisms of Pharmacological Action;Pharmacologic Actions;Various Alimentary Tract and Metabolism Products","approved;investigational","DB00348","Phenylalanine metabolism"
"CHEBI:30909","PLA2G6","CHEBI:8711","1-alkyl-sn-glycero-3-phosphocholine","quinacrine","Acridines;Aminoacridines;Anthelmintics;Anti-Infective Agents;Anticestodal Agents;Antimalarials;Antinematodal Agents;Antineoplastic Agents;Antiparasitic Agents;Antiparasitic Products, Insecticides and Repellents;Antiplatyhelmintic Agents;Antiprotozoals;Chemical Actions and Uses;Cytochrome P-450 CYP3A4 Substrates;Enzyme Inhibitors;Heterocyclic Compounds;Heterocyclic Compounds, 3-Ring;Molecular Mechanisms of Pharmacological Action;P-glycoprotein/ABCB1 Inhibitors;Pharmacologic Actions;Therapeutic Uses","approved","DB01103","Ether lipid metabolism"
"CHEBI:30909","PLA2G4A","CHEBI:8711","1-alkyl-sn-glycero-3-phosphocholine","quinacrine","Acridines;Aminoacridines;Anthelmintics;Anti-Infective Agents;Anticestodal Agents;Antimalarials;Antinematodal Agents;Antineoplastic Agents;Antiparasitic Agents;Antiparasitic Products, Insecticides and Repellents;Antiplatyhelmintic Agents;Antiprotozoals;Chemical Actions and Uses;Cytochrome P-450 CYP3A4 Substrates;Enzyme Inhibitors;Heterocyclic Compounds;Heterocyclic Compounds, 3-Ring;Molecular Mechanisms of Pharmacological Action;P-glycoprotein/ABCB1 Inhibitors;Pharmacologic Actions;Therapeutic Uses","approved","DB01103","Ether lipid metabolism"
"CHEBI:30909","PLA2G2A","CHEBI:49662","1-alkyl-sn-glycero-3-phosphocholine","indometacin","Acetic Acid Derivatives and Related Substances;Analgesics;Analgesics, Non-Narcotic;Anti-Inflammatory Agents;Anti-Inflammatory Agents, Non-Steroidal;Antiinflammatory Agents, Non-Steroids;Antiinflammatory and Antirheumatic Products;Antiinflammatory and Antirheumatic Products, Non-Steroids;Antiinflammatory Preparations, Non-Steroids for Topical Use;Antirheumatic Agents;Cardiac Therapy;Cardiovascular Agents;Cardiovascular System;Central Nervous System Agents;Chemical Actions and Uses;Cyclooxygenase Inhibitors;Cytochrome P-450 CYP2C19 Inhibitors;Cytochrome P-450 CYP2C19 Substrates;Cytochrome P-450 CYP2C9 Substrates;Enzyme Inhibitors;Gout Suppressants;Heterocyclic Compounds;Heterocyclic Compounds, 2-Ring;Indoles;Molecular Mechanisms of Pharmacological Action;Musculo-Skeletal System;Ophthalmologicals;P-glycoprotein/ABCB1 Inhibitors;P-glycoprotein/ABCB1 Substrates;Peripheral Nervous System Agents;Pharmacologic Actions;Physiological Effects of Drugs;Reproductive Control Agents;Sensory Organs;Sensory System Agents;Therapeutic Uses;Tocolytic Agents;Topical Products for Joint and Muscular Pain;UGT1A1 Inhibitors","approved;investigational","DB00328","Ether lipid metabolism"
"CHEBI:30909","PLA2G2A","CHEBI:47381","1-alkyl-sn-glycero-3-phosphocholine","Diclofenac;diclofenac","Acetic Acid Derivatives and Related Substances;Acids, Carbocyclic;Analgesics;Analgesics, Non-Narcotic;Anti-Inflammatory Agents;Anti-Inflammatory Agents, Non-Steroidal;Antiinflammatory Agents, Non-Steroids;Antiinflammatory and Antirheumatic Products;Antiinflammatory and Antirheumatic Products, Non-Steroids;Antiinflammatory Preparations, Non-Steroids for Topical Use;Antirheumatic Agents;Carboxylic Acids;Central Nervous System Agents;Chemical Actions and Uses;Cyclooxygenase Inhibitors;Cytochrome P-450 CYP1A2 Inhibitors;Cytochrome P-450 CYP1A2 Substrates;Cytochrome P-450 CYP2B6 Substrates;Cytochrome P-450 CYP2C19 Substrates;Cytochrome P-450 CYP2C8 Substrates;Cytochrome P-450 CYP2C9 Inhibitors;Cytochrome P-450 CYP2C9 Substrates;Cytochrome P-450 CYP2E1 Inhibitors;Cytochrome P-450 CYP3A4 Substrates;Dermatologicals;Enzyme Inhibitors;Molecular Mechanisms of Pharmacological Action;Musculo-Skeletal System;Ophthalmologicals;Organic Chemicals;P-glycoprotein/ABCB1 Inhibitors;Peripheral Nervous System Agents;Pharmacologic Actions;Phenylacetates;Physiological Effects of Drugs;Sensory Organs;Sensory System Agents;Therapeutic Uses;Topical Products for Joint and Muscular Pain","approved;vet_approved","DB00586","Ether lipid metabolism"
"CHEBI:30915","ABAT","CHEBI:39867","2-oxoglutaric acid","valproic acid","Acids, Acyclic;Anticonvulsants;Antimanic Agents;Carboxylic Acids;Central Nervous System Agents;Central Nervous System Depressants;Chemical Actions and Uses;Cytochrome P-450 CYP1A2 Inhibitors;Cytochrome P-450 CYP2A6 Inducers;Cytochrome P-450 CYP2A6 Substrates;Cytochrome P-450 CYP2B6 Substrates;Cytochrome P-450 CYP2C19 Inhibitors;Cytochrome P-450 CYP2C19 Substrates;Cytochrome P-450 CYP2C8 Inhibitors;Cytochrome P-450 CYP2C9 Inhibitors;Cytochrome P-450 CYP2C9 Inhibitors (moderate);Cytochrome P-450 CYP2C9 Substrates;Cytochrome P-450 CYP3A Inhibitors;Enzyme Inhibitors;Fatty Acid Derivatives;Fatty Acids;Fatty Acids, Volatile;GABA Agents;Lipids;Molecular Mechanisms of Pharmacological Action;Nervous System;Neurotransmitter Agents;Organic Chemicals;Pentanoic Acids;Pharmacologic Actions;Physiological Effects of Drugs;Psychotropic Drugs;Therapeutic Uses;Tranquilizing Agents;Valerates","approved;investigational","DB00313","Propanoate metabolism;Valine, leucine and isoleucine degradation;beta-Alanine metabolism"
"CHEBI:30915","OGDH","CHEBI:39867","2-oxoglutaric acid","valproic acid","Acids, Acyclic;Anticonvulsants;Antimanic Agents;Carboxylic Acids;Central Nervous System Agents;Central Nervous System Depressants;Chemical Actions and Uses;Cytochrome P-450 CYP1A2 Inhibitors;Cytochrome P-450 CYP2A6 Inducers;Cytochrome P-450 CYP2A6 Substrates;Cytochrome P-450 CYP2B6 Substrates;Cytochrome P-450 CYP2C19 Inhibitors;Cytochrome P-450 CYP2C19 Substrates;Cytochrome P-450 CYP2C8 Inhibitors;Cytochrome P-450 CYP2C9 Inhibitors;Cytochrome P-450 CYP2C9 Inhibitors (moderate);Cytochrome P-450 CYP2C9 Substrates;Cytochrome P-450 CYP3A Inhibitors;Enzyme Inhibitors;Fatty Acid Derivatives;Fatty Acids;Fatty Acids, Volatile;GABA Agents;Lipids;Molecular Mechanisms of Pharmacological Action;Nervous System;Neurotransmitter Agents;Organic Chemicals;Pentanoic Acids;Pharmacologic Actions;Physiological Effects of Drugs;Psychotropic Drugs;Therapeutic Uses;Tranquilizing Agents;Valerates","approved;investigational","DB00313","Citrate cycle (TCA cycle)"
"CHEBI:30915","ABAT","CHEBI:63638","2-oxoglutaric acid","vigabatrin","Acids, Acyclic;Amino Acids;Amino Acids, Peptides, and Proteins;Aminobutyrates;Anticonvulsants;Butyrates;Carboxylic Acids;Central Nervous System Agents;Central Nervous System Depressants;Chemical Actions and Uses;Enzyme Inhibitors;Fatty Acid Derivatives;Fatty Acids;Fatty Acids, Volatile;GABA Agents;gamma-Aminobutyric Acid;Lipids;Molecular Mechanisms of Pharmacological Action;Nervous System;Neurotransmitter Agents;Organic Chemicals;Pharmacologic Actions;Physiological Effects of Drugs;Therapeutic Uses","approved","DB01080","Propanoate metabolism;Valine, leucine and isoleucine degradation;beta-Alanine metabolism"
"CHEBI:32816","ABAT","CHEBI:39867","pyruvic acid","valproic acid","Acids, Acyclic;Anticonvulsants;Antimanic Agents;Carboxylic Acids;Central Nervous System Agents;Central Nervous System Depressants;Chemical Actions and Uses;Cytochrome P-450 CYP1A2 Inhibitors;Cytochrome P-450 CYP2A6 Inducers;Cytochrome P-450 CYP2A6 Substrates;Cytochrome P-450 CYP2B6 Substrates;Cytochrome P-450 CYP2C19 Inhibitors;Cytochrome P-450 CYP2C19 Substrates;Cytochrome P-450 CYP2C8 Inhibitors;Cytochrome P-450 CYP2C9 Inhibitors;Cytochrome P-450 CYP2C9 Inhibitors (moderate);Cytochrome P-450 CYP2C9 Substrates;Cytochrome P-450 CYP3A Inhibitors;Enzyme Inhibitors;Fatty Acid Derivatives;Fatty Acids;Fatty Acids, Volatile;GABA Agents;Lipids;Molecular Mechanisms of Pharmacological Action;Nervous System;Neurotransmitter Agents;Organic Chemicals;Pentanoic Acids;Pharmacologic Actions;Physiological Effects of Drugs;Psychotropic Drugs;Therapeutic Uses;Tranquilizing Agents;Valerates","approved;investigational","DB00313",""
"CHEBI:32816","ABAT","CHEBI:63638","pyruvic acid","vigabatrin","Acids, Acyclic;Amino Acids;Amino Acids, Peptides, and Proteins;Aminobutyrates;Anticonvulsants;Butyrates;Carboxylic Acids;Central Nervous System Agents;Central Nervous System Depressants;Chemical Actions and Uses;Enzyme Inhibitors;Fatty Acid Derivatives;Fatty Acids;Fatty Acids, Volatile;GABA Agents;gamma-Aminobutyric Acid;Lipids;Molecular Mechanisms of Pharmacological Action;Nervous System;Neurotransmitter Agents;Organic Chemicals;Pharmacologic Actions;Physiological Effects of Drugs;Therapeutic Uses","approved","DB01080",""
"CHEBI:33094","ABAT","CHEBI:39867","L-3-Amino-isobutyrate","valproic acid","Acids, Acyclic;Anticonvulsants;Antimanic Agents;Carboxylic Acids;Central Nervous System Agents;Central Nervous System Depressants;Chemical Actions and Uses;Cytochrome P-450 CYP1A2 Inhibitors;Cytochrome P-450 CYP2A6 Inducers;Cytochrome P-450 CYP2A6 Substrates;Cytochrome P-450 CYP2B6 Substrates;Cytochrome P-450 CYP2C19 Inhibitors;Cytochrome P-450 CYP2C19 Substrates;Cytochrome P-450 CYP2C8 Inhibitors;Cytochrome P-450 CYP2C9 Inhibitors;Cytochrome P-450 CYP2C9 Inhibitors (moderate);Cytochrome P-450 CYP2C9 Substrates;Cytochrome P-450 CYP3A Inhibitors;Enzyme Inhibitors;Fatty Acid Derivatives;Fatty Acids;Fatty Acids, Volatile;GABA Agents;Lipids;Molecular Mechanisms of Pharmacological Action;Nervous System;Neurotransmitter Agents;Organic Chemicals;Pentanoic Acids;Pharmacologic Actions;Physiological Effects of Drugs;Psychotropic Drugs;Therapeutic Uses;Tranquilizing Agents;Valerates","approved;investigational","DB00313","Valine, leucine and isoleucine degradation"
"CHEBI:33094","ABAT","CHEBI:63638","L-3-Amino-isobutyrate","vigabatrin","Acids, Acyclic;Amino Acids;Amino Acids, Peptides, and Proteins;Aminobutyrates;Anticonvulsants;Butyrates;Carboxylic Acids;Central Nervous System Agents;Central Nervous System Depressants;Chemical Actions and Uses;Enzyme Inhibitors;Fatty Acid Derivatives;Fatty Acids;Fatty Acids, Volatile;GABA Agents;gamma-Aminobutyric Acid;Lipids;Molecular Mechanisms of Pharmacological Action;Nervous System;Neurotransmitter Agents;Organic Chemicals;Pharmacologic Actions;Physiological Effects of Drugs;Therapeutic Uses","approved","DB01080","Valine, leucine and isoleucine degradation"
"CHEBI:4047","ANPEP","CHEBI:49040","L-cysteinylglycine","ezetimibe","Anticholesteremic Agents;Antimetabolites;Azetidines;Azetines;BCRP/ABCG2 Substrates;Cardiovascular System;Chemical Actions and Uses;Cytochrome P-450 CYP3A Inhibitors;Heterocyclic Compounds;Heterocyclic Compounds, 1-Ring;Hypolipidemic Agents;Lipid Modifying Agents;Lipid Modifying Agents, Plain;Lipid Regulating Agents;Molecular Mechanisms of Pharmacological Action;Noxae;OATP1B1/SLCO1B1 Substrates;P-glycoprotein/ABCB1 Substrates;Pharmacologic Actions;Therapeutic Uses;Toxic Actions","approved","DB00973","Glutathione metabolism"
"CHEBI:47013","PNP","CHEBI:567361","D-ribofuranose","cladribine","2-Chloroadenosine;Adenosine;Antimetabolites;Antineoplastic Agents;Antineoplastic and Immunomodulating Agents;BCRP/ABCG2 Substrates;Carbohydrates;Chemical Actions and Uses;Deoxyadenosines;Deoxyribonucleosides;Glycosides;Heterocyclic Compounds;Heterocyclic Compounds, 2-Ring;Immunologic Factors;Immunosuppressive Agents;Myelosuppressive Agents;Nucleic Acids, Nucleotides, and Nucleosides;Nucleosides;OCT2 Substrates;Pharmacologic Actions;Physiological Effects of Drugs;Purine Analogues;Purine Nucleosides;Purines;Ribonucleosides;Therapeutic Uses","approved;investigational","DB00242",""
"CHEBI:47013","PNP","CHEBI:490877","D-ribofuranose","didanosine","Anti-HIV Agents;Anti-Infective Agents;Anti-Retroviral Agents;Antiinfectives for Systemic Use;Antimetabolites;Antiviral Agents;Antivirals for Systemic Use;Carbohydrates;Chemical Actions and Uses;Deoxyribonucleosides;Dideoxynucleosides;Direct Acting Antivirals;Enzyme Inhibitors;Glycosides;Heterocyclic Compounds;Heterocyclic Compounds, 2-Ring;Inosine;Molecular Mechanisms of Pharmacological Action;Noxae;Nucleic Acid Synthesis Inhibitors;Nucleic Acids, Nucleotides, and Nucleosides;Nucleoside and Nucleotide Reverse Transcriptase Inhibitors;Nucleoside Reverse Transcriptase Inhibitors;Nucleosides;OAT3 Substrates;Pharmacologic Actions;Purine Nucleosides;Purines;Reverse Transcriptase Inhibitors;Ribonucleosides;Therapeutic Uses;Toxic Actions","approved","DB00900",""
"CHEBI:48517","HPRT1","CHEBI:50667","Xanthine","Mercaptopurine;mercaptopurine","Antimetabolites;Antimetabolites, Antineoplastic;Antineoplastic Agents;Antineoplastic and Immunomodulating Agents;Chemical Actions and Uses;Enzyme Inhibitors;Heterocyclic Compounds;Heterocyclic Compounds, 2-Ring;Immunologic Factors;Immunosuppressive Agents;Inorganic Chemicals;Molecular Mechanisms of Pharmacological Action;Myelosuppressive Agents;Noxae;Nucleic Acid Synthesis Inhibitors;Organic Chemicals;Pharmacologic Actions;Physiological Effects of Drugs;Purine Analogues;Purines;Sulfhydryl Compounds;Sulfur Compounds;Therapeutic Uses;Thiopurine Analogs;Toxic Actions","approved","DB01033","Purine metabolism"
"CHEBI:48517","HPRT1","CHEBI:2948","Xanthine","azathioprine","6-Mercaptopurine;Antimetabolites;Antimetabolites, Antineoplastic;Antineoplastic Agents;Antineoplastic and Immunomodulating Agents;Antirheumatic Agents;Carbohydrates;Chemical Actions and Uses;Glycosides;Heterocyclic Compounds;Heterocyclic Compounds, 2-Ring;Immunologic Factors;Immunosuppressive Agents;Inorganic Chemicals;Molecular Mechanisms of Pharmacological Action;Noxae;Nucleic Acids, Nucleotides, and Nucleosides;Nucleosides;Organic Chemicals;Pharmacologic Actions;Physiological Effects of Drugs;Purines;Sulfhydryl Compounds;Sulfur Compounds;Therapeutic Uses;Thionucleosides;Thiopurine Analogs;Toxic Actions","approved","DB00993","Purine metabolism"
"CHEBI:48517","XDH","CHEBI:40279","Xanthine","allopurinol","Antigout Preparations;Antimetabolites;Antioxidants;Antirheumatic Agents;Chemical Actions and Uses;Enzyme Inhibitors;Free Radical Scavengers;Gout Suppressants;Heterocyclic Compounds;Heterocyclic Compounds, 2-Ring;Molecular Mechanisms of Pharmacological Action;Musculo-Skeletal System;Noxae;Pharmacologic Actions;Physiological Effects of Drugs;Preparations Inhibiting Uric Acid Production;Protective Agents;Purines;Specialty Uses of Chemicals;Therapeutic Uses;Toxic Actions;Xanthine Oxidase Inhibitors Inhibitors","approved","DB00437","Purine metabolism"
"CHEBI:48517","HPRT1","CHEBI:2208","Xanthine","Mercaptopurine;purine-6-thiol","Antimetabolites;Antimetabolites, Antineoplastic;Antineoplastic Agents;Antineoplastic and Immunomodulating Agents;Chemical Actions and Uses;Enzyme Inhibitors;Heterocyclic Compounds;Heterocyclic Compounds, 2-Ring;Immunologic Factors;Immunosuppressive Agents;Inorganic Chemicals;Molecular Mechanisms of Pharmacological Action;Myelosuppressive Agents;Noxae;Nucleic Acid Synthesis Inhibitors;Organic Chemicals;Pharmacologic Actions;Physiological Effects of Drugs;Purine Analogues;Purines;Sulfhydryl Compounds;Sulfur Compounds;Therapeutic Uses;Thiopurine Analogs;Toxic Actions","approved","DB01033","Purine metabolism"
"CHEBI:48517","PNP","CHEBI:567361","Xanthine","cladribine","2-Chloroadenosine;Adenosine;Antimetabolites;Antineoplastic Agents;Antineoplastic and Immunomodulating Agents;BCRP/ABCG2 Substrates;Carbohydrates;Chemical Actions and Uses;Deoxyadenosines;Deoxyribonucleosides;Glycosides;Heterocyclic Compounds;Heterocyclic Compounds, 2-Ring;Immunologic Factors;Immunosuppressive Agents;Myelosuppressive Agents;Nucleic Acids, Nucleotides, and Nucleosides;Nucleosides;OCT2 Substrates;Pharmacologic Actions;Physiological Effects of Drugs;Purine Analogues;Purine Nucleosides;Purines;Ribonucleosides;Therapeutic Uses","approved;investigational","DB00242","Purine metabolism"
"CHEBI:48517","PNP","CHEBI:490877","Xanthine","didanosine","Anti-HIV Agents;Anti-Infective Agents;Anti-Retroviral Agents;Antiinfectives for Systemic Use;Antimetabolites;Antiviral Agents;Antivirals for Systemic Use;Carbohydrates;Chemical Actions and Uses;Deoxyribonucleosides;Dideoxynucleosides;Direct Acting Antivirals;Enzyme Inhibitors;Glycosides;Heterocyclic Compounds;Heterocyclic Compounds, 2-Ring;Inosine;Molecular Mechanisms of Pharmacological Action;Noxae;Nucleic Acid Synthesis Inhibitors;Nucleic Acids, Nucleotides, and Nucleosides;Nucleoside and Nucleotide Reverse Transcriptase Inhibitors;Nucleoside Reverse Transcriptase Inhibitors;Nucleosides;OAT3 Substrates;Pharmacologic Actions;Purine Nucleosides;Purines;Reverse Transcriptase Inhibitors;Ribonucleosides;Therapeutic Uses;Toxic Actions","approved","DB00900","Purine metabolism"
"CHEBI:52249","ENPP1","CHEBI:63580","UDPglucose","ribavirin","Anti-Infective Agents;Antiinfectives for Systemic Use;Antimetabolites;Antiviral Agents;Antivirals for Systemic Use;Carbohydrates;Chemical Actions and Uses;Direct Acting Antivirals;Glycosides;Molecular Mechanisms of Pharmacological Action;Noxae;Nucleic Acids, Nucleotides, and Nucleosides;Nucleosides;Nucleosides and Nucleotides Excl. Reverse Transcriptase Inhibitors;Pharmacologic Actions;Ribonucleosides;Therapeutic Uses;Toxic Actions","approved","DB00811","Starch and sucrose metabolism"
"CHEBI:52249","UGCG","CHEBI:50381","UDPglucose","miglustat","Alimentary Tract and Metabolism;Anti-HIV Agents;Anti-Infective Agents;Anti-Retroviral Agents;Antiviral Agents;Chemical Actions and Uses;Enzyme Inhibitors;Gaucher Disease;Glycoside Hydrolase Inhibitors;Hypoglycemic Agents;Molecular Mechanisms of Pharmacological Action;Pharmacologic Actions;Physiological Effects of Drugs;Therapeutic Uses;Various Alimentary Tract and Metabolism Products","approved","DB00419","Sphingolipid metabolism"
